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Abstract
Molecular drug design begins with the identification of a problem to solve. This work
identifies the growing resistance among human pathogens to current treatments. Once
the problem is identified and understood, solutions must be proposed. This one is straight
forward, we need new antimicrobial drugs. More specifically, we need to identify novel
targets to inhibit. A large portion of antibiotics focus on disruption of macromolecular
production while only a few target metabolic systems. Finally, you need to propose
solutions based on the information gathered. In order to avoid existing resistance, it is
important to avoid the macromolecular route and focus on metabolic enzymes. Preferably,
the pathway would have little overlap or similarity with pathways found in the treatment
organism. With this in mind, the non-mevalonate (NMA) pathway poses as a very good
target for drug design. Many pathogens have been found to be strictly dependent on
this pathway while it is absent in humans. Additionally, fosmidomycin has already been
shown to inhibit this pathway. Initially thought to just inhibit the 1-deoxy-D-xylulose 5-
phosphate (DXP) reductoisomerase (DXR), it has been shown to inhibit several enzymes
along the path to a lesser extent. Ideally, this could be repeated or improve upon for
future drug design.
With this in mind, the initial stages of the first two enzymes of the NMA pathway were
examined utilizing quantum mechanical/molecular mechanical (QM/MM) techniques.
The first enzyme was DXP synthase (DXS), which catalyzes a transketolase-like con-
densation of pyruvate and glyceraldehyde-3-phosphate to produce DXP. DXS and other
transketolases are dependent on the thiamine diphosphate (TDP) cofactor, which must
be deprotonated of the imidazolium C2 atom producing a highly reactive ylide. A tau-
tomerization occurs prior to this deprotonation to prime the pyrimidinium ring N4 atom
to perform the C2 abstraction. The question at hand was the identity of a general base
vi
to perform the N4 abstraction. The results favored a water-mediate mechanism with a
higher than usual ∆E‡ of 22.7 kcalcotmol−1. An observation pertaining the tautomer-
ization pertained to the aromaticity of the pyrimidine ring. Upon further investigation,
aromaticity was found to play a significant role in the ∆E‡ observed. Aromaticity might
contribute 14.2 kcalcotmol−1 to the barrier height. This high energy would drive the
reaction forward producing the ylide.
Investigation of the DXR enzyme followed this work. Initially, the work was going
to focus on the 2 mechanisms proposed for activity, α-ketol rearrangement and retro-
aldol/aldol mechanism. Subsequent publications involving secondary kinetic isotope ef-
fects (KIEs) add to the pile of evidence supporting the retro-aldol/aldol mechanism. So
the project was retooled to investigate the energetic differences between two metal bind-
ing modes. The results of this work support a metal coordination across the C3-C4 bond,
which eventually extends coordination to include the C2 oxygen. This conformation was
help explain the tight binding effecting observation of the putative intermediates (tran-
sition states) and aldehyde intermediate. Additionally, as the C2-C3 mode consistently
transfers a proton to the phosphate group of DXP or produces an elongated C-O bond,
the C2-C3 mode would not be favorable.
Further investigations of these enzymes (e.g. completing the step begin, continuing
through the reaction) could provide further illumination into the mechanism of action
and possibly reveal new avenues of drug design. Examining the enzymes downstream
in the NMA pathway might provide details of interest. Of particular interest is the
radical reaction proposed for HDR/IspH. The final step of the pathway produces IDP
and DMADP in a 4:1 proportion, which corresponds to the general system requirements
for production of the long chain, branched isoprenoids. It would be interesting to compute
the mechanism to see if energetics could provide further insights. Additionally, normal
mode analysis coupled with vibrational subsystem analysis could identify allosteric sites
for feedback sensitivity.
vii
Chapter 1
Introduction
1.1 Isoprenoids
Accounting for nearly 60% of natural product diversity, isoprenoids (or terpenoids), with
55,000 known compounds, comprise the largest family of natural products56,59. Many
of these compounds serve important biological functions. The lipid-soluble vitamins (A,
D, E, And K) and cholesterol are some of the most common examples161. Cholesterol is
subsequently utilized as a biosynthetic precursor of various steroid hormones, including
glucocorticoids, estrogens and androgens. Some synthetic analogs are used in many thera-
peutic applications. All isoprenoids are derived from two phosphate C5 isoprene building
blocks, isopentenylallyl diphosphate (IDP) and dimethylallyl diphosphate (DMADP).
The diversity of isoprenoids comes from number of IDP and DMADP molecules strung
together. The string of isoprenes in combination with functional groups such as ketones,
aldehydes, alcohols, peroxides, ethers and esters contribute to the considerable diversity
amoungst the family of natural products47.
The family is roughly divided into six major categories (Figure 1.1. These categories
are based on the number of isoprene units linked. Monoterpenoids contain two isoprene
units and therefore have a ten carbon skeleton. These are the major component of the
fragrant oils from leaves, flowers and fruits (e,g, limonene and nerol). Sesquiterpenoids
consist of three isoprene units to form 15 carbon cyclic and acyclic compounds. The next
category is called diterpenoid and are composed of 20 carbon atoms derived from geranyl
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Table 1.1: Examples of Biologically Significant Isoprenoids
Cyclic terpene utilized for
citrus flavor by the cosmetic
industry
Plant hormone required for
development processes
Required for vision and de-
rived from vitamin A
Utilized as part of the elec-
tron transport chain for cel-
lular respiration
Precursor to bile acids,
steroid hormones and vi-
tamin D; required for cell
membrane fluidity
Antioxidant to reduce the
production of reactive oxy-
gen species formation during
lipid oxidation
geranoil diphosphate (a 10 carbon unit). Vitamin A, phytohormone and tetrahydro-
cannabinol are a few of the more well characterized examples of diterpenes. Ophiobolin
A, a fungal metabolite, is an example of the next category, sesterterpenoids. These are
derived from 25 carbon framework. Cholesterol are a member of the triterpenoids which
are desired from the squalene precursor. Carotenoids are comprised of eight isoprene
units to make forty carbon chains with conjugated double bonds. Carotenoids utilize the
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absorption properties arising from their conjugated structures to assist in photosynthesis
and the prevention of photo-oxidative cellular damage.
1.2 Pathways for Isoprenoid Biosynthesis
1.2.1 Mevalonic Acid Dependent Synthesis of Isoprenoid Building Blocks
The first pathway for isoprenoid biosynthesis was discovered based on interest in choles-
terol for the obvious health related interests. During the investigation of cholesterol, re-
searchers discovered deuterium integration originating from labeled acetate via the IDP
unit which meant IDP was the direct precursor to cholesterol16. Subsequent studies lead
to the discovery and characterization of the mevalonate (MVA) pathway in the 1950s
named after the key intermediate (3R)-3,5-dihydroxy-3-methylpentanoic acid (mevalonic
acid, MVA). For the following decades, the MVA pathway dominated this area of research
as it was thought to be the sole route for IDP and DMADP synthesis in living systems.
The work in this area lead to a nobel prize in physiology for Lynen and Bloch in 1964,
and in Chemistry for Cornforth in 197515,40.
As figure 1.1 illustrates130, the initial step of the MVA pathway is the production of
acetoacetyl-CoA via the condensation of two acetyl-CoA molecules catalyzed by acetyl-
CoA acetyltransferase. A third acetyl-CoA molecule is attached to the acetoacetyl-CoA
to produce 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) catalyzed via an aldol reaction
performed by HMG-CoA synthase. HMG-CoA is reduced by two equivalents of NADPH
performed by HMG-CoA reductase producing MVA. The HMG-CoA reduction is the rate-
limiting step of this pathway, thus MVA production is the rate-limiting, or key, interme-
diary step in the pathway. Two consecutive phosphorylations performed by mevalonate
kinase and phosphomevalonate kinase produces mevalonate-5-diphosphate (MDP). An
ATP-coupled decarboxylation catalyzed by MDP decarboxylase yields IDP130. The IDP
isomer, DMADP, is produced via two structurally unrelated IDP:DMADP isomerases
3
Figure 1.1: An illustration of the complete Mevalonate and Non-Mevalonate pathways
culminating in the production of IDP and DMADP.
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(Figure 1.1).
1.2.2 Mevalonate-Independent Synthesis of IDP and DMADP
Decades following the MVA pathway discovery, further isotopic labeling studies were per-
formed to trace the fate acetate in producing lycopene, hopanoids, taxol and sterols. The
distribution of the labeled material in the subsequent terpenoids was inconsistent with a
single source of isoprenic production. Following from these results, several independent
research groups discovered a mevalonate-independent (or non-mevalonate, NMA) path-
way in eubacteria, green algae, and higher plants. Rohmer et al. identified the conversion
of pyruvate to 1-deoxy-D-xylulose 5-phosphate (DXP) as the first step of the NMA path-
way by following the incorporation of 13C-labeled pyruvate or glycerol into ubiquinone.
Additional independent studies carried out by Arigoni et al. traced the incorporation
of [1-13C]- and [2,3,4,5-13C 4]-DXP into the formation of β-carotene, lutein, phytol and
sitosterol in cell cultures of Catharanthus roseus and demonstrated the involvement of
DXP in the NMA pathway. The studies conducted by Arigoni et al. provided further
insight into the compartmentalization of isoprenoid synthesis, as well as, the description
of the rearrangement proposed by Eisenreich et al. In order to elucidate the NMA path-
way (Figure 1.1, further labelling studies were performed and revealed the pathway to be
composed of 7 enzymes that catalyze 8 reactions. Background on each of the enzymes
found in the NMA pathway can be found in the following paragraphs.
1-Deoxy-D-xylulose 5-Phosphate Synthase (DXS)
The aforementioned conversion of pyruvate to DXP is performed by DXP synthase (DXS)
and employs glyceraldehyde-3-phosphate (G3P) (Figure 1.2). DXS is a member a large
family of enzymes dependent upon the cofactor thiamine diphosphate (TDP)176. Par-
ticularly, the structure and reaction catalyzed are highly reminiscent of members of the
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subfamily of transketolases (TKs). Structurally, DXS is similar in composition to other
members of the subfamily. Each monomer is composed of 3 subunits (I, II and III). In
solution, DXS is more commonly found in a homodimer that is functionally significant
as each active site communicates with the other. The formation of the active site pocket
distinguishes DXS from other members of the TK subfamily. The active site in other
TKs exists between domain I of one monomer and domain II of the other monomer II
in a twisted conformation that arises via formation of the homodimer. In contrast, the
DXS active site resides in a pocket between domains I and II of the same197. Despite this
distinction, several key residues remained highly conserved with the rest of the subfamily.
Mechanistically speaking, DXS corresponds to the α-hydroxyketone (acyloin) conden-
sation and proceeds via a mechanism highly analogous to other TKs. Prior to substrate
binding, the TDP cofactor undergoes a deprotonation of the thiazolium ring forming a
carbanion ylide necessary for enzymatic. The usually high pK a of the thiazolium proton
makes this reaction highly unlikely in solution84. The active site of DXS and other TKs
binds the TDP into a energetically strained ‘V’-shaped conformation; which brings the
N4 of the pyrimidine ring into proximity of the C2 thiazolium proton197. The proxim-
ity of nitrogen and strained structure lowers the pK a significantly84,125. Therefore, the
carbanion ylide is free to perform a nucleophilic attack on the pyruvate. Subsequently,
the electrophilic iminium acts as an electron sink during decarboxylation and results in
a carbanion/enamine. The enamine performs a second nucleophilic attack on carbonyl
carbon of glyceraldehyde-3-phosphate (G3P). A final deprotonation step releases the new
Figure 1.2: The abridged representation of the DXS catalyzed condensation of pyruvate
with glyceraldehyde-3-phosphate to produce 1-deoxy-D-xylulose 5-phosphate.
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DXP molecule and regenerates the TDP ylide for further catalysis. The substrate binding
mechanism of other TKs has been thought to work through either a ping-pong or sequen-
tial mechanism60. Recent studies of DXS have suggested a random sequential mechanism
thus illustrating a further distinction between DXS and other TKs. DXS does show a
preferred order involving the formation of the C2α-lactylthiamin diphosphate (LTDP)
intermediate as an unusually stable ternary complex of TDP and pyruvate. The hydrox-
yaldehyde moiety of G3P was found to trigger and accelerate the decarboxylation which
produces the enamine utilized in the second nucleophilic reaction21.
1-Deoxy-D-xylulose 5-Phosphate Reductisomerase (DXR)
The next step in the NMA pathway is actually the first committed step of the path-
way. DXP reductoisomerase (DXR) catalyzes the conversion DXP into 2-C-methyl-D-
erythritol 4-phosphate (MEP) with preferential dependence on NADPH as reducing agent
and Mn2+ as a divalent ion3,94,118,157,179. The carbon-skeleton rearrangement in this re-
action is thought to proceed via the aldehyde intermediate, 2-C-methyl-D-erythrose 4-
phosphate (MEsP), which is subsequently reduced by NADPH (Figure 1.3). The idea
behind the aldehyde intermediate arose due to similarities between DXR and ketol-acid re-
ductoisomerase (KARI; EC 1.1.1.86); which catalyzes a similar rearrangement-reduction
sequence in the conversion of 2-acetolactate to 2,3-dihydroxy-3-methylbutyrate132. In
both situations, the intermediate has never been directly observed as it is either tightly
bound prior to reduction or in such low concentration due to it’s transient nature. An
experiment by Rohmer and co-workers provided the strongest evidence in support of the
MEsP intermediate. The researchers synthesized MEsP and demonstrated its kinetic
competency with DXR in the presence of NADPH and Mn2+ or Mg2+. They also ob-
served a 7% conversion of MEsP to DXP in the presence of NADP+37.
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Figure 1.3: The abridged representation of the DXR catalyzed rearrangement cou-
pled reduction of 1-deoxy-D-xylulose 5-phosphate by NADPH to produce 2-C-methyl-
D-erythritol 4-phosphate.
Similar to DXS, DXR is most commonly found in a homodimer of the V-shaped
monomers producing a saddle-like quaternary structure. The monomers can be further
subdivided into three distinct domains. A dinucleotide-binding domain acts as a binding
site for the NADPH cofactor is found in the N-terminal region of each monomer. The
central domain harbors the catalytic portion of the enzyme and is responsible for the
crucial conformational changes required for substrate binding and turnover. The central
domain contains a highly flexible loop, which acts as a lid upon substrate binding creating
a protected active-site cavity. The final domain is the C-terminal domain consisting of a
four-helix bundle and is characterized by its flexibility. The role of this flexible domain
is to aid in dimerization118,151,199,200.
Despite the similarities between DXR and KARI, differences in amino acid sequences
and crystal structures suggest different mechanisms for DXR37,49,95. Three mechanisms
were originally considered for DXR’s rearrangement of DXP to MEsP: 1) an α-ketol
rearrangement, 2) a retro-aldolization/aldolization and 3) a sequential 1,2-hydride and
1,2-methyl shift64. This last proposal was readily eliminated when the 13C-glucose in-
corporation studies failed to yield the appropriate labeled products. More over, 2-13C
and 3,4,5-13C3 labeled DXP experiments strictly yielded [2-
13C]- and [1,3,4-13C3]-MEP,
respectively, which supports the rejection of the sequential shift mechanism3,73,160. The
α-ketol (sigmatropic) rearrangement occurs via the migration of the C3-C4 bond to form
a C2-C4 bond in order to form MEsP, the aldehyde intermediate. This migration re-
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quires a partial positive charge on the C2 atom which can be achieved via protonation
or the ketol coordinating with the divalent metal ion. There is evidence to support the
latter approach. The metal has been shown to be chelated by the hydroxy groups of
DXP. A deprotonation of the C3 hydroxyl group of DXP is required for aldehyde forma-
tion Thus, the deprotonation and bond-cleavage/-formation would result in the MEsP78.
Alternatively, the retro-aldol/aldol reaction begins with the deprotonation of the C4 hy-
droxyl group followed by cleavage of the C3-C4 bond in a retro-aldolization. The result of
this reaction is the formation of a hydroxyacetone enolate and glycoaldehyde phosphate.
Subsequently, an aldol condensation will result in the same MEsP intermediate80,95,109.
Kinetic isotope effects (KIEs) measurements are not compatible with the α-ketol rear-
rangement mechanism. The hydroxyacetone and glycoaldehyde phosphate intermediates
have not been directly observed. Neither have they been successfully incorporated when
incubated with DXR and the necessary cofactors. These conflicting results indicate there
is further work to be done on the DXR mechanism. Despite the rearrngement mechanism,
the subsequent reduction produces MEP in the same way. Deuterium-labeled NADPH
and crystal structures have revealed details of the reduction reaction. The Re face of
MEsP protonated by the pro-S hydrogen from the nicotinamide C4 to the C1 of the
aldehyde5,132.
4-Diphosphocytidyl-2C-methyl-D-erythritol Synthase (CMS/IspD)
The discovery of DXS and DXR allowed for the identification and characterization of
additional NMA enzymes in quick succession. Utilizing [2-14]C-labeled MEP in E. coli,
research groups were able to track the formation of new radioactive products155. The first
product identified was 4-diphosphocytidyl-2C-methyl-D-erythritol (CDP-ME) in nuclear
magnetic resonance (NMR) spectroscopic assays (Figure 1.4). A database search of corre-
sponding enzymatic activity pointed researchers towards the ygbP gene101. Subsequently
several experiments showed MEP turnover and IPP production are dependent upon ygbP
9
and several other open reading frames101,155. The distribution of the new protein corre-
lated well with the expected presence of the NMA pathway in eubacteria. Following the
confirmation of ygbP, now designated IspD (CMS), activity assays revealed the necessity
of a divalent cation (Mn2+, Mg2+, or Co2+) with a preference for Mg2+. CMS appears to
be substrate specific with low but measurable activity with GTP and ATP. The incorpo-
ration of CTP’s α-phosphate instead of the β- or γ-phosphates was confirmed utilizing
radioactive phosphorous isotopes101,155.
Figure 1.4: The abridged representation of reaction catalyzed by CMS/IspD which at-
taches a cytidyl group to the phosphate tail of 1-deoxy-D-xylulose 5-phosphate producing
4-diphosphocytidyl-2C-methyl-D-erythritol.
Several crystal structures of CMS have been solved from a variety of organisms62,88,152.
To continue the trend of the first two enzymes, CMS is found commonly as a homod-
imer. Each structure revealed strong overall structural conservation with each other
and other nucleoside-binding proteins, particularly cytidyltransferases152. The domain
of each monomer hold a certain characteristic inline with other homologues. One of the
domains consists of a so-called β-arm, composed of overlapping parallel and anti-parallel
β-strands, which protrudes from the main globular domain at a wide angle. This β-
arm acts as a hook-like structure that interlocks closely with another monomer which
aids in dimerization62,88,152. The tertiary structures with all necessary cofactors pro-
vided valuable insights into ligand binding and enzymatic activity. A large network of
hydrogen-bonding interactions between ligands and side chains as well as backbone car-
bonyl and amide groups revealed that both the substrate and products are fixed to the
active site. Direct interaction between the protein and cytosine moiety of CTP, in part,
explains the selectivity and preference for pyrimidines over purine nucleosides152. Basic
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residues are proposed to position the triphosphate tail for catalysis. Additionally, these
residues might play a role in stabilizing the pentacoordinate transition state during the
reaction. Additional phosphate coordinations of MEP and CTP is provided by the Mg2+
despite its lack of direct interactions with the enzyme62,88.
The crystal structures of CMS has lead to the proposal of 2 reaction mechanisms. One
proposal involves the formation of a reactive metaphosphate CMP molecule via elimina-
tion of a disphosphate group. The metaphosphate CMP is subsequently attacked by the
4-phosphate of MEP to form CDP-ME. The alternative mechanism proposed starts with
a direct nucleophilic attack on the α-phosphate of CTP by the 4-phosphate of MEP.
The collapse of the pentacoordinate intermediate produces CDP-ME and PPi. Current
mutagenesis and structural data favor the second mechanism over the first152,154.
4-Diphosphocytidyl-2C-methyl-D-erythritol Kinase (CMK/IspE)
The expanding knowledge of the first three enzymes continued to facilitate the discov-
ery of the next downstream catalyst. Genomic analyses showed E. Coli ychB and its
orthologous sequences showed similar patterns in eubacteria and plants as other NMA
genes. Overexpression, purification, and characterization of ychB revealed the production
of 4-diphosphocytidyl-2C-methyl-D-erythritol 2-phosphate (CDP-MEP) from CDP-ME
(Figure 1.5); which corresponds to a phosphorylation of the C2 hydroxy group117. Sub-
sequently, the reaction and structure of ychB, later designated CMK or IspE, resembles
those catalyzed by the GHMP superfamily of enzymes. In addition to galactokinases and
homoserine kinases, two enzymes of the MVA pathway, mevalonate and phosphomeval-
onate kinases, defines the enzymes of GHMP superfamily117,185.
Following from the observed sequential conservation, CMK homologues strongly re-
semble each other as well as other members of the GHMP superfamily. One distinction
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Figure 1.5: The abridged representation of the phosphorylation of 4-diphosphocytidyl-
2C-methyl-D-erythritol by CMK/IspE producing 4-diphosphocytidyl-2C-methyl-D-
erythritol 2-phosphate.
between CMK and other GHMP enzymes, CMK is commonly found in a monomeric
state where as GHMP family members are commonly found in a homodimeric struc-
tures85,126,168,185. Each CMK monomer consists of predominantly 2 domains. An N-
terminal domain responsible for cofactor binding and a C-terminal domain in charge of
substate binding. CMK has an overall clamshell-like shape and the catalytic center is
formed in an open cavity between the domains after the clamshell closes. This closure
brings the substrate and cofactor into proximity in order to promote phosphorylation of
CDP-ME126,168,169,185.
Based on similarities to GHMP kinases, a catalytic mechanism was proposed. Not on
direct observations of the actions of the actual enzyme61,97. The C2 hydroxyl group of
CDP-ME forms hydrogen bonds with the side chains and carboxyl groups of highly con-
served lysine and aspartate residues. This network helps to further polarize the hydroxyl
group126,168,185. Due to this polarization, one of the aspartate residues can act as a base
to deprotonate the hydroxyl group. The resulting reactive alkoxide undergoes nucleotide
attack of the γ-phosphate of ATP resulting in a similar pentacoordinate intermediate for
CMS/IspD. The subsequent collapse of the intermediate results in ADP and CDP-MEP
being released with turnover126,168,185. A divalent metal ion is required for catalytic ac-
tivity similar to other GHMP family members. The ion is responsible for positioning
and orienting the phosphate moiety in proximity for attack by the acceptor molecule.
Additionally, it stabilizes the pentavalent transition state the bond between the β- and
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γ-phosphates of ATP34,61,70,97. Though, no CMK crystal structure has been observed to
contain the metal ion and lack of a highly conserved glutamate residue involved in po-
sitioning the metal ion suggests unique role in CMK. Additionally, some have proposed
coordinated water molecules might act in place of the metal ion in certain kinases. The
exact role of the metal remains to be determined34,126,168,185.
2C-Methyl-D-erythritol-2,4-cyclodiphosphate Synthase (MCS/IspF)
When CMS was identified as the third enzyme of the NMA pathway, the ygbP gene ex-
pression was found coupled to another unannotated ygbB gene sequence with a few cases
even fused inside a single open reading frame75,155. Correspondingly, the species distri-
butions of the gene orthologues parallel the presence of NMA based isoprenoid biosyn-
thesis. Attempts to identify the activity of the corresponding protein was determined by
challenging the enzyme with CDP-ME and CDP-MEP which produced 2-C-methyl-D-
erythritol-3,4-cyclophosphate (MEcP) and 2-C-methyl-D-erythritol-2,4-cyclodiphosphate
(MEcDP), respectively75,181. MEcDP was found to have been previously detected as a
bacterial metabolite. These results support MEcDP as a new intermediate between DXP
and IDP or DMADP (Figure 1.6); while MEcP was regarded as an in vitro artifact with
no physiological relevance. Subsequently, the name of the enzyme was changed MEcDP
synthase or IspF to reflect its function and position in the pathway75.
Figure 1.6: The cyclization of 4-diphosphocytidyl-2C-methyl-D-erythritol 2-phosphate
and subsequent expulsion of cytidyl release catalyzed by MCS/IspF.
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Structural characterizations have been published for the E. coli, Plasmodium falciparum,
Plasmodium vivax, and A. thaliana MCS enzymes28,87,139,153,177. While there are differ-
ences in the spacial grouping and composition of the asymmetric unit, the structures all
showed the formation of a tightly associated homotrimer. The multimeric assembly buries
a large surface area that contributes to the MCS enzyme’s heightened stability even in the
face of mass spectrometric analysis. This trimeric structural feature is a common feature
observed between MCS and any of its wider structural or functional homologues87,153.
A series of anti-parallel β-sheets form a largely hydrophobic channel at the core of the
trimer. This channel is thought to play a role in feedback regulation87,89,153,177. The
active site is found at the interface of two subunits with both side chains contributing to
the catalytic center. Conformational stabilization of the substrate and intermediates is
accomplished via interaction with a few key amino acids, and two distinct essential met-
als, a Zn2+ and either a Mg2+ or Mn2+. A zinc ion responsible for positioning the cytidyl
moiety of the substrate; which itself is tetrahedrally coordinated by an aspartate and two
histidine residues as well as the β-phosphate of MEcDP. Both the α- and β-phosphates
of the CDP substructure is coordinated and stabilized by either a Mg2+ or Mn2+. These
phosphate groups additionally play a role in the octahedral coordination of the Mg2+ or
Mn2+ ions with three water molecules and a glutamate residue filling in the rest of the
coordination sites87,153,177.
The intramolecular cyclization of CDP-MEP to MEcDP and concomitant CMP re-
lease catalyzed by MCS is thought to proceed via an in-line mechanism. Analogous to
the previous two enzymes, the reaction involes the nucleophilic attack on a phosphate
moiety thus forming a pentacoordinated transition state. The subsequent collapse of
the transition state releases the two products, CMP and MEcDP87,153,177. The protective
flexible loop closes off the catalytic cavity from the surrounding solvent. Interactions with
CDP and MEP substructures via hydrogen-bonding and hydrophobic regions of the cavity
accountants for the high degree of selectivity of MCS. The diphosphocytidyl moiety align-
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ment is accomplished primarily by the active site metal ions with additional help from
hydrogen-bonding and hydrophobic interactions of active site residues. Of particular in-
terest for reactivity, the Zn2+ ion increases the electrophilic character of the β-phosphate
in addition to aiding in lining up the nucleophilic attack by the 2-phosphate of the MEP
moiety. Additionally, the enzyme restricts the flexibility of the substrate bringing the
electron donor and acceptor in close proximity153. The negative charge of the cyclic tran-
sition state is compensated by the positive charge of the 2 metal ions87,153,177.
1-Hydroxy-2-methyl-2-(E)-butenyl 4-diphosphate Synthase (HDS/IspG)
Unlike the previous upstream catalysts were discovered and characterized in relatively
quick succession, the final two steps proved more elusive. The unannotated gcpE gene
was originally discovered in association with a histidyl tRNA synthetase59. Utilizing
bioinformatic approaches, an association was observed between the gcpE gene and other
NMA pathway enzymes were observed to reflect the characteristic distribution patterns.
As with DXS, DXR and IspD-IspF, the new gene sequence was detected in various bacte-
rial species, plants and apicomplexa, but not in eukaryotes such as yeast2,29. Disruption
of this gene was lethal as with the other NMA genes. Isotopic labeling coupled with
NMR analysis identified the new intermediate as 1-hydroxy-2-methyl-2-(E)-butenyl 4-
phosphate (HMBDP) (Figure 1.7), which can be produced via a reductive deoxygenation
of MEcDP71. The gene was renamed to IspG to reflect the new position in the NMA path-
way. Subsequent, recombinant expression and purification was straightforward, observed
activities were low. The presence of three highly conserved cysteines and similarities with
sequence motifs of ferrodoxin and aconitase enzymes suggested the presence of a catalytic
iron-sulfur, [4Fe4S]71,192. Further assays performed under anaerobic conditions and the
presence of an reducing agent for regenerative purposes resulted in the efficient produc-
tion of HMBDP from MEcDP. Additional confirmation of the presence of the cluster
was UV-vis absorption spectrum, which matched previously observed spectrum of simi-
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Figure 1.7: The penultimate step of the NMA pathway producing 1-hydroxy-2-methyl-
2-(E)-butenyl 4-phosphate from 2-C-methyl-D-erythritol-2,4-cyclodiphosphate.
lar proteins92,166.
As with DXS, DXR and CMS, HDS is commonly found in a homodimer. Each
monomer is composed of two domains106. The N-terminal domain is an 8-stranded β-
barrel globular subunit similar to the common (βα)8-fold of the triose phosphate iso-
merase (TIM) barrel superfamily. The iron-sulfur cluster is found in the C-terminal
domain. Coordination of the cluster is supplied via 3 cysteine residues and a glutamate
residue106,149,150. MEcDP binds in the active formed between the C-domain of a monomer
and the N-domain of the other monomer. All published HDS crystal structures are highly
similar; particularly with respect to the N-domain106. The C-domains are absent in some
structures (probably due to lack of resolution), while the Plasmidium falciparum struc-
ture has an additional domain. This additional domain is thought to fold into a second
TIM barrel to allow for monomeric activity113,204.
Mechanistic details remained elusive despite the identification of the substrate, prod-
uct and resolution of several crsytal structures. The reaction was known to involve
the [4Fe4S] cluster, elimination of the C3 hydroxyl and a 2 electron reduction. Re-
sults of isotopic-exchange experiments, electron paramegnetic resonance (EPR) spec-
troscopy, and many other experiments permitted the description of the HDS mecha-
nism23,92,156,166,186,187. Upon binding MEcDP, a conformational closure causes the dis-
placement of the glutamate residue from the fourth iron while promoting the formation
of a covalent bond with the substrate. A deprotonation of the C3 hydroxyl group by a
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second glutamate assists in the Fe-O bond formation106,150,204. Once bond, the ring of
MEcDP opens and closes consistently198. The introduction of the first single external
electron breaks the ring permenantly either a carbocation or radical (formed via internal
electron transfer) and begins the reaction in ernest. The addition of a second external
electron produces a C2 carbanion146,186,187. Formation and release of HMBDP proceeds
via an E1cb elimination results. A localized proton relay change results in the release of
H2O from the cluster and regeneration of the enzyme
146.
1.3 Isoprenoids as Drug Target
Molecular medicine has provided means for mankind to overcome many diseases caused
by various microbial life forms. Lately, there has been a growing resistance to current
therapies. The discovery of multi-drug resistance forms of many diseases (e.g. tuberculo-
sis and malaria) are poised to return us to the time prior to anti-microbial drugs96,122,165.
In an age of growing drug resistance, there are very few companies investing in developing
novel treatments due to the low returns and high upfront costs. Amongst the now grow-
ing list of neglected disease, Tropical diseases (i.e. malaria, leishmaniasis, tuberculosis)
represented the most neglected diseases in the world. This due in large part to their
concentration in the developing nations. Malaria is one of the most profound problems
due to its high morbidity rate and millions of reported cases a year. In the age of modern
globalization, growing resistance is a world wide problem122,183.
Malaria presence a growing international concern. High mortality aside, malaria can
cause economic downturns in high areas of infection due to an acutely infected individuals
inability to work. Long term effects can be seen by life-long learning impairments caused
when children are infected. Malaria is caused by four species of Plasmodium but the ma-
jority of the mortalities are cause by two of them, P. falciparum and P. vivax24,183. Both
show evidence of a growing resistance to long standing therapies such as chloroquine and
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fansidar; which has hastened the need to develop novel treatments.
Primarily, drug resistance has been found via mutations in enzymes which reduce
the inhibitive effects of the therapy. Additional mutations found in transporter proteins
make up a large portion of the remaining resistance196. These transporters (i.e. pfmdr1)
act by removing the drug from the target sites. This is similar to the developing of
β-lactamases in infectious bacteria to destroy antibiotics such as penicillin while develop-
ing mutations in the target peptidase enzymes. It is a two fold development in resistance.
The NMA pathway has great promise as a target for anti-microbial activity. The
most significant benefit is the seeming absence of orthologous enzymes in mammalian
cells. Particular absence in humans is a huge benefit. In other words, the entire pathway
seems to be absent in humans which rely on the MVA pathway for IDP and DMADP pro-
duction. The combination of the completion of the human genome project, subsequent
expansion in mapping other species genomes, and the identification of the genes and en-
zymes of the NMA pathway allowed researchers to perform scans. Table 1.2 represents
highlights of species and the isoprenoids biosynthesis pathways present. There are a few
species that rely on both but have one isolated in an organelle, therefore the products of
one of the pathways aren’t readily available to use in a crisis59,63.
As indicated in table 1.2, several protozoal genomes (e.g. P. falciparum, and P. vivax)
have genes corresponding to the NMA pathway. Subsequent studies have revealed these
genes to be predominantly located in the apicoplast; which is necessary for survival
in the intraerythrocytic and intrahepatic stages of plasmodium. The inhibition of the
NMA pathway via fosmidomycin can only be save via exogenous introduction of IDP and
DMADP suggests this pathway as a new source of anti-malarial drugs59,201.
18
Additionally, there is evidence of NMA being a good source of anti-bacterial drugs.
A majority of current antibiotics work via the interruption of the biosynthesis of macro-
molecular components (e.g. DNA, RNA, cell wall) of the bacterium6,52. The remaining
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few target metabolic enzymes. Arigoni et al. conducted a study using bioinformatics
to identify 30 E. coli necessary for survival which could also be found in other bacterial
species. The NMA pathway is amongst these necessary genes6. Several pathogenic bac-
teria, including E. coli and Mycobacterium tuberculosis, carrying deletions in the NMA
genes could only be rescued via exogenous introduction of isoprenoids55,122. The presence
of the NMA pathway in several pathogenic species but absence in ours indicates this path-
way as a key source of novel therapies to combat the growing resistance problem. There
are a couple of issues. There are two enzymes belonging to large families of enzymes.
DXS and IspE belong the TDP-dependent enzyme and GHMP families, respectively.
High sequence similarity between these enzymes and their families poses unintended con-
sequences. This has been observed consistently in work with kinases. Trying to develop
a highly specific inhibitor is troubling at best. These considerations should not inhibit
our attempts at developing new therapies base on this pathway.
1.4 Computational Methodology
Biochemistry is the study of the chemical reactions involved in biological processes. At
the heart of this endeavor are enzymes that facilitate these processes. Hence, it became
rapidly apparent a deeper understanding of enzymes was needed. When studying en-
zymes some key questions are: “What amino acids are participating in the enzymatic
action? What are their roles? And what are the possible transition states?”116,148,182.
In pursuit of answers to these questions, biochemists developed laboratory techniques
to probe the relative importance of certain amino acids (AAs) and the motions of these
highly dynamic macromolecules. Some of these experimental methods are kinetic isotope
effects (KIE); site directed mutagenesis, and Forster resonance energy transfer (FRET). It
was hoped that they could give insights into transition state structures and a better view
of the molecular level interactions occurring in enzyme active sites. These techniques
have contributed significant knowledge of the inner workings of the enzymes, however
21
they do have limitations. With the advent of macromolecular crystallography and later
NMR based methods, the ability to see at the molecular level was greatly enhanced.
Computational biochemistry can provide an even more detailed look into enzyme
mechanisms. This includes but is not limited to the investigation of the motion of en-
zymes, de Novo design of transition state analog inhibitors, and investigating protein-
protein interactions93. My current focus is in 3 areas: application of computational
techniques to elucidate mechanistic detail of two enzymatic processes.
The study of condensed phase chemical and biochemical processes has been major fo-
cus for both experimental and computational chemists for several decades now. Though
QM approaches for computation are more accurate, the computational cost prohibits the
use of these approaches with any biologically relevant systems. This limitation of QM
methods was a driving force behind the growing use of more efficient MM methods that
are more empirically driven. Significant time and effort has been put into attempting to
improve the efficiency of traditional QM methods recently. Though these advances have
shown benefits for small molecule chemistry, they are still prohibitively expensive for full
scale biochemical applications. A problem that has been mitigated in part through the
development of more efficient QM codes and the growing use of hybrid QM/MM meth-
ods. Standard methods of QM/MM attempt to couple the cost efficiency of MM methods
with the accuracy and precision of QM methods through the division of the system into
subsystems. These subsystems are treated at different levels of theory. One region, that
is usually made up of the active site or site of most significant interest, is labelled the QM
region and treated with the highest level of computational theory. An MM region is also
defined and the protein environment that surrounds the QM region. The third region is
an interface region that connects the QM and MM regions previously defined. The third
region is only necessary if in the course of defining the QM region from the MM region,
any bonds found along their borders are split between the regions, becoming the interface
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region. A coupled potential is responsible for the inclusion of electrostatic and van der
Waals interactions from the QM and MM through the interface region136,182,188.
Several methods for the implementation of hybrid QM/MM schemes have been re-
ported. Empirical valence bond (EVB) and semi-empirical methods have been employed
typically to describe the QM region, due to their relative efficiency in comparison to
ab initio QM theory. Though they have been used effectively, several weaknesses that
have been well documented. Recently, there has been a bigger push to overcome the
deficiencies in these methods through the implementation of more accurate and rigorous
computational methods such as ab initio and Density Functional Theory (DFT). Herein,
we will be applying QM/MM methodology with the QM region being treated with the
more rigorous DFT methodology162.
A major advantage of using hybrid QM/MM techniques is the ability to compute
barriers for biological processes (e.g. NOX production). The relative free energy (∆ G)
of each step along the reaction will be calculated in order to ascertain (within relative
degrees of certainty) the profile of a proposed mechanism and therefore suggest the most
energetically favorable mechanism136,182,188. ∆G has been defined as a measure of the
driving force behind a reaction. Thus by calculating the driving force, the mostly prob-
able reaction will be uncovered. In addition, key residues involved in the stabilization of
the transition state or destabilization of the reactant state will be idenitified and ana-
lyzed for relative electrostatics in determining the relative energetics of different reaction
mechanisms.
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Chapter 2
Thiamin Diphosphate Activation in 1-deoxy-D-xylulose 5-Phosphate
Synthase: Insights into the Mechanism and Underlying Intermolecular
Interactions
2.1 ACS Permissions
Reprinted with permission from White, J.K.; Handa, S; Vankayala, S.L.; Merkler, D.J.
;Woodcock, H.L., Thiamin Diphosphate Activation in 1-Deoxy-d-xylulose 5-Phosphate
Synthase: Insights into the Mechanism and Underlying Intermolecular Interactions, J.
Phys. Chem. B, 2016, 120 (37), pp 99229934, DOI: 10.1021/acs.jpcb.6b07248. Copy-
right 2016 American Chemical Society.
2.2 Abstract
1-deoxy-D-xylulose 5-phosphate synthase (DXS) is a thiamin diphosphate (TDP) depen-
dent enzyme that marks the beginning of the methylerythritol 4-phosphate isoprenoid
biosynthesis pathway. The mechanism of action for DXS is still poorly understood and
begins with the formation of a thiazolium ylide. This TDP activation step is thought to
proceed through an intramolecular deprotonation by the 4′-aminopyrimidine ring of TDP;
however, this step would occur only after an initial deprotonation of its own 4′-amino
group. The mechanism of the initial deprotonation has been hypothesized, by analogy to
transketolases, to occur via a histidine or an active site water molecule. Results from hy-
brid quantum mechanical / molecular mechanical (QM/MM) reaction path calculations
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reveal an ∼10 kcal/mol difference in transition state energies, favoring a water medi-
ated mechanism over direct deprotonation by histidine. This difference was determined
to be largely governed by electrostatic changes induced by conformational variations in
the active site. Additionally, mutagenesis studies reveal DXS to be an evolutionarily
resilient enzyme. Particularly, we hypothesize that residues H82 and H304 may act in a
compensatory fashion if the other is lost due to mutation. Further, nucleus-independent
chemical shifts (NICS) and aromatic stabilization energy (ASE) calculations suggest that
reduction in TDP aromaticity also serves as a factor for regulating ylide formation and
controlling reactivity.
2.3 Introduction
Isoprenoids are one of the largest and most diverse families of biomolecules with a num-
ber of them essential for life99,158,161. An example would be Vitamin A, which plays a
role in human growth and development as well as immune system maintenance. Two
isoprene molecules are variably employed in the construction of all isoprenoids. Isopen-
tenyl diphosphate (IDP) and dimethylallyl diphosphate (DMADP) are produced via two
distinct biosynthetic pathways (Figure 2.1): mevalonate pathway (MVA) and methylery-
thritol 4-phosphate pathway (MEP pathway)17,33,191. The MVA pathway was discovered
in the 1950s and was considered the sole pathway until the 1990s when discrepancies
in isotopic labeling studies led researchers to hypothesize an alternative, MEP path-
way51,159. Subsequent, genetic studies have revealed a large variety of life (e.g., algae,
bacteria, etc.) to have varying degrees of dependence upon MEP pathway for isoprenoid
production; in addition to a number of human pathogens (e.g., Plasmodium spp., and
M. tuberculosis)52,66,110,147. Interestingly, the MEP pathway is absent in all mammalian
genomes meaning that the enzymes of this pathway are ideal targets for novel antibiotics
and antimalarials81. For example, fosmidomycin is known to be an effective agent against
several of the Plasmodium spp. (malarial pathogens) and targets MEP pathway’s second
step, 1-deoxy-D-xylulose 5-phosphate reductoisomerase (DXR)81,100,203.
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Figure 2.1: Schematic of isoprene production via MVA or MEP pathway. MVA pathway
produces DMADP via a secondary enzyme, IDP Isomerase45,171. MEP pathway directly
synthesizes both isoprene molecules.
MEP pathway is comprised of eight reactions catalyzed by seven enzymes begin-
ning with 1-deoxy-D-xylulose 5-phosphate synthase (DXS)18,53,69,103,114,115,124,176. DXS
catalyzes the condensation of glyceraldehyde-3-phosphate (G3P) and pyruvate to pro-
duce 1-deoxy-d-xylulose 5-phosphate (DXP). Aside from isoprenoid production, DXP is
utilized in the production of vitamin B1 (thiamin) and vitamin B6 (pyridoxine) biosyn-
thetic pathways14,53,76 suggesting increased significance to understanding the mechanism
of DXS. Further, DXS is believed to be a rate-limiting step due to the observed correla-
tion between isoprenoid product levels and DXS levels.53 DXS is a member of the thiamin
diphosphate (TDP) dependent family of proteins; specifically a member of the transke-
tolase (TK) enzyme subclass and also possesses pyruvate decarboxylase activity.7,114,176
TKs are a class of TDP dependent enzymes responsible for the transfer of a ketol donor
group to an aldehyde or ketone acceptor molecule41,60,163. In 2007, Xiang et al. pub-
lished crystal structures and mutagenesis results of DXS from E. coli and D. radiodurans
and compared them to the E1 subunit of pyruvate dehydrogenase (PDH) and yeast TK
(members of the same class of enzymes)197. The comparison revealed significant simi-
larities between these four enzymes: 1) each enzyme is composed of three domains (I,
II, and III), 2) all possess a TDP cofactor, and 3) all contain a GDGX25-30N motif that
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plays a role in producing the twisted ‘V’ shape of the TDP cofactor in the active site197.
The strained cofactor conformation has been shown to play a role in lowering the pKa
of a hydrogen on the thiazolium ring’s C2 atom (Figure 2.2)25,26,60,84,125. The active
site of DXS contains a number of strictly/highly conserved residues (e.g., Glu370/372,
Asp152/154 in E. coli/D. radiodurans, respectively) that are common among TDP de-
pendent enzymes, particularly TKs. These similarities have led researchers to propose
a DXS reaction mechanism based, primarily, on mechanistic data of other TK enzymes
(Figure 2.2)41,163,173.
Figure 2.2: Proposed general mechanism for DXP biosynthesis. Pieces of each step
are labeled with different colors to indicate where they originate from. Red represents
pyruvate and blue are the pieces affiliated with G3P.
Although DXS contains many of the strictly/highly conserved residues of the TDP-
dependent superfamily of enzymes (vide supra), it displays distinct structural features197.
Specifically, the domain arrangement of DXS; homodimeric with a deep pocket between
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two domains of the same monomer rather than at the dimer interface as is the case with
other TDP enzymes. These structural differences logically lead to questions of mech-
anistic similarity. Until the discovery of DXS, it was believed that all TDP enzymes
functioned via a classical “ping-pong” mechanism (i.e., pyruvate binding −→ CO2 re-
lease −→ G3P binding)60. However, Eubanks and Poulter in 2003 concluded that DXS
operates via an ordered mechanism (i.e., irreversible pyruvate binding −→ G3P binding
−→ CO2 release) and hypothesized a side reaction for producing CO2 via binding of a
second pyruvate molecule54. This hypothesized side reaction was subsquently confirmed
by Brammer and Meyers in 200919. However, the following year a steady-state kinetics
study examining a herbicide metabolite (ketoclomazone, a derivative of clomazone) pro-
vided evidence of a traditional ping-pong mechanism for DXS123. Nearly, simultaneously
(in 2010), a single-molecule force spectroscopy nano sensor was developed and used to
observe an approximate 2-fold binding enhancement of G3P in the presence of pyruvate;
suggesting an ordered DXS mechanism174. As part of this work, the authors cast doubt
on the reliability of previous results based upon assays that measure bulk phenomena
rather than single-molecule behavior. To further confound the situation, Meyers and co-
workers (in 2011) proposed an unprecedented TDP-based mechanism; G3P and pyruvate
were found to bind independently and reversibly. Thus, they concluded DXS functions
via a rapid equilibrium, random sequential mechanism20. In the following year, Meyers
and co-workers revealed a 600 fold acceleration in the decarboxylation of the lactyl-TDP
intermediate upon binding of G3P. This result further distinguishes DXS from other
TDP-dependent enzymes.
Two recent studies have called into question our understanding of the active sites of
the large class of TDP dependent enzymes. For instance, the benzaldehyde lyase (BAL)
enzyme is devoid of all but two acid-base residues around the TDP active site: a histi-
dine and highly conserved glutamate22,121. Most interesting is the lack of any apparent
acid-base residues in glyoxylate carboligase (GCL)86. These recent discoveries represent
glaring gaps in our understanding of TDP-dependent enzymes and bolster the importance
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of investigating distinct related enzymes (i.e., DXS).21,22,86,121 Here, computation is an
ideal partner to experiment.
Of particular interest in this work is the “true first step” of this process: TDP acti-
vation, of which significant mechanistic details are still largely uncertain. For example,
a proposed mechanism for ylide formation begins with an initial deprotonation of the
4′-aminopyrimidine (AP) state that produces the 1′,4′-iminopyrimidine (IP) state114,176.
A general base (GB) is required for this deprotonation, however, the identity of this
group remains unknown. One hypothesized GB is a highly conserved histidine (His434 in
D. radiodurans DXS) found proximal to TDP’s 4′-amino group60,82. The aforementioned
mutation studies (i.e., H434A) showed approximately 95% activity retention, which sug-
gests an alternative mechanism. A more recent 2014 study by Querol et al. suggests H431
(E. coli equivalent of D. radiodurans H434) plays a role in transition state stabilization
but not required for catalysis145. Additionally, numerous structural differences between
DXS and TK enzymes (vide supra) support the possibility of an alternative mechanism197.
One possible alternative mirrors that of human TKs; where a water molecule would re-
place H434 as the GB with a Gln residue acting to stabilize this via coordination134,173,190.
This results in two possible TDP activation mechanisms: a water-mediated mechanism
(WMM) or direct histidine mechanism (DHM). Even though the WMM utilizes a water
molecule as the initial general base, it is possible that H434 plays a role in this mechanism
as either a coordination site for the water molecule or as the final location of the proton.
TDP has been shown to exist in four different tautomeric/ionization states (Fig-
ure 2.3); however, the exact mechanism for producing the final ylide form remains un-
clear8,9,133,141. Figure 2.3 illustrates two possible mechanisms: (1) a concerted AP to IP
conversion followed by ylide formation or (2) a step wise mechanism where the AP is
first ionized to a 4′-aminopyrimidinium ion (APH+) and, subsequently, converted to the
IP and ylide, respectively. Although direct spectroscopic evidence of the APH+ state
remains elusive, its existence has been inferred from alternative experiments (e.g., pH
rate profiles, solid-state NMR) and hypothesized to assist in promoting IP formation via
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stabilization of the tautomerization reaction8,83,133. An elevation in the pKa of TDP’s
N1 atom is proposed to account for the APH+ state’s existence; which is justified by its
proximity to a strictly conserved glutamate residue. This idea, however, does not con-
sider the possibility of an accompanying elevation in the pKa of the glutamate residue.
Recent studies have determined the pKa for the N1 atom in DXS to be 7.5
141 and a
PROPKA11,108,138,175 calculation has estimated the E373 residue to have a pKa of 8.4.
1
These pKa values suggest an equilibrium between the AP, and APH
+ states; which is
consistent with the enzyme stabilizing the IP formation via pKa modulation. Addition-
ally, Jordan et al. supports the equilibria presented in Figure 2.3; particularly for apo
(TDP-bound enzyme lacking substrate) enzymes83. Therefore, it is not necessary to
select between the step wise or concerted mechanism for the purposes of this study.
Figure 2.3: Structure and relationship of the 4 possible tautomeric/ionization states
proposed for the cofactor of TDP dependent enzymes8,9,125,133,141. Key atoms have been
given names for reference purposes throughout this article.
1The pKa for the N1 atom of DXS was determined via pH rate profile studies. The E373 pKa was
estimated using PROPKA3.1 with TDP but without pyruvate and G3P. The complete output of the
PROPKA3.1 calculation can be found in the supporting information.
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The rate of activation and turnover of TDP shows a substantial increase when bound
to an enzyme rather than in solution84. Several factors leading to the increase in activity
have been proposed. One factor includes the strained conformation the cofactor adopts
upon binding. This conformation places the 4′-amino group in close proximity to the
thiazolium C2 atom; both introducing strain and lowering the pKa of the C2 hydrogen
from 14-19 (depending on solvent) to approximately 965,82. The electronics of the pyrim-
idine ring of TDP would also undoubtedly change during the activation process. These
changes could lead to a disruption of the aromaticity and more indirectly influence the
energetics of TDP activation. The link between aromaticity and TDP activation has not
been investigated previously. Uncovering such a link will provide better understanding of
DXS and raise the question if this phenomenon is general for all TDP dependent enzymes
(e.g., TK, PDH, etc.).
Herein, a hybrid quantum mechanical/molecular mechanical (QM/MM) study is car-
ried out using the D. radiodurans DXS crystal structure197. The energy profile of the
DHM and WMM are computed to determine the most favorable activation mechanism.
Active site electrostatics are also probed to elucidate the stabilizing/destabilizing effects
that govern this process. Further, two metrics of aromaticity are employed to quantify
this effect and determine its role as a possible driving force in activation of TDP de-
pendent enzymes. In addition to the computational work, a kinetics study, utilizing a
coupled enzyme assay, was performed on mutant and wild-type forms of the D. radiodu-
rans DXS enzyme. As part of the mutagenesis work, we have re-examined the H434A
mutation; which is of particular interest in this study. Our study focuses on the KM and
kcat due to their relationship with substrate affinity and reaction turnover, respectively.
The combination of computational and experimental results helps bridge the gap between
bulk behavior and atomistic understanding; ultimately leading to new insights into this
unique enzyme.
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2.4 Methods
2.4.1 Computational Methods
The DXS active homodimer structure was used throughout this study. The crystal struc-
ture for the D. radiodurans DXS (PDB ID:2O1X)197 enzyme with TDP bound was pro-
cessed and parsed via www.charmming.org127. A TDP molecule can be broken down into
three moieties: a thymine-like pyrimidine ring, a pyrophosphate (residue name utilized
in the topology file), and a thiazolium ring(Figure 2.2). Parameters for all three of these
have been developed as part of the CHARMM General Force Field (CGenFF)184. Final
TDP parameters were thus obtained by connecting the respective components and mod-
ifying charges (see SI). Parameter validation was done with respect to the TDP crystal
conformation based on the RMSD (see SI).
Structural modifications were performed to ensure the active site Glu373 was proto-
nated in agreement with experimental evidence90,112. CGenFF and CHARMM22 protein
(C22) force fields119 were used throughout. The system was solvated in a rhombodo-
dechedron crystal structure and neutralized with KCl salt to a final concentration of
0.15M. The system was heated from 110K to 310K over 100ps and equilibrated for 200ps
at constant pressure (1atm) and temperature (310K). The total system size was then
reduced by removing all of the water and salt ions beyond 12A˚ from the surface of the
protein. The reduced structure was then QM/MM minimized, without applying cutoffs,
to a gradient tolerance of 0.002 kcal·mol−1·A˚−1. All QM/MM calculations employed the
Q-Chem4.0\CHARMM27,170,194 interface at the B3LYP/6-31G* level of theory13,68,105.
Additionally, the single link atom scheme was used to account for truncation of the QM
region and employed group electrostatic exclusions to prevent over polarization of the
QM region.
Reaction pathway calculations employed a combination of the replica path method
(RPATh) and harmonic distance restraints (RESDi)36,194,195. The RPATh method per-
mits the user to divide the system into discrete subsystems (replicas), which are allowed
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to change independently of the remaining “environment”. A subsystem was defined to be
6.5A˚ around the QM region, which was comprised of TDP, Glu373, His120, and His434
(Figure 2.4a, 98 QM atoms). The QM region for the WMM included a water molecule
(Wat9709) coordinating with the 4′-amino group of the pyrimidine ring of TDP and the
N of His434. Wat9709 was removed from the initial structure prior to QM/MM mini-
mization (vide supra) for the DHM. Two replicas of the subsystem were used to model
successive steps along the reaction coordinate (δ), which was defined as a linear combina-
tion of the bond being broken and the bond being formed (Figure 2.4b, 101 QM atoms).
The δ values were defined incrementally for each mechanism starting from the reactant
state. The DHM scanned a range of -3.0A˚ to 3.0A˚ in increments of 0.3A˚ with smaller
increments of 0.1A˚ used around the transition state (i.e., -1.0A˚ to 1.0A˚) to provide finer
detail. The WMM scanned a range of -1.1A˚ to 1.1A˚ in increments of 0.1A˚.
The Charge Perturbation Analysis (CPA)12,42,67,107 technique involves QM/MM single
point energy calculations where a single residue’s classical charge is scaled to zero to probe
its electrostatic contribution. ∆E is computed by taking the difference of the modified
(zero-charge residue) and the full QM/MM electronic energy: ∆ECPA = E
ZeroChargeRes
elec (QM/MM) -
EFullMMelec (QM/MM). CPA calculations were performed for the reactant state (RS) and
transition state (TS) of the DHM and WMM as determined by RPATh+RESDi calcula-
tions. The reactant state was the starting δ value for each mechanism while the TS cor-
responded to the point along the path with the highest energy. ∆∆ECPA = ∆ECPA(RS) -
∆ECPA(TS) provides insight into stabilizing/destabilizing electrostatic effects with respect
to RS and TS. CPA was performed on all 82 residues found within 5A˚ of the QM re-
gion for both mechanisms. To further characterize long range electrostatic changes, the
QM/MM dipole moments were calculated around the QM region for the RS and TS of
each mechanism. The QM/MM dipoles take into account the external charge contri-
butions of the MM region on the QM region. The calculations were carried out using
Q-Chem 4.0170 and initially visualized in IQmol with final rendering using PyMOL.
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Two metrics were employed to quantify aromaticity and gauge the level of signifi-
cance of it as a possible driving force of ylide formation: nucleus-independent chemi-
cal shifts (NICS)164 and aromatic stabilization energy (ASE)43,44. NICS directly mea-
sures the aromatic character of a compound35,39,43,164 while ASE reveals the stabiliza-
tion/destabilization that arises from the aromaticity of a compound1. Due to computa-
tional limitations, NICS calculations were performed on reduced versions of the RS and
TS subsystems. The reduced subsystems contained 232 or 235 atoms for the DHM or
WMM, respectively. The difference of 3 atoms being the absence of Wat9709 from the
DHM. Ghost atoms were placed perpendicular to the plane of TDP’s pyrimidine ring. Due
to the non-symmetric protein active site, the NICS(0) (ring center), NICS(1), and NICS(-
1) (atoms 1A˚ above and below the plane of the ring) will be reported herein10,35,44,98. All
NICS calculations were performed using Q-Chem 4.0170 at the B3LYP/6-31G* level of
theory13,68,105. ASE is typically computed via a reference homodesmotic reaction1,189. A
homodesmotic reaction must be defined such that equal numbers of each type of atom
(sp3, sp2, sp) and bond (sp3-sp3, sp3-sp2, sp2-sp2, etc...) exist in both reactants and
products189. All structures used in ASE calculations were optimized at the B3LYP/6-
311+G** level of theory. Energies for each molecule were corrected by subtracting out
their respective zero point energy obtained from subsequent frequency calculations.
2.4.2 Experimental Methods
Materials
TDP, pyruvate, G3P, DXP sodium salt, bovine serum albumin, and LB-broth were pur-
chased from Sigma Aldrich. NADPH was purchased from Alexis Biochemical, Ni-NTA
resin was purchased from Invitrogen, and β-mercaptoethanol (β-Me) was purchased from
Fisher. E. coli XL-10 cells, deoxynucleotide mix PCR grade, pfuUltra Hotstart DNA
polymerase, QuikChange II site directed mutagenesis kit and acetonitrile (HPLC grade)
were purchased from Agilent. The DNA vectors pET28a(+) and pET15b(+) and E. coli
BL-21 B(DE3) cells were purchased from EMD Biosciences. DNA sequencing services and
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primers were purchased from MWG operon. All the other reagents were of the highest
quality commercially available.
Cloning of D. radiodurans DXS and E. coli DXR
A synthetic, codon optimized D. radiodurans dxs gene with 5′-NdeI and 3′-XhoI restric-
tion sites in a pMK vector was purchased from Geneart (Germany). The dxs gene was
excised from the pMK vector and cloned into the NdeI and XhoI sites of a pET28a(+)
vector (kanamycin resistance) with an N-terminal His6-tag to yield the pET28a(+)-DXS
plasmid. Successful cloning of the D. radiodurans dxs gene was confirmed by DNA se-
quencing at MWG Operon.
A synthetic, codon optimized E. coli dxr gene with 5′-NdeI and 3′-BamHI restriction
sites in a pMK vector was purchased from Geneart (Germany). The dxr gene was excised
from pMK vector and cloned into NdeI and BamHI restriction sites of pET15b(+) vector
with a C-terminal His6 tag to yield the pET15b(+)-DXR plasmid. Gene insertion was
confirmed by DNA sequencing.
Production of the D. radiodurans DXS Mutants
Site-directed mutagenesis was carried out using the QuikChange II site-directed mutage-
nesis kit. Briefly, the mutagenesis mixture consists of 50-100 ng plasmid pET28a(+)-DXS
as a template, 1X PCR reaction buffer, 0.4 mM each of the forward and reverse primer,
0.25 mM dNTP mixture, 5 µL Quik solution, and 2.5 units of pfuUltra hotstart poly-
merase in a 50 µL reaction. The overlap extension method was used to produce the DXS
mutants that were difficult to create via site directed mutagenesis77. The sequence of the
mutant DNA was confirmed by DNA sequencing.
Assays for DXS Activity
We employed a DXS-DXR coupled assay to determine the wild-type and mutant DXS
enzyme activities. In this way, the DXS-dependent production of DXP is ultimately
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coupled to the oxidation of NADPH to NADP+ via the DXR enzyme. The solution for
the DXS-DXR coupled contained 100 mM HEPES pH 8.0, 100 mM NaCl, 1 mg/mL BSA,
1 mM TDP, 1.5 mM MnCl2, 2 mM β-Me, 0.15 mM NADPH, 0.2 mg/mL DXR, and
varying concentrations of pyruvate or G3P79. Steady-state kinetic experiments were
performed by varying pyruvate or G3P at a fixed saturating concentration of the co-
substrate. A DXS-DXR reaction solution was incubated at 37◦C for 5 min, the reaction
was initiated by addition of 358 nM DXS, and the progress of the reaction monitored
spectrophotometrically at 340 nm for the oxidation of NADPH. The DXS and DXR
employed in this assay were over-expressed and purified based on the methods presented
in the supporting information. Each sample was stored at -80◦C until used for the assay.
The steady state initial velocity for DXS measured at various concentrations of pyruvate
and G3P were fit to equation 1 (see SI for plots) using nonlinear regression analysis in
Sigma-Plot 12.0.
v =
Vmax[S]
KM + [S]
(2.1)
2.5 Results and Discussion
A central aim of this investigation is to determine and characterize the mechanism of
TDP activation in DXS (Figure 2.2). There are two hypothesized mechanisms acting by
a different GB: WMM (Wat9709) and DHM (His434). Though most TK enzymes are
thought to rely on a histidine residue as the GB, key structural differences and mutage-
nesis results suggest DXS might diverge from the majority of TK enzymes20,54,60,129,141.
The reactant state QM/MM minimized structures (Figure 2.4a, 2.4b) provides some
initial insight into this process. Coordination of the water oxygen to the Hn (2.0A˚,Figure
2.4b) suggests water could act as the GB. Further, the distance between Ho and N (1.8A˚,
Figure 2.4b) suggests that this could be the final destination of this proton. Alternatively,
in the absence of Wat9709, His434 directly interacts with TDP albeit more distantly
(4.2A˚, Figure 2.4a)197.
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Figure 2.4: Representations of the RS for DHM (a) and WMM (b). The dashed black
lines illustrate the proton transfer reaction.
To determine each mechanism’s feasibility, the RPATh+RESDi technique was em-
ployed and respective minimum energy pathways were computed. A plot of ∆E with
respect to δ (Figure 2.5) values illustrates the energetic favorability of the WMM over
the DHM. A δ value of 0.3A˚ corresponds to the TS of both mechanisms. The differ-
ence between barriers can partially be explained by a conformational change that occurs
during the DHM (Figure 2.6). This involves the movement of His434 into a conformation
more favorable for deprotonation of the 4′-amino moiety. His434’s movement induces a
strain in the protein backbone and perturbs the configuration of the local environment.
This change in configuration accounts for a portion of the energetic differences between
the WMM and DHM but does not provide a complete explanation. Further, a ∆E‡WMM
value of 22.7 kcal·mol−1 is considerably higher than one might expect for an enzyme
catalyzed proton transfer and cannot be explained by a simple conformational change142.
The reaction pathway calculations applied a restraint to the proton transfer involved
in the DHM or WMM. No other restraints were applied to the system. Upon examination
of structural changes during the reaction, a second proton was observed to spontaneously
transfer from E373 to the N1 atom of TDP’s AP ring in both mechanisms (Figure 2.7).
Since E373 was included in the QM region, the proton transfer occurred in response
to electronic changes encountered during each mechanism. The combination of the re-
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Figure 2.5: Minimum energy profiles computed for the WMM and DHM. The different
x-axes are used because of differences in the reaction coordinate ranges for WMM vs
DHM; both are associated with the same y-axis. The ∆E‡ are 22.7 kcal·mol−1 and 33.7
kcal·mol−1 for the WMM (gray circles) and DHM (black squares), respectively.
strained reaction path proton transfer and unrestrained E373 to N1 atom proton transfer
represents the tautomerization of the AP to IP state (Figure 2.3). The formation of
Figure 2.6: Representative conformational changes between the RS (yellow) and TS
(green) of the DHM.
the ylide state is dependent upon first forming the IP state. There is some debate in
the literature over the exact details of the IP state formation (vide supra)8,9,133,141. Most
studies propose an equilibrium between the AP, APH+, and IP TDP states (Figure 2.3)
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particularly for apo enzymes83. As highlighted in the introduction, the pKas of TDP’s
N1 atom and E373 residue (see SI and Introduction) are approximated to be close to
one another using experimental and empirically based computational techniques. The
combination of the pKas and observed responses from QM/MM calculations suggests a
concerted mechanism as previously thought. Additional studies are underway to more
fully address this unresolved question.
Figure 2.7: Illustration of the proton transfer from E373 to TDP’s AP ring during the
tautomerization reaction. (a) and (b) represent the reactant and product states, respec-
tively. While this figure only depicts the structures of the WMM, a similar response was
observed during the DHM.
The CPA method, which approximates electrostatic contributions of a single active
site residue, was used to determine the stabilizing/destabilizing effects of active site
residues as a function of both states (i.e., RS vs TS) and mechanisms (i.e., WMM vs
DHM). Negative ∆∆E values indicate that a particular residue is more stabilizing to-
wards the TS; whereas positive ∆∆E values show stabilization of the RS. From the 82
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∆∆EDHM ∆∆EWMM
K101 2.0 7.5
H51 -10.1 -1.2
K289 -12.3 -2.5
D430 -21.3 -10.8
Table 2.1: ∆∆E values for four residues of interest in the WMM and DHM. Negative ∆∆E
values indicate preferential stabilization of the TS; while positive ∆∆E show stabilization
of the RS preferentially. All values are in kcal·mol−1.
active site residues examined, there were 4 that showed substantive differences (Table
2.1). Residues found stabilizing the TS were D430, K289, and H51, and Wat10307. K101
were found to preferentially stabilize the RS. K101, H51 and D430 were found in a
Figure 2.8: Active site conformation of the residues discussed in the CPA results. Images
show both the RS (yellow) and TS (green). (a) illustrates the DHM while (b) shows the
WMM.
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catalytic triad-like configuration in the active site (Figure 2.8). It is unlikely that they
play a direct role in this reaction due to their distance from the site of activity (7.2A˚). A
cluster of water molecules were found to span the distance between the reaction site and
triad; which suggests an electrostatic role. K289 coordinates to the negatively charged
phosphate tail of TDP (Figure 2.8) and is highly conserved in D. radiodurans, as well
as other TDP dependent enzymes. In fact, most TDP dependent enzymes are found to
require a divalent metal ion and positive residues near the phosphate tail to anchor the
cofactor.
The magnitude of ∆∆EDHM values were consistently larger than the magnitudes of
∆∆EWMM values. This behavior is attributed to the structural change that the DHM TS
must adopt in order to position His434 for deprotonation of TDP’s 4′-amino group. The
increased TS stabilization for this mechanism suggests the enzyme is tuned to accom-
modate alternative activation routes although they may not be the most favorable. For
example, active site mutations are a common way that bacteria and other lower life forms
(i.e., those that rely on MEP pathway) can adapt to changes in chemical environments.
By tuning the DXS active site to stabilize TDP activation via varying general bases,
evolutionary fitness is maximized.
To better characterize long range electrostatic effects, QM/MM dipole moments for
the RS and TS for each mechanism were computed and visualized (Figure 2.9). The
RS dipole moments of both the WMM and DHM were essentially the same. Further,
WMM dipoles, both RS and TS, are indistinguishable (Figure 2.9b) whereas the DHM
TS dipole moment is significantly perturbed (Figure 2.9a). Again, this effect is attributed
to the conformation change His434 undergoes during the DHM and appears to be the
underlying source of DXS’s ability to stabilize non-water mediated TDP activation.
Herein, we also report experimental kinetics studies of pyruvate and G3P binding
and reaction in DXS and several DXS mutants (Table 2.2). For H434A, there exists
negligible increase in catalytic rate for pyruvate as well as G3P in comparison to wild-type,
respectively. KM values also slightly increased by 6.1 and 4.6 folds, respectively. G3P’s
negatively charged phosphate tail is thought to bind in a positively charged region of the
active site; which contains the polar H434 residue. Additionally, the negatively charged
pyruvate is thought to interact with the same positive region but, not as strongly197.
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Figure 2.9: Illustrated above are the computed RS (yellow) and TS (green) dipoles of the
WMM and DHM. (a) is the DHM and (b) is the WMM.
Therefore, the mutagenesis results suggest that the electrostatic effects that accompany
the H434A mutation have a clear destabilizing effect on substate binding while enhancing
turnover. This behavior is contrary to what would be expected if H434 is required for
initial TDP activation. Thus, the H434A mutant supports the conclusion favoring a
WMM for TDP activation.
Another interesting correlation between CPA and mutagenesis results is related to the
D430A mutant. As previously discussed, D430 is found in a electrostatic triad of residues
that includes K101 and H51 (Figure 2.8). While the kcat for D430A mutant remains rela-
tively unchanged, the KM for pyruvate and G3P increases 1.9 and 2.4 times, respectively.
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This behavior indicates a role in substrate binding rather than catalysis, similar to H434.
The corresponding residue in yeast TK (D477) has been studied previously135. D477 was
shown to a have a rather large effect on activity and substrate binding. In comparison,
DXS shows only a 50% loss of activity that is caused by decreased substrate affinity. This
speaks to the difference between DXS and other TK enzymes and highlights the need to
study this unique subclass of enzyme.
Pyruvate
KM (mM) kcat/KM (s
−1M−1) kcat (s−1) %WT
Wild-type 0.28 ± 0.03 2.6 × 104 7.4 ± 0.3 100
H82A 0.23 ± 0.02 1.7 × 103 0.38 ± 0.01 5.1
H304A 1.7 ± 0.5 5.8 × 102 0.90 ± 0.01 12.1
D430A 0.52 ± 0.5 1.4 × 104 7.2 ± 0.2 97.3
H434A 1.7 ± 0.1 5.9 × 103 9.9 ± 0.2 133.8
G3P
KM (mM) kcat/KM (s
−1M−1) kcat (s−1) %WT
Wild-type 0.05 ± 0.01 1.5 × 105 7.9 ± 0.4 100
H82A 0.03 ± 0.01 1.3 × 104 0.37 ± 0.02 4.7
H304A 0.08 ± 0.02 1.1 × 104 0.90 ± 0.1 11.4
D430A 0.12 ± 0.01 6.6 × 104 7.7 ± 0.2 97.5
H434A 0.23 ± 0.01 4.2 × 104 9.6 ± 0.3 121.5
Table 2.2: DXS steady-state kinetics data (wild-type and mutants) for both pyruvate
and G3P. %WT was determined by comparing the mutant kcat to the wild-type kcat.
Two histidine residues are in close proximity to each other (3.7A˚ between N atoms for
H82 and H304) and the center of activity (5.1A˚ and 5.7A˚ from the thiazolium C2 atom re-
spectively for H82 and H304) of DXS. Table 2.2 shows that the H82A and H304A mutants
produce catalytically defective enzymes resulting in only 2-12% kcat and kcat/KM values
when compared to wild-type. The loss of activity can be explained by their proximity to
the thiazolium C2 atom. These residues can assist in stabilizing the α-carbanion\enamine
intermediate following pyruvate decarboxylation (Figure 2.2, step 5).While activity in
these mutants is significantly retarded, detectable levels of activity are retained. This re-
tention might be explained by the proximity of these two residues to one another. Upon
the loss of one histidine, it is possible for the other His residue to recover partial function-
ality. There is one noticeable difference in the results of these two mutants. The H304A
KM for pyruvate has increased compared to the wild type; while KM value for H82A
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remain similar to the wild-type value. This indicates that while both residues are clearly
catalytically important, H304A protrudes into the pyruvate binding site and, therefore,
plays a role in binding; which can not be replaced by H82. Thus, accounting for observed
differences in mutant KM values for pyruvate.
Figure 2.10: Analysis for 18 ns of the unrestrained simulation of the 2O1X DXS structure
utilized in this investigation. (a) the distances over time for N of H434 to N4
′ of TDP’s
amino group. (b) shows the fluctuations for backbone (black), and side chains (grey)
for residues H51, K101, H124, K289, E373, D430, and H434. These residues represent
the QM region and key CPA residues previously discussed. (c) snapshot from the 18 ns
trajectory with H434 in proximity to the 4′-amino group. (d) is representative of H434
in the second conformation.
With these mutagenesis results, it became apparent that a longer simulation was
required to examine active site conformational dynamics. Thus, the 2O1X structure
was simulated for an additional 20 ns with the first 2 ns discarded (details found in
supplementary information). The trajectories were compared to the QM/MM minimized
RS. The distance between the 4′-amino group and the N atom of H434 revealed two major
conformations (Figure 2.10a). The first conformation lasts for ∼5.0 ns and has H434 3.5A˚
from the AP ring on average. The second conformation has H434 7.1A˚ from the AP ring
on average and remains throughout the simulation. The fact that the 2nd conformation
is stable for the majority of the simulation and places the histidine beyond the range of
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direct deprotonation of its 4′-amino group provides further support for a water mediated
mechanism. Additionally, the backbone and side chain fluctuations were calculated for
significant CPA residues ( e.g., E373 and H434, Figure 2.10b). The conformational change
of H434 to a position proximal to K101 and D430 accounts for the larger side chain
fluctuations of K101 and D430 (Figure 2.10). The introduction of H434’s imidazole would
force K101 and D430 to move in order to accommodate the bulky polar side chain. The
combination of the motion of these residues with H434 being the final resting place of the
proton abstracted from TDP’s amino group suggests a possible regulatory role for H434.
H434 could act as a shuttle involved in regenerating the TDP-ylide for further reactions
by displacing the abstracted proton onto D430. This perfectly aligns with experimental
results showing that the removal of this residue (H434A) slightly increases kcat, allowing
any proton transfer from TDP’s amino group to D430 to occur more rapidly via a water
mediated process (picosecond time scale) rather than the H434 side chain motion that
likely occurs on the nanosecond time scale.
DHM-RS DHM-TS ∆NICS
NICS(1) -7.1 -5.7 1.4
NICS(0) -5.0 -2.7 2.3
NICS(-1) -9.3 -6.7 2.6
Average 2.1
WMM-RS WMM-TS ∆NICS
NICS(1) -6.8 -4.7 2.1
NICS(0) -4.6 -2.2 2.5
NICS(-1) -8.8 -6.3 2.5
Average 2.4
Table 2.3: Calculated NICS values for the WMM and DHM RS and TS. The NICS(0)
values are taken from the center of the pyrimidine ring. The NICS(1) and NICS(-1) values
are points away and towards a proximal phenylalanine (F398), respectively. A comparison
set of benzene (-9.8) and cyclobutadiene (27.6) were computed to show reference aromatic
and antiaromatic values, respectively. The average ∆NICS values represent a 29.4% and
35.6% decrease in aromaticity for DHM and WMM, respectively.
TDP reactivity is clearly dependent on the surrounding environment, e.g., rate of
reaction increases a billion-fold when bound to an enzyme84. Several attempts to deter-
mine the underlying energetics have attributed this behavior to the strained ‘V’ shape
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TDP adopts upon binding25,26,82. Given the pKa changes this conformation induces, it is
surprising that the barrier to activation (i.e., proton transfer) is significantly higher than
expected; ∆E‡=22.7 kcal·mol−1 vs. 5-10 kcal·mol−1 for typical proton transfers142. One
possible cause of this is the loss of aromaticity that occurs during ylide formation. Addi-
tionally, overestimation of the barrier may be due to the inability to carry out free energy
simulations; nevertheless, the energy barrier difference is a more meaningful quantity
when seeking to differentiate two possible mechanisms.
To examine the former, i.e., aromaticity effects, both NICS and ASE were computed.
NICS calculations estimate the aromaticity of a molecule; negative NICS values indicating
aromaticity and positive NICS values antiaromaticity. Table 2.3 reports NICS results for
RS and TS of TDP activation via DHM and WMM. An average of the ∆NICS values
was used to quantify the relative change in aromatic character. Results indicate the AP
ring is aromatic in both the RS and TS with values close to those published for similar
pryimidine analogs1. However, the TS consistently shows lower aromatic character than
the RS; which supports our hypothesis of aromaticity regulating ylide formation.
Calculating the ASE for TDP’s AP state should provide additional information about
the importance of aromaticity in ylide formation. A homodesmotic reaction (Figure 2.11)
provides a reference for determining ASE. Thiamin serves as a model compound for this
purpose and represents the key components (e.g., 4′-amino and thiazolium moieties) of
TDP. Systems with positive values of ASE are considered to be aromatic, whereas those
with negative values are antiaromatic. ASE values are determined as the difference in
energies between both halves of the reference reaction (Figure 2.11). Thiamin has an ASE
Figure 2.11: Homodesmotic reaction used in evaluating the aromatic stabilization energy
for a model TDP.
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of 37.6 kcal·mol−1; which is again in close agreement with previously published results of
similar pyrimidine derivatives1.
Combining ASE values with the average decrease in aromaticity (i.e., ∆NICS, Table
2.3), we approximate the stabilization lost at the TS of each mechanism. Aromaticity
losses of 13.4 kcal·mol−1 and 11.1 kcal·mol−1 for WMM and DHM were computed, re-
spectively. Interestingly, we again observe the DHM TS being less destabilized when
compared to the WMM TS. This provides further evidence that DXS is well adapted
to stabilizing alternative mechanisms of TDP activation. Finally, when the total barrier
heights are considered it becomes clear that the loss of aromaticity plays a major role in
TDP activation and the initial step of isoprenoid biosynthesis.
2.6 Conclusion
The ∆∆E‡ of 10.0 kcal·mol−1 difference between the WMM and DHM mechanisms in-
dicates the WMM is the energetically favorable route for ylide formation in DXS. The
RPATh+RESDi results seem to suggest the mechanism of proton transfer acts in a con-
certed fashion proceeding via the tautomeric route between the AP and IP state. Further
investigation is ongoing to confirm the relative energetics of a step-wise versus concerted
mechanism.
CPA results were indicative of H434 playing a role in long range electrostatic stabi-
lization; which is more clearly illustrated upon examination of the RS and TS active site
dipole moments. Mutagenesis studies performed reveal H434 to play a role in substrate
binding but not likely a direct role in catalysis. The H434A mutant results reinforce the
CPA results. Additionally, a D430A mutant revealed a lower catalytic significance for
DXS in comparison to the corresponding yeast TK mutant135; again illustrating mechanis-
tic differences. Furthermore, H82A and H304A DXS mutants showed significant decreases
in activity (2-12% of wild-type). Given their proximity and retention of measurable ac-
tivity, it is likely these residues function as back-ups to each other. This comports nicely
with computational results that indicate DXS is well suited to functioning via alterna-
tive mechanisms (i.e., different general bases), something that would offer a significant
evolutionary advantage.
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∆E‡WMM is significantly higher than what might be expected for a relatively simple
proton transfer142. CPA results could not account for such behavior. However, upon ex-
amination of the 4′-amino moiety, it was evident from structural changes that aromaticity
may be changing. The results of NICS and ASE calculations showed that indeed the AP
ring was losing aromaticity. If the aromatic contribution is taken into consideration, the
new ∆E‡WMM would be closer to 8.5 kcal·mol−1; which is in the range of similar reactions.
This clearly shows that loss of aromaticity plays a key role in controlling activation of
TDP in DXS. Further, restoration of this aromaticity upon intramolecular proton trans-
fer from the C2 of the thiazolium ring to the 4′-amino group should ultimately drive the
final ylide formation.
2.7 Supporting Information (SI)
The following can be found in Appendix A: PDB files for the transition states of the
WMM and DHM; link atom details for QM/MM reaction path calculations; CPA results;
topology and parameter files for TDP; methods for the over-expression and purification
of DXS and DXR; steady-state initial velocity plots with varying concentrations of G3P
and pyruvate; details about 20ns simulations; results of PROPKA3.1 calculations on DXS
Chain A.
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Chapter 3
Computational Examination of the Magnesium Ion Binding Modes of
1-Deoxy-D-xylulose 5-Phosphate Reductoisomerase
3.1 Introduction
There exists a vast and varied class of natural products derived from two five-carbon iso-
prene precursors, isopentenyl diphosphate (IDP) and dimethylallyl diphosphate (DMADP),
and serve several essential roles for all living organisms144. These are generally known as
Isoprenoids. The broad variety of uniques molecules comprising this family are derived
via a combination of elongations, rearrangements, cyclizations, and oxidations utilizing
IDP and DMADP in various combinations38. A few of the important biological roles
filled by isoprenoids are prenyl lipids in archaebacteria46, sterols in eubacteria and eu-
karyotes128, light-harvesting pigments such as carotenoids, electron transport carrier such
as ubiquinone and menaquinone, and several growth and development regulators (Figure
3.1)161. Additionally, there are several known herbicides or herbivore repellents identified
to be isoprenoids48.
The biosynthesis of the IDP and DMADP building blocks were originally thought
to derive from a single enzyme pathway (Figure 3.1132. This pathway is known as the
mevalonate dependent (MVA) pathway; which was named after the key committed inter-
mediate formed from the condensation and reduction of 3 acetyl-CoA molecules producing
mevalonic acid (or mevalonate in ionic state). Continuing discrepancies in the results of
isotope labeling studies30,31,57,140,205 led several researchers to postulate the existence of
a second yet unidentified pathway. Efforts by researchers such as Rohmer, Arigoni, Lich-
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Figure 3.1: Illustration of the two biosynthetic pathways of IDP and DMADP and rep-
resentative isoprenoids produced from the building blocks
tenthaler, and Seto, etc. eventually discovered a new pathway completely distinct from
the MVA pathway32,91,111. Initially, the pathway had names reflecting the distinction
between MVA and the novel, mevalonate-independent or non-mevalonate (NMA) path-
way. Seven enzymes catalyzing 8 reactions comprise the NMA pathway132. Rohmer and
co-workers159 established the formation of 1-deoxy-D-xylulose 5-phosphate (DXP) via
the decarboxyl condensation of pyruvate and glyceraldehyde-3-phosphate (G3P). DXP
is additionally utilized as an intermediate for the biosynthesis of vitamins B1 and B6 as
well as isoprenoid biosynthesis114,160. Therefore, DXP is required and considered the first
step of the pathway but not the committing step in the NMA pathway. The succeed-
ing reaction catalyzed by DXP reductoisomerase (DXR) bares the distinction of being
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the committed step in the NMA pathway. The product of this reaction, 2-C-methyl-D-
erythritol 4-phosphate (MEP), lends its name to the pathway, as the NMA pathway is
frequently referred to as the MEP pathway100.
DXP reductoisomerase catalyzes a carbon-skeleton rearrangement of DXP and sub-
sequently reduced. DXR activity requires a divalent metal cation cofactor and NADPH
co-substrate. Out of the divalent metal ions attempted, DXR is activated by only Mn2+,
Co2+ and Mg2+, in decreasing order respectively3,94,102,118,179,202. Additionally, NADH
was tested in place of NADPH as the co-substrate with DXRs derived from E. coli,
M. tuberculosis and S. leopoliensis. The results were a decrease in activity in some cases
as much as a 100-fold decrease in activity. Decreased affinity is responsible for the lost
activity primarily due to the loss of the 2′-phosphate of NADPH. Therefore, the phos-
phate is a binding determinant and not likely directly involved in catalysis since kcat was
unaffected3,179.
Results of isotopic labeling studies demonstrated the required isomerization proceed-
ing via a C3/C2 bond transition. The isomerization results in an aldehyde intermediate
2-C-methyl-D-erythrose 4-phosphate (MEsP), which is subsequently reduced on the re
face of MEsP by the C4 pro-S hydride of NADPH4,5. The proposal of this intermediate
was originally based on analogy to ketol-acid reductisomerase (KARI), which catalyzes
a similar reaction during the biosynthesis of branched-chain amino acids. As with the
KARI reaction, the MEsP aldehyde intermediate has never been directly detected50,100,179.
Several attempts have been made to isolate the aldehyde intermediate with no success.
These results suggest the intermediate might be more transient than originally thought or
very tightly bound prior to NADPH reduction78,179;which has been similarly proposed for
KARI50. Rohmer and co-workers produced the first compelling evidence supporting the
aldehyde intermediate theory by introducing exogenously synthesized MEsP and demon-
strating kinetic competency. When incubated with DXR in the presence of NADPH and
Mg2+ or Mn2+, a factor of 4 and 1.6, respectively, increase in conversion to MEP was
observed. While the oxidized coenzyme was present, a 7% conversion of MEsP to DXP
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was detectable37. Additionally, the Km for MEsP was found to be greater than DXP
by a factor of 4 and 1.6 in the presence of Mg2+ or Mn2+, respectively. The argument
has been made based on these values against the tight-binding of MEsP. This is flawed
though since Kd and Km are only equal when substrate dissociation is rapid
78,137.
Despite the overall similarities of DXR- and KARI-catalyzed reactions, amino acid
differences suggest different mechanism of action37,49,95. Three mechanisms were pro-
posed to explain the carbon-skeleton rearrangement: 1) an α-ketol rearrangement, 2) a
retro-aldolization/aldolization, and 3) a sequential 1,2-hydride and 1,2-methyl shift64. A
dismissal of the third mechanism was accomplished based on 13C-glucose and 13-DXP
incorporation studies3,72. Therefore, further investigations looked to distinguish between
the remaining α-ketol rearrangement or retro-aldol/aldol mechanism (Figure 3.2).
The retro-aldol/aldol mechanism should form 2 putative intermediates of glycoalde-
hyde phosphate and the enolate of hydrxyacetone. If these intermediate could be detected
during or following the reaction, it would provide strong evidence in support of the retro-
aldol/aldol mechanism. Several attempts were made with no success58,78,104. Though the
lack of detection is consistent with both mechanisms as the results can be explained as
the intermediates fragments are tightly confined to the active site. Additionally, these
putative fragments could be so transient, they never truly form. Subsequent, experiments
have tended to favor the retro-aldol/aldol mechanism, such as the modification or removal
of the C4 hydroxyl group. The α-ketol rearrangement doesn’t require the C4 hydroxyl
group and therefore any turnover would support. Though turnover was not observed for
1,4-dideoxy-D-xylulose 5-phosphate,the Ki values similar to the Km indicates a depen-
dence on the C4 moiety for turnover but not binding. The C4 epimer and fluorinated
version of DXP produces similar results143,193. Due to the relatively good binding of these
modified ligands, the retro-aldol/aldol mechanism is favored.
The analogues studies have provided some significant evidence in support of the retro-
aldol/aldol mechanism over the α-ketol rearrangement. Kinetic isotope effects (KIEs)
provide a means of further probing the mechanism. In order to differentiate between
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Figure 3.2: The above illustration compares the steps for the α-ketol rearrangement and
retro-aldol/aldol mechanisms in a side-by-side view. Each concludes in the aldehyde in-
termediate 2-C-methyl-D-erythrose 4-phosphate (MEsP), which is subsequently reduced
by NADPH to form the 2-C-methyl-D-erythritol 4-phosphate (MEP) product.
the two mechanisms, α-secondary KIEs were measured for [3-2H]- and [4-2H]-DXP. The
α-ketol rearrangement predicts a shift from sp3 to sp2 at the C3 position while the C4
position remained sp3, which translates into KIEs>1 and unit KIE values, respectively.
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In contrast, the retro-aldol cleavage both C3 and C4 undergo changes from sp3 to sp2 with
normal KIE values (KIE>1)131. The results of 1.04 for [3-2H] and 1.11 for [4-2H]-DXP
supports the retro-aldol/aldol mechanism. When compared to muscle aldolase, which
has a similar mechanism, the lower KIEs are thought to reflect the partially rate-limiting
rearrangement or an early transition state131. Finally, a 2D [13C,1H]-HSQC NMR based
technique was used to analyze 1313 KIEs. The method measures the reactive competition
between light and heavy C substrates in the same mixture with the enzyme. The ratio
of 13C/12C represents the KIE. The ratios were measured for 2-, 3-, and 4-13C with
results of 1.0031, 1.0303 and 1.0148, respectively120. The sigmotropic rearrangement
would result in large changes at all locales while retro-aldol predicts larger changes at
the C3 and C4 position with little effect on the 2C position. The results of these KIE
experiments supports the retro-aldol/aldol mechanism as the most likely mechanism.
The only major issue left to challenge the retro-aldol/aldol mechanism is the failure
to detect the putative hydroxyacetone and glycoaldehyde intermediates. Currently, the
best explanation revolves around the tight binding of these intermediates and/or the
molecules exist in such a high energy state, they aren’t around long enough to be a true
intermediate132.
Figure 3.3: Illustration of the C2-C3 and C3-C4 binding modes in the reactant state.
These structures were utilized for the purposes the replica path calculcations as the
starting point.
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The retro-aldol mechanism was originally proposed with the metal ion coordinated
between the C2-C3 hydroxyl groups. Results of incubating DXR with Mg2+, NADPH
and DXP in the presence of 18O-labeled water to explore the incorporation of the isotope
into MEP109 dispute this proposal. Retro-aldol/aldol mechanism produces carbonyls,
if transiently, at each position during the reaction, thus allowing for solvent exchange
at the C2, C3, and C4 positions of DXP. Since the only hydroxyl affected was the C2
of DXP, there had to be a protective effect at the C3 and C4 positions. Coordination
of the divalent ion would act as protection from solvent exchange, therefore the results
suggest a C3-C4 binding mode. This binding mode helps to explain the tight binding
of both fragments since the retro-aldol cleavage occurs along the C3-C4 bond74,118,172,178.
During the bond breaking and subsequent C2-C4 bond forming steps, the Mg2+ would
remain coordinated to both fragments inhibiting release. It is still possible to interpret
the results of these experiments in support of the C2-C3 binding mode. The Lewis acid
characteristics of the metals would increase the electrophilicity of the C2 carbonyl thus
promoting hydration. Furthermore, the transiency of the intermediates may explain the
lack of solvent exchange. Exchange of the C1 or C3 oxygen atoms requires the rate of
on-enzyme hydration to rival rates of hydride transfer and aldolization132.
Examining the energetics of the metal binding modality will be the focus of this
work. Mac Sweeney et. al. published a crystal structure of E. coli DXR (PDB:1Q0Q)
with DXP and NADPH bound in the active site118. The experimental results published
to this point provide strong support for the retro-aldol/aldol mechanism being the most
likely reaction mechanism, so it was decided to focus on this pathway for our calculations.
In particular, we focused on the retro-aldol calculation, which is thought to be the true
limiting step of this reaction. The putative intermediates are even thought to not be
proper intermediates but possibly transition states. QM/MM techniques were utilized
to compute the free energy surface of the retro-aldol reaction with the metal ion in the
C2-C3 or C3-C4 position.
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3.2 Computational Methods
The crystal structure published by Mac Sweeney et. al. (PDB:1Q0Q) was utilized for
all calculations in this paper118. Although, DXR is generally found to be in a homod-
imer in solution, there is no evidence currently supporting catalytic interdependence of
active sites. Thus, allowing up to focus on a single monomer. The structured was parsed
utilizing www.charmming.org127. Parameters for DXP were built based on similar struc-
tures already found in the CHARMM General Force Field (CGenFF)184. The necessary
bonds were added based on the most similar structures and the charges were corrected
via quantum mechanical calculation. Final validation was performed utilizing the crystal
structure as the comparison.
The protein was built and E234 was protonated based on values determined by
ProPKA3.1 (see Appendix B)138,175. CHARMM22 protein and CGenFF force fields were
used throughout these calculations119. A Mg2+ ion was built separately and added to
the composed enzyme. The ion was brought into C2-C3 and C3-C4 orientation via use of
the harmonic distance restraint (RESDi) while fixing the rest of the system followed by
an unrestrained minimization. The system was solvated in a rhombododechedron crystal
structure and neutralized with KCl salt to a final concentration of 0.15M. The system
was heated from 110K to 310K over 100ps and equilibrated for 200ps at constant pres-
sure (1atm) and temperature (310K). The total system size was subsequently reduced to
cut down on computational costs in the following QM/MM calculations by removing all
waters/ions beyond 12A˚ from the protein surface. The reduced structure was treated
to a QM/MM minimization without cut-offs to a tolerance of 0.002 kcal·mol−1·A˚−1.
All QM/MM calculations employed the Q-Chem4.0\CHARMM27,170,194 interface at the
B3LYP/6-31G* level of theory13,68,105. Additionally, the single link atom scheme was used
to account for truncation of the QM region and employed group electrostatic exclusions
to prevent over polarization of the QM region (23 atoms)167. The QM region was defined
as the D231, MG, and DXP only. The NADPH molecule was excluded because it is not
thought to play a role in the skeletal rearrangement.
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Reaction path calculations were performed using the Replica Path (RPATh) in com-
bination with RESDi values to define the steps along the reaction coordinate36,194,195.
RPATh allows the user to define a subsection of the structure which will be duplicated
into replicas. These replicas are free to react normally as the reaction progresses while
the larger system is constrained thus cutting down on the computational costs. The
replicas utilized in these calculations were included the QM region and a buffer region
of 6.5A˚ around the QM section. For our purposes, two replicas were utilized. In order
to provide a buffer from the constrained system, the replicas were defined as all residues
within 6.5A˚ from the QM region. One replica was incrementally progressed along the
reaction. This was performed by defining two reaction coordinates (δ1, δ2); which were
defined with reference to reaction component being controlled.
δ1 = Bond−BreakingC3−C4; δ2 = Bond−BreakingO4−H9 − Bond−FormingH9−OE2
(3.1)
As the retro-aldolization is composed of two parts, δ1, corresponding to the breaking
of DXP’s C3-C4 bond, could be easily be defined while δ2, corresponding to the depro-
tonation of the C4 hydroxyl by residue D231, was defined as a linear combination of
distances. A two-dimensional energy surface was produced with respect to these reaction
coordinates. While the progression along δ2 was easily defined as beginning at -2.0 (re-
actant state) and ending at 2.0 (intermediates) as an assumption like previous work, the
path of δ1 was more difficult. Since δ1 refers to a single bond breaking, the C3-C4 bond
of DXP was elongated by 2.0A˚. δ2 was progressed in 0.2A˚ increments and δ1 was allowed
0.1A˚ increments for a 21x21 point 2D surface. After the completion of these calculations,
normal mode analysis was utilized to identify the reaction steps corresponding to states
of interest (“products”)180. This was performed by QM calculations utilizing Q-Chem
as “freq” jobs. The output frequencies were analyzed for unique asymmetric vibrations
corresponding the changes desired.
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3.3 Results and Discussion
The first response to the complete 2D-energy surface indicates our initial ranges for the
reaction coordinates may have been too broad. Both the C2-C3 and C3-C4 show a range
of values produce very strained structural states. A few of these values were repeated
to verify with similar results, therefore the rest of the work focused on results prior
to δ2=0.8-2.0 for C2-C3 and δ2=1.2-2.0 for C3-C4 calculations. The structures present
structures representing over extended CO bonds and massively contorted structures.
Before continuing discussions of the energy results, it is important to discuss the
identification of the “products”; which correspond to the putative intermediates between
the retro-aldol and aldol steps of the DXR reaction. Systems with unique normal modes
were found at δ1;δ2=3.40;0.60 for C2-C3 coordinated state and δ1;δ2=3.40-3.60;1.00 for
the C3-C4 metal coordination. This results supports the proposal to exclude the results
mentioned previously.
Figure 3.4: Two-dimensional energy surfaces with outlier values removed. With the
outliers for the C2-C3 (image (a)) and C3-C4 (image(b)) removed from the surface plot,
the details are more easily observed. The valley in the top right of image (b) might
indicate a step-wise mechanism.
The results of the reaction path calculations (Figure 3.4) reveal some distinct differ-
ences between the binding modes. While the C3-C4 binding mode has distinct peaks
and valleys, the C2-C3 surface is ever increasing (Figure 3.4a). This result is not really
grounds for dismissal of the binding mode. As the “products” of the retro-aldol reac-
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Figure 3.5: One-dimensional representation of the center path across the two-dimensional
energy surfaces for the C2-C3 and C3-C4 binding modes.
tion are, in actuality, intermediates or more likely transient transition states during the
skeletal rearrangement phase of the DXR reaction. Both binding modes conclude at high
energy states (33.0 kcal·mol−1 and 30.9 kcal·mol−1 for C2-C3 and C3-C4 binding modes,
respectively).
For easier comparison, scatter point plots of pathways representing the best path be-
tween points were produced (Figure 3.5). The results suggest the binding modes to be
rather similar. The barrier energies are 36.0 and 37.6 kcal·mol−1 for the C2-C3 and C3-
C4 mode, respectively. So overall, the energetics of the C2-C3 compared to C3-C4 isn’t
sufficient to address the question binding modes. A structural comparison of the “prod-
ucts” in conjunction with the energetics makes for a different outcome. The retro-aldol
reaction needs a deprotonation to activate the breaking of the C3-C4 bond producing
the hydroxyacetone enolate and glycoaldehyde phosphate “products”132. The base is
proposed to be the D231 residue found in proximity of the DXP hydroxyl groups, which
was controlled by the δ2 reaction coordinate. Figure 3.6 illustrates the “products” states
of each binding mode. The C3-C4 binding mode (Figure 3.6b) are a clear representa-
tion of the intended hydroxyacetone enolate, glycoaldehyde phosphate and protonated
D231 residue “products”. The “product” state for the C2-C3 binding mode (Figure 3.6a)
reveals an intermolecular protonation of the phosphate group despite the presence of a
59
restraint directing proton transfer. There are two possible explanations for this differ-
ence configurations. The C3-C4 binding mode held the C4 hydroxyl group in a favorable
position for deprotonation by the D231 oxygen. Secondly, the metal, acting as a lewis
acid, could have further polarized the O4-H bond, thus promoting deprotonation by the
glutamate.
Figure 3.6: The final structures of “products” for the retro-aldol reaction are the hydrox-
yacetone enolate and glycoaldehyde phosphate at the bottom of the two images above.
Image (a) above represents the C2-C3 binding mode that results in a intermolecular pro-
tonation of the phosphate group and preferential coordination with the C2-C3 oxygens.
On the right, image (b) is the C3-C4 binding mode which produced the desired products
and protonation states.
Along with the possible structural highlights for the mechanism, figure 3.6 illustrates
another key difference in the binding modes. Namely, the position of the metal ion after
preparation and RPATh calculations. While the magnesium remains straddling the O2
and O3 atoms of the C2-C3 mode (Figure 3.7a,c), the C3-C4 binding mode actually
transitions into an all oxygen coordination (Figure 3.7b). The conformational change
occurs spontaneously after the heating and equilibration phases of the build phase. Figure
3.7 reveals the differences in coordination between the pre- and post-equilibration steps
for each binding mode. Figure 3.7b shows the Mg2+ to rest 2.76 A˚ from the O2 atom prior
to equilibration, which likely represents a local minimum on the energy potential. After
the injection of energy from heating and equilibration, the distance from the O2 atom
reduces to 2.31 A˚. The conformational change observed between these steps occurred
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Figure 3.7: Pre-equilibrium and post-equilibrium for for each binding mode. Images
(a) and (c) represent the C2-C3 binding mode pre-equilibration and post-equilibration,
respectively. Images (b) and (d) represent the C3-C4 binding mode pre-equilibration
and post-equilibration, respectively. The side-by-side comparison highlights the changes
made.
with no restraints on the system. In contrast, the C2-C3 structures show no interesting
in reaching out the O4 atom of DXP. The post-equilibrated structure looks like what one
might expect. The originally minimized structure shows some leveling out between the
coordination bonds.
The putative intermediates, hydroxyacetone enolate and glycoaldehydephosphate, and
reaction intermediate, MEsP, have never been observed directly78,179, which is the remain-
ing hope for the α-ketol rearrangement mechanism. An explanation is the tight binding
of the reactants in the active site104. This spontaneous coordination to all DXP oxygens
might be further support for the tight binding hypothesis. While the C2-C3 binding
mode would only effect the binding of the hydroxyacetone intermediate, the glycoalde-
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hyde phosphate might actually be able to leave the active site. Additionally, an all oxygen
coordination might aid in the subsequent aldolization by holding all the intermediates
together and aiding in stabilizing the C2-C4 bond.
As previously mentioned, the C3-C4 energy surfaces have values with mechanistic im-
plications. Generally, the retro-aldolization requires a deprotonation of the C4 hydroxyl
group, and is thought to occur concurrently with the C3-C4 bond breakage (Figure 3.8c).
The energetics displayed during these calculations are the first hints of a step-wise retro-
aldol reaction beginning with the proton transfer from a highly polarized hydroxyl group
and proceeding to the C-C bond breakage. The other valley corresponding to C-C bond
breakage occurring first does not contain any structures with unique normal mode fre-
quencies, so this valley is probably an outlier in the data. Figures 3.8a,b are scatter point
plots of each proposed step (figure 3.8c, respectively. The ∆E‡ for the deprotonation of
30 kcal·mol−1 is considerably higher than one might expect. Therefore, the ∆E‡ indicates
the deprotonation as the rate-limiting step. The relatively high energy of the deproto-
nated state produces a reduced ∆E‡ to the final retro-aldolization “products” produced
by C3-C4 bond breakage. These results are far from conclusive but provide a new area
of further study.
3.4 Conclusion
The energetics of the two binding modes suggest a preference for the C3-C4 binding mode
over the C2-C3 binding mode. It is a slight difference of 2.1 kcal·mol−1; which means the
energetics aren’t definitive. The combination with the fact the C2-C3 “products” show
an intermolecular proton transfer suggests the C2-C3 binding mode to be unfavorable.
In addition to the energetics, configurational differences between the binding modes
provide further evidence in support of the C3-C4 binding mode. The spontaneous shift
of the C3-C4 mode into a C2-C3-C4 mode enhances the arguments for DXR strongly
binding the intermediates; which explains why they haven’t been directly observed. Re-
action assistance provided by the expanded binding mode could explain the formation
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Figure 3.8: Image (a) is the scatter point plot for the deprotonation step while image
(b) is the C3-C4 bond breakage. The new step-wise process and old concerted process
is illustrated in image (c) with a quick reference to the 2D energy surface for the C3-C4
mode retro-aldol reaction.
of the desired “products” unlike the C2-C3 while holding the intermediate in proximity
necessary for the aldolization. This aldolization assistance could provide further evidence
these intermediates being truly transition states.
Further work should start with analyzing the changes in active site contributions over
the reaction. The mapping of the aldol reaction should be performed starting at the
“product” state of the retro-aldol reaction for both binding modes to see if there is a
change in preference between the stages of the skeletal rearrangement.
3.5 Supporting Information (SI)
The following can be found in Appendix B: The ProPKA3.0 results of crystal structure
for DXR produced by MacKerrell (PDB:1Q0Q).
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Chapter 4
Conclusion and Future Work
The work shown in this document represent the initial steps in gaining understanding of
the reactions involved in the NMA pathway for Isoprenoid biosynthesis. The work on
1-deoxy-D-xylulose 5-phosphate (DXP) synthase (DXS) focused on the deprotonation of
the N4 atom of the thiamine diphosphate (TDP) cofactor, which occurs in preparation
of the formation of the ylide via deprotonation of the C2 atom. This step highlights
the significance of QM/MM reaction path calculations. Work similar to this can provide
insights into reaction steps of an enzyme or even a portion of a step. Kinetics can provide
similar insights but are dependent on the step of interest being the rate-limiting step,
which provides no assistance with DXS and other TDP dependent enzymes. The ylide
activation step is required for activity but happens at the rate of diffusion so experimental
practices are currently ineffective. By utilizing computational techniques, it is possible
focus on pieces of a reaction and tweeze out pieces of information of significance. Both
experiments in this document deal with half of a reaction commonly referred to as a
single reaction because they can’t be measured experimentally.
4.1 1-Deoxy-D-xylulose 5-Phosphate Synthase Summary and Conclusion
The mechanism of DXS consists of 3 major pieces: ylide activation, pyruvate binding,
and pyruvate decarboxylation couples with transferral of acetyl group to glyceraldehyde-
3-phosphate (G-3-P). The conclusion is the production of DXP; which is utilized in the
production of the isoprenoid precursors of isopentenyl diphosphate (IDP) and dimethy-
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lallyl diphosphate (DMADP). The rate-limiting step of the reaction is the pyruvate step.
The ylide formation is thought to happen at the rate of diffusion but is required for
enzymatic activity since the ylide acts as the reactive center for the enzyme. Prior
to activation, a deprotonation happens at the N4 atom of the TDP pyridinium ring
producing a tautomeric transition between the 4′-aminopyrimidine (AP) state to the
1′,4′-iminopyrimidine (IP) state. The identity of a general base was unknown which
could not be easily determined using experimental techniques. A water-mediate mecha-
nism (WMM) or direct histidine mechanism (DHM) mechanisms were proposed primarily
comparison with the other enzymes sharing sequence and structural similarities to other
TDP-dependent enzymes and transketolases, in particular. While the active sites of this
family of enzymes have a high degree of similarity, the recent discovery of an enzyme
deplete of acid/base residues in the active site and a transketolase lacking the requisite
histidine provided impulse to investigate DXS further. A reaction coordinate, define as
bond-breaking minus bond-forming, was used to incrementally change the system between
the reactant and product states
The WMM proposal was found to be preferential by a 11 kcal·mol−1 difference in
barrier heights. Computational results can be used in tandem with experimental results
to help explain or reinforce conclusions made based on the experimental work. A H434A
mutant revealed an effect on substrate binding while not effecting turnover. Thus, H434
was proposed not play a direct role in catalysis; which was supported in computationally
via charge perturbation analysis. The charge of the H434 residue was artificially turned
off and the result compared to the active site when the charge was on. The shift in the
dipole resulting from this change illustrated the significance of this residue on long range
electrostatics but no direct role in catalysis. Thus, the experimental work was bolstered
and explained by the computational results.
Utilizing computational techniques, it is possible to investigate contributing factors
otherwise inaccessible through experimental methods. The ∆E‡WMM was significantly
higher than what would normally be expected for a simple proton transfer. A value of
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22.7 kcal·mol−1 for the WMM path vs 5-10 kcal·mol−1 for representative proton transfers
suggested some significant contributions. The deprotonation of TDP’s N4 atom produces
a tautomerization from the AP state to the IP state, which we realized interrupts the
aromaticity of the pyrimidinium ring. There is no method for directly computing the
change in aromaticity in an enzyme reaction. There is a method for determining the
aromaticity of the base TDP molecule and another for determining the percent change
in aromaticity in reaction. By combining these methods, it was revealed by taking into
account the change in aromaticity the ∆E‡WMM would be closer to 8.5 kcal·mol−1. The
new value being closer to values previously published supported the conclusion of aro-
maticity playing a part in higher barrier energy. The higher energetic position of the
IP state might also act as a driving force in the deprotonation of TDP’s C2 atom and
production of the ylide required for TDP-dependent activity.
4.2 1-Deoxy-D-xylulose 5-Phosphate Reductoisomerase Summary and Con-
clusion
When the work began on 1-deoxy-D-xylulose 5-phosphate reductisomerase (DXR), there
was much more of a debate in the literature over the last two mechanisms, α-ketol
rearrangement or retro-aldol/aldol mechanism. The reduction by NADPH has been
pretty well understood since the enzymes initial characterizations. Along the way, papers
were published with secondary kinetic isotope effects (KIEs) which supported the retro-
aldol/aldol mechanism with the only remaining hope for the α-ketol rearrangement was
the refutation of the putative intermediates of the retro-aldol/aldol mechanism, namely
hydroxyacetone enolate and glycoaldehyde phosphate. Since the lack of direct observa-
tion could be explained with a relatively simple assumption of being tightly bound in
the active site requires less assumptions than trying to produce complicated assumptions
to explain KIEs, Occam’s razor tentatively rules out the α-ketol rearrangement in favor
of the retro-aldol/aldol mechanism. So, the work was refocused on a new question per-
taining to the binding of the Mg+2 ion. Previously, it was thought that the metal bound
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across the C2-C3 bond coordinated by their bound oxygens, but the same secondary
KIEs shed light on the possibility of a second option. This option being bound across the
C3-C4 bond via their oxygens. Besides explaining the observed KIEs, it would help to
explain the lack of finding any intermediates since the metal would actually stretch over
both intermediates instead of just one like in the C2-C3 mode.
The mechanistic work turned to helping to answer the binding mode question. Initial
calculations attempted to utilize a single restraint as was done in the DXS mechanism.
A single restraint was found wanting though. The results consistently produced highly
strained configurations. In order to have better control, a second reaction coordinate was
employed. The coordinates controlled related to the C3-C4 bond breaking and proton
transfer from DXP O4 hydroxyl to a carboxyl atom of a glutamate residue 231. Since
the first coordinate was a bond breakage, the δ1 was just stretched from 1.60A˚ to 3.60A˚
with 0.1A˚ increments. Similar to that of DXS, the proton transfer was a combination of
the O4-H9 bond breaking and the H9-OE2 bond forming starting at the reactant state
and progressing to the positive opposite value (i.e. -2.0A˚ to 2.0A˚) over 0.2A˚ with the
expectation the the final value would be shorter than the final 2.0A˚ mark.
The 2D-surfaces produced an ever increasing field for the C2-C3 binding mode while
the C3-C4 binding mode had contours of interest for the retro-aldol reaction. The reaction
consists of a deprotonation and C-C bond breakage producing the putative intermediates.
Usually considered to be concerted, the C3-C4 energy surface has a valley at a point
corresponding to the proton transfer progressing while the C-C breaking hadn’t begun.
Proposing the possibility of a step-wise retro-aldol process might be a possibility. The C2-
C3 surface lacks any signs suggesting this as a possible conclusion. Both of the final states
were found to have comparatively high energies of 30.9 kcal·mol−1 and 33.0 kcal·mol−1
for the C3-C4 mode and C2-C3 mode, respectively. In addition to the energetics, the
structure of the C2-C3 final state has a proton transferred to the phosphate tail of DXP
instead of the D231 carboxyl group despite the restraint directing the other way. It is
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possible the metal ion plays a role in preferential conformation stability and electron
stabilization of the transition state through hydroxyl bond polarization.
Additional structural differences indicate a preference for the C3-C4 binding mode.
Upon equilibration, this binding mode spreads across the C2-C3-C4 oxygens thus helping
to coordinate the entire molecule. The additional binding would support the claims of
tight binding in the active site throughout the reaction. The coordination promote the
formation of the C2-C4 bond necessary the skeletal rearrangement. If this coordination is
indeed necessary for aldolization, it might explain the lack of turnover when the hydrox-
yacetone and glycoaldehyde phosphate intermediate were exogenously introduced. The
formation of the metal coordination might be very unlikely with the two intermediates
compared to the single reactant.
4.3 Future Work
As previously mentioned, the projects above represent parts of a complete step of a
reaction. The DXS work focused on the first half of ylide formation while the DXR
project focuses on the retro-aldol reaction of the retro-aldol/aldol mechanism. Therefore,
the follow up work should look to compute the completion of each step in the reaction.
Additionally mapping the following reactions of DXS could provide valuable insight into
residue contribution while the reactions are well understood. A project of interest would
be the decarboxylation of pyruvate and subsequent transferral to G-3-P. Originally, the
decarboxylation was thought to take place prior to G-3-P binding, but recent evidence
suggests a pause until G-3-P binding. The energetics of decarboxylation with and without
G-3-P and environmental analysis might provide unique insights into DXS.
These two enzymes represent the steps of the NMA pathway. Aspects the down-
stream enzymes might be ascertained utilizing computational techniques while experi-
mental methods don’t have the ability. The IspD enzyme is responsible for the trans-
ferral of the CMP group of CTP with a hide degree of specificity. Determining aspects
to the specificity might be gleamed via Normal Mode Analysis coupled with Vibrational
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Subsystem Analysis. Normal mode computes the frequencies of a system while vibration
subsystem analysis determines how the large modes have on a subsystems of interest.
Thus, mapping changes brought on via simulations might provide insight in the changes
upon binding CTP; which in turn would provide further insights into residues of interest.
A mechanism keenly designed for computational investigation might be that the iron-
sulfur cluster dependent IspG and IspH. Of particular interest would be IspH, the enzyme
is able to produce by IDP and DMADP in a 4:1 ratio via a radical reaction. The ratio of
4:1 also represents the relative usage in downstream isoprenoids. An investigation into
differences in the active site or energetics of the reaction might provide insight into how
this eznyme preforms such an operation. There are many enzymes that have undesirable
biproducts but no to my knowledge that produce both products of a pathway. The MVA
pathway for instance utilizes isomerase to convert between IDP and DMADP.
NMA pathway enzymes are not found in mammalian cells suggest this pathway to
be wonderful target to novel anti-biotic research. This is bolster by the fact that fos-
midomycin is a known anti-malarial drug and inhibits DXR activity. There are other
chemicals going through clinical trials currently with hopes of becoming a cheaper and
better treatment for disease. Fosmidomycin has also been shown to inhibit IspD and IspE
in addition to DXR though to a reduced extent. So it might even be possible to design a
drug that target multiple enzymes, thus producing a stronger anti-microbial compound.
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Appendix A: Supporting Information for “Thiamine Diphosphate Activation
in 1-deoxy-D-xylulose 5-Phosphate Synthase: Insights into the Mechanism
and Underlying Intermolecular Interactions”
A.1 Methods
A.1.1 Topology and Parameters for Thiamine Diphosphate (TDP)
TDP has never been parameterized for use in MM calculations. In order to build 1-
deoxy-d-xylulose 5-phosphate synthase (DXS), it was necessary to develop a topology
and parameter file that would reproduce the TDP crystal structure. TDP has a pyrimi-
dine ring, thiazole ring, and an inorganic phosphate tail; each of which have been devel-
oped for use in CHARMM calculations. The topology and parameters for each moiety
were used and augmented to account for TDP’s final structure. The additional bonds
and parameters were determined based on structures with homologous chemical prop-
erties. QM calculations at the B3LYP/6-31G* level of theory were used to determine
acquire initial charges for undefined atoms (e.g., C1 atom, vide infra). These charges
were combined with those already established for each moiety. MacKerrell’s charge rules
(mackerell.umaryland.edu/ff dev.html) for substituents was followed to account for the
linkers between groups. Finally, the atomic charges were balanced via manual manip-
ulation and chemical intuition to equal the final -2.0 charge for TDP. A minimization
of TDP was performed using the topology and parameter files to a tolerance of 0.002
kcal·mol−1·A˚−1. The minimized structure’s RMSD was compared to that of the crystal
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structure. The two structures were found to deviation by 0.1A˚.
*Topology File for Thiamine Diphosphate using CGenFF Atom Types
*
36 1
RESI TDP -2.00 !
GROUP ! 0.00
ATOM C1 CG331 0.43 ! H2
ATOM H1 HGA3 0.16 ! |
ATOM H2 HGA3 0.16 ! H1--C1--H3
ATOM H3 HGA3 0.16 ! |
ATOM C2 CG2R64 -0.50 ! C2
ATOM N1 NG2R62 -0.49 ! / \\
ATOM N2 NG2R62 -0.54 ! / \\
ATOM C3 CG2R62 -0.04 ! N1 N2
ATOM H4 HGR62 0.11 ! || |
ATOM C4 CG2R64 0.45 ! C3 C4
ATOM N3 NG2S3 -0.80 ! / \ // \
ATOM H31 HGP4 0.38 ! H4 \ // N3--H31
ATOM H32 HGP4 0.38 ! C5 |
ATOM C5 CG2R62 0.14 ! | H32
GROUP ! 1.00
ATOM C6 CG324 -0.24 ! H5-C6-H6
ATOM H5 HGA2 0.11 ! |
ATOM H6 HGA2 0.11 ! H8 N4(+)
ATOM N4 NG2R52 0.59 ! | / \\
ATOM C7 CG2R53 -0.41 ! H7--C10--C8 C7--H71
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ATOM H71 HGR52 0.14 ! | || |
ATOM S1 SG2R50 0.73 ! | || /
ATOM C8 CG2R51 0.40 ! H9 C9--S1
ATOM C9 CG2R51 -0.25 ! |
ATOM C10 CG331 -0.54 ! H10--C11--H11
ATOM H7 HGA3 0.12 ! |
ATOM H8 HGA3 0.12 ! H12--C12--H13
ATOM H9 HGA3 0.12 ! |
GROUP ! -3.00
ATOM C11 CG321 -0.30 ! O1
ATOM H10 HGA2 0.10 ! |
ATOM H11 HGA2 0.10 ! O4==P1==O3 (-)
ATOM C12 CG321 -0.16 ! |
ATOM H12 HGA2 0.10 ! O2
ATOM H13 HGA2 0.10 ! |
ATOM O1 OG303 -0.62 ! O7==P2==O6 (-)
ATOM P1 PG1 1.50 ! |
ATOM O2 OG304 -0.74 ! O5 (-)
ATOM O3 OG2P1 -0.80 !
ATOM O4 OG2P1 -0.80 !
ATOM P2 PG2 1.10 !
ATOM O5 OG2P1 -0.86 !
ATOM O6 OG2P1 -0.86 !
ATOM O7 OG2P1 -0.86 !
ATOM O4 OG2P1 -0.80 !
ATOM P2 PG2 1.10 !
ATOM O5 OG2P1 -0.86 !
ATOM O6 OG2P1 -0.86 !
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ATOM O7 OG2P1 -0.86 !
BOND C1 H1 C1 H2 C1 H3
BOND C1 C2 N1 C2 N1 C3
BOND C2 N2 N2 C4 C4 N3 N3 H31 N3 H32
BOND C4 C5 C5 C3 C3 H4
BOND C5 C6 C6 H5 C6 H6 C6 N4
BOND N4 C7 C7 H71 N4 C8 C8 C10
BOND C10 H7 C10 H8 C10 H9
BOND C8 C9 C9 S1 C9 C11 S1 C7
BOND C11 H10 C11 H11 C11 C12
BOND C12 H12 C12 H13 C12 O1
BOND O1 P1 P1 O2 P1 O3 P1 O4
BOND O2 P2 P2 O5 P2 O6 P2 O7
IC C2 N1 C3 C5 0.0000 0.0 0.0 0.0 0.0000
IC C3 N1 C2 N2 0.0000 0.0 0.0 0.0 0.0000
IC N1 C2 N2 C4 0.0000 0.0 0.0 0.0 0.0000
IC N2 C4 N3 H31 0.0000 0.0 0.0 0.0 0.0000
*Parameter File for Thiamine Diphosphate
*
BONDS
CG324 NG2R52 400.00 1.4580
CG2R51 CG334 229.63 1.5000
CG2R62 CG324 222.50 1.4900
CG2R62 NG2R62 302.00 1.3430
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CG2R64 CG331 230.00 1.4780
ANGLES
CG321 CG2R51 SG2R50 45.80 124.00
CG331 CG2R51 NG2R52 45.80 124.00
CG331 CG2R64 NG2R62 45.80 121.00
CG2R62 CG324 HGA2 55.00 110.10
NG2R52 CG324 HGA2 33.43 110.10
CG2R62 CG324 HGP5 49.30 107.50
CG2R51 CG321 CG321 58.35 114.00
CG2R51 NG2R52 CG324 70.00 126.90
CG2R53 NG2R52 CG324 70.00 126.90
CG2R62 CG2R62 CG324 45.80 119.00
CG2R64 CG2R62 CG324 45.80 119.00
NG2R62 CG2R62 HGR62 44.00 115.00
NG2R52 CG2R53 HGR52 32.00 126.00
CG2R62 NG2R62 CG2R64 40.00 110.50
CG2R64 CG2R62 NG2R62 20.00 124.00
CG2R62 CG2R62 NG2R62 85.00 122.90
NG2R52 CG2R53 SG2R50 110.00 117.20
NG2R52 CG324 HGP5 33.43 110.10 22.53 2.179
CG2R64 CG331 HGA3 33.43 110.10 22.53 2.179
CG2R62 CG324 NG2R52 45.00 102.30 35.00 2.101
DIHEDRAL
HGA3 CG331 CG2R64 NG2R62 2.8000 2 180.00
CG321 CG321 OG303 PG2 0.0000 3 0.00
CG331 CG2R64 NG2R62 CG2R62 1.0000 2 180.00
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CG331 CG2R64 NG2R62 CG2R64 1.0000 2 180.00
CG324 CG2R62 CG2R62 HGR62 2.4000 2 180.00
CG324 NG2R52 CG2R53 HGR52 2.0000 2 180.00
CG331 CG2R51 CG2R51 CG321 1.2000 2 180.00
CG324 NG2R52 CG2R51 CG331 3.0000 2 180.00
NG2S3 CG2R64 CG2R62 CG324 0.0000 2 180.00
CG324 NG2R52 CG2R51 CG2R51 5.4000 2 180.00
CG324 NG2R52 CG2R53 SG2R50 6.0000 2 180.00
CG2R51 CG321 CG321 HGA2 0.1500 3 0.00
CG2R51 CG321 CG321 OG303 0.4000 3 180.00
CG2R62 CG324 NG2R52 CG2R53 0.2300 2 180.00
CG2R62 CG324 NG2R52 CG2R51 0.2300 2 180.00
CG2R51 NG2R52 CG324 HGA2 0.0000 3 0.00
CG2R53 NG2R52 CG324 HGA2 0.0000 3 0.00
CG2R62 CG2R62 CG324 HGA2 0.0000 3 0.00
CG2R64 CG2R62 CG324 HGA2 0.0000 2 0.00
NG2R52 CG2R51 CG331 HGA3 0.1900 3 0.00
SG2R50 CG2R51 CG321 HGA2 0.1900 3 0.00
CG2R51 CG2R51 CG321 CG321 0.2000 1 0.00
CG2R51 CG2R51 CG321 CG321 0.2700 2 0.00
CG2R51 CG2R51 CG321 CG321 0.0000 3 0.00
SG2R50 CG2R51 CG321 CG321 0.1900 3 0.00
CG2R62 CG2R62 CG324 NG2R52 0.1500 2 180.00
CG2R64 CG2R62 CG324 NG2R52 0.1500 2 180.00
CG2R51 NG2R52 CG2R53 HGR52 2.0000 2 180.00
CG2R64 NG2R62 CG2R62 HGR62 4.5000 2 180.00
CG2R53 NG2R52 CG2R51 CG331 3.0000 2 180.00
CG2R53 SG2R50 CG2R51 CG321 8.5000 2 180.00
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NG2R62 CG2R62 CG2R62 CG324 0.0000 2 180.00
NG2R62 CG2R64 CG2R62 CG324 3.1000 2 180.00
SG2R50 CG2R51 CG2R51 CG331 3.0000 2 180.00
CG2R64 NG2R62 CG2R62 CG2R62 1.2000 2 180.00
CG2R64 NG2R62 CG2R64 CG2R62 2.0000 2 180.00
NG2R62 CG2R62 CG2R62 CG2R64 3.0000 2 180.00
NG2R52 CG2R53 SG2R50 CG2R51 8.5000 2 180.00
NG2R62 CG2R64 NG2R62 CG2R62 3.1000 2 180.00
NG2R52 CG2R51 CG2R51 SG2R50 7.0000 2 180.00
SG2R50 CG2R53 NG2R52 CG2R51 2.0000 2 180.00
END
A.1.2 Extended 20 ns Molecular Dynamics Simulation
The crystal structure for the D. radiodurans DXS (PDB ID:201X)197 enzyme with TDP
bound was processed and parsed via www.charmming.org127. The topology and param-
eters for TDP shown above were used in generating the structure used in this extended
simulation. Structural modifications were performed to ensure the active site Glu373 was
protonated in agreement with experimental evidence90,112. CGenFF and CHARMM22
protein (C22) force fields119 were used throughout. The system was solvated in a cubic
crystal structure and neutralized with KCl salt to a final concentration of 0.15M. The
system was heated from 110K to 310K over 100ps. The system was simulated for 20 ns
at constant pressure (1atm) and temperature (310K). For the purposes of analysis, the
first 2 ns were discarded to allow for an equilibration period.
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A.1.3 Over-expression and Purification of Wildtype DXS and
the DXS Mutants
Plasmids containing the wild type D. radiodurans dxs gene or the mutant dxs gene were
transformed into E. coli BL-21 B(DE3) cells and used for protein expression. An overnight
culture of E. coli in LB broth containing 50 µg/ml kanamycin was diluted 100-fold, cul-
tured at 37◦C until the absorbance at 600 nm reached ∼ 0.6, and then cooled to 20◦C.
Expression was induced by the addition of 0.5 mM isopropyl β-D-1-thiogalactopyranoside
(IPTG). The cells were harvested by centrifugation (6,000 × g for 10 min) after being
shakem for 6 hrs at 20◦C and the resulting cell pellets stored at -80◦C before purification.
Cells were thawed and all the purification steps were performed at 4◦C. Cells were resus-
pended in binding buffer (20 mM Tris, 500 mM NaCl, 5 mM imidazole, 10 mM β-Me,
pH = 7.5) supplemented with 1 mM phenylmethanesulfonylfluoride (PMSF), 4 µg/mL
leupeptin, and 2 µg/mL pepstatin, sonicated using a Heat systems W-380 ultrasonic pro-
cessor, and centrifuged (16,000 × g for 20 min) to remove cell debris. The supernatant
from the cell lysate was applied to a 1.5 cm × 5 cm column packed with Ni-NTA resin
that had been equilibrated with binding buffer. Non-bound proteins eluted from the
column by first washing with 5 column volumes of binding buffer followed by 20 column
volumes of wash buffer (20 mM Tris pH 7.5, 500 mM NaCl, 60 mM imidazole, and 10
mM β-Me). The bound DXS (wildtype or mutant) was eluted from the Ni-NTA resin
using elution buffer (20 mM Tris pH 7.5, 500 mM NaCl, 250 mM imidazole, and 10 mM
β-Me). A flow rate of 1.5 mL/min was maintained through the Ni-NTA column for all
the loading and washing steps. DXS-containing fractions containing were combined, ex-
haustively dialyzed at 4◦C against 20 mM Tris pH 7.5, 100 mM NaCl, and 10 mM β-Me,
and concentrated by ultrafiltration. The final yield of DXS (wildtype or mutant) was 7-8
mg/L of E. coli culture medium. Enzyme was flash frozen in liquid nitrogen, stored at
-80◦C. The purity of the DXS (wildtype or the mutant) was evaluated by SDS-PAGE.
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Figure A.1: An illustration of the QM regions of both the direct histidine mechanism
(DHM, image (a)) and the water-mediated mechanism (WMM, image (b)). DHM’s QM
region contained 98 atoms; which were made up from H124, E373, H434 and TDP.
WMM’s QM region was comprised of all the same residues as the DHM with the addition
of Wat9709 (reactive water) making the total 101 atoms. Additionally, linker atoms were
used the CO–Cα bond (purple atoms).
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Figure A.2: Plots of the initial velocities versus varying concentrations of pyruvate or
G3P. Plots a and b are for wild-type DXS while plots c and d represent the H82A mutant.
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Figure A.3: Graphs of initial velocities versus varying concentrations of pyruvate or G3P.
Plots a and b are for the H304A mutant. Plots c and d represent the D430A mutant.
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Figure A.4: Plots of the initial velocities versus varying concentrations of pyruvate or
G3P. All graphs are for the H434A mutant discussed in primary manuscript.
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A.2 ProPKA3.1 Results
Below will be found the ProPKA3.1 results for monomer A of DXS:
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ASP   9 A   3.88     0 %    0.12  160   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.05 ARG  43 A
ASP   9 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.01 ASP  14 A
ASP  14 A   2.41     0 %    0.49  266   0.00    0   -0.72 SER   8 A    0.00 XXX   0 X   -0.00 N+    5 A
ASP  14 A                                           -0.54 THR  10 A    0.00 XXX   0 X   -0.02 ARG  43 A
ASP  14 A                                           -0.32 ARG  94 A    0.00 XXX   0 X   -0.02 HIS  17 A
ASP  14 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.27 ARG  94 A
ASP  21 A   2.72     0 %    0.44  281   0.00    0   -0.22 ARG  24 A   -0.78 HIS  17 A   -0.04 LYS  20 A
ASP  21 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.01 LYS  23 A
ASP  21 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.28 ARG  24 A
ASP  21 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.20 HIS  17 A
ASP  60 A   2.08    83 %    3.05  513   1.08    0   -0.61 THR  34 A   -0.07 ASP  60 A   -0.10 LYS 291 A
ASP  60 A                                           -1.58 ARG  38 A    0.00 XXX   0 X   -1.13 ARG  38 A
ASP  60 A                                           -1.60 HIS 262 A    0.00 XXX   0 X   -0.77 HIS 262 A
ASP  70 A   4.70*   20 %    0.75  338   0.17    0   -0.36 ARG  73 A   -0.03 ASP  70 A   -0.09 LYS  20 A
ASP  70 A                                            0.67 ASP  74 A    0.00 XXX   0 X   -0.28 LYS  23 A
ASP  70 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.02 HIS 117 A
ASP  70 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.08 HIS 147 A
ASP  70 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.27 ARG  73 A
ASP  70 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.43 ASP  74 A
ASP  74 A   1.39*   50 %    1.78  422   0.40    0   -0.67 ASP  70 A   -0.78 ASP  70 A   -0.07 LYS  23 A
ASP  74 A                                           -1.60 HIS 147 A   -0.82 HIS 147 A   -0.05 ARG  73 A
ASP  74 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.03 ARG 139 A
ASP  74 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.56 HIS 147 A
ASP  79 A   4.78   100 %    4.09  606   0.40    0   -0.73 SER 128 A   -0.81 SER 126 A   -0.22 ARG 401 A
ASP  79 A                                           -0.85 SER 156 A   -0.01 THR 127 A   -0.24 HIS  82 A
ASP  79 A                                            0.00 XXX   0 X   -0.64 SER 128 A    0.00 XXX   0 X
ASP  95 A   3.85     4 %    0.26  292   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.17 ARG  94 A
ASP  95 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.03 ASP  14 A
ASP  95 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.06 HIS  17 A
ASP  99 A   2.75     0 %    0.31  243   0.00    0   -0.85 LYS 102 A    0.00 XXX   0 X   -0.13 ARG  47 A
ASP  99 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.38 LYS 102 A
ASP 118 A   0.14    82 %    3.19  510   0.81    0   -1.60 HIS  87 A   -0.75 LYS 111 A   -0.01 LYS 111 A
ASP 118 A                                           -1.47 ARG  93 A    0.00 XXX   0 X   -0.08 HIS  66 A
ASP 118 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.15 HIS 117 A
ASP 118 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -1.47 HIS  87 A
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ASP 118 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.99 LYS  88 A
ASP 118 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -1.13 ARG  93 A
ASP 140 A   2.00     5 %    0.64  295   0.06    0   -0.84 ARG 139 A    0.00 XXX   0 X   -0.25 LYS 175 A
ASP 140 A                                           -0.74 ARG 174 A    0.00 XXX   0 X   -0.41 ARG 139 A
ASP 140 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.26 ARG 174 A
ASP 145 A   3.69     0 %    0.16  216   0.00    0    0.00 XXX   0 X   -0.10 ASP 145 A   -0.04 ARG 139 A
ASP 145 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.11 LYS 175 A
ASP 145 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.04 ASP  74 A
ASP 145 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.08 HIS 147 A
ASP 145 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.03 ASP 276 A
ASP 154 A   4.87*   95 %    3.64  546   1.01    0   -0.18 ASN 183 A   -0.38 ASP 154 A   -4.07 MG   MG A
ASP 154 A                                           -0.04 TDP O22 A   -0.08 GLY 155 A   -0.19 LYS 289 A
ASP 154 A                                            0.28 ASP 182 A   -0.23 ASN 183 A   -0.11 HIS 284 A
ASP 154 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.86 ASP 182 A
ASP 154 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.55 TDP O21 A
ASP 171 A   3.96     0 %    0.17  171   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.01 ARG 174 A
ASP 182 A   1.80    62 %    1.88  456   0.13    0   -0.28 ASP 154 A   -0.55 GLU 184 A   -1.03 MG   MG A
ASP 182 A                                           -1.60 HIS 284 A    0.00 XXX   0 X   -0.55 HIS 284 A
ASP 260 A   3.25    18 %    0.74  332   0.02    0    0.00 XXX   0 X   -0.82 HIS 262 A   -0.01 ARG  38 A
ASP 260 A                                            0.00 XXX   0 X   -0.29 ASN 263 A   -0.06 LYS 291 A
ASP 260 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.14 ASP  60 A
ASP 260 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.26 HIS 262 A
ASP 276 A   3.36     3 %    0.32  290   0.01    0   -0.51 HIS 147 A    0.00 XXX   0 X   -0.02 LYS 175 A
ASP 276 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.04 ASP  74 A
ASP 276 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.28 HIS 147 A
ASP 278 A   3.75     0 %    0.17  212   0.00    0    0.00 XXX   0 X   -0.02 ASP 278 A   -0.15 LYS 175 A
ASP 278 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.06 ARG 254 A
ASP 278 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.01 ASP 276 A
ASP 299 A   3.71    21 %    0.81  341   0.02    0    0.00 XXX   0 X   -0.08 ILE 301 A   -0.04 LYS 289 A
ASP 299 A                                            0.00 XXX   0 X   -0.81 TYR 302 A    0.00 XXX   0 X
ASP 310 A   3.71     0 %    0.43  201   0.00    0    0.00 XXX   0 X   -0.10 ASP 310 A   -0.00 LYS 308 A
ASP 310 A                                            0.00 XXX   0 X   -0.42 THR 313 A    0.00 XXX   0 X
ASP 339 A   3.64    42 %    1.76  398   0.09    0   -0.84 THR 342 A   -0.74 ARG 341 A   -0.21 ARG 341 A
ASP 339 A                                            0.00 XXX   0 X   -0.06 THR 342 A   -0.04 ARG 365 A
ASP 339 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.12 ARG 389 A
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ASP 368 A   5.57    80 %    2.37  505   0.53    0    0.00 XXX   0 X   -0.40 ALA 348 A   -0.19 ARG 350 A
ASP 368 A                                            0.00 XXX   0 X   -0.69 GLY 370 A    0.05 GLU 189 A
ASP 368 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.11 GLU 351 A
ASP 404 A   4.06     0 %    0.33  254   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.22 HIS 408 A
ASP 404 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.15 ASP 409 A
ASP 409 A   2.62     3 %    0.59  291   0.03    0   -0.85 THR 378 A    0.00 XXX   0 X   -0.32 HIS 408 A
ASP 409 A                                           -0.63 HIS 408 A    0.00 XXX   0 X    0.00 XXX   0 X
ASP 422 A   4.51   100 %    3.67  576   1.07    0   -0.84 SER 325 A   -0.74 ARG 423 A   -0.05 ARG 480 A
ASP 422 A                                           -0.62 ARG 423 A    0.00 XXX   0 X   -1.77 ARG 423 A
ASP 430 A   0.37   100 %    2.39  582   0.00    0   -0.85 LYS 101 A    0.00 XXX   0 X   -0.16 ARG 423 A
ASP 430 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.32 ARG 480 A
ASP 430 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.03 HIS 304 A
ASP 430 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.02 HIS 597 A
ASP 430 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.84 HIS  51 A
ASP 430 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -2.03 LYS 101 A
ASP 430 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -1.57 HIS 434 A
ASP 439 A   5.32   100 %    4.06  640   0.42    0   -0.60 SER 396 A   -0.03 ASP 439 A    0.13 ASP 561 A
ASP 439 A                                           -0.42 ARG 477 A    0.00 XXX   0 X   -2.03 ARG 477 A
ASP 456 A   4.07    55 %    1.47  436   0.00    0    0.00 XXX   0 X   -0.22 ALA 458 A   -0.27 LYS 455 A
ASP 456 A                                            0.00 XXX   0 X   -0.67 GLU 459 A   -0.03 ARG 536 A
ASP 471 A   3.58     0 %    0.21  257   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.08 ARG 389 A
ASP 471 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.10 ARG 450 A
ASP 471 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.18 HIS 414 A
ASP 471 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.06 HIS 470 A
ASP 493 A   2.83     0 %    0.28  240   0.00    0   -0.85 LYS 465 A    0.00 XXX   0 X   -0.02 HIS 470 A
ASP 493 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.38 LYS 465 A
ASP 506 A   3.37     0 %    0.31  230   0.00    0    0.00 XXX   0 X   -0.26 ASP 506 A   -0.20 ARG 501 A
ASP 506 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.28 ARG 552 A
ASP 507 A   3.96     6 %    0.54  299   0.04    0   -0.09 ARG 554 A    0.00 XXX   0 X   -0.38 ARG 554 A
ASP 507 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.04 ASP 506 A
ASP 518 A   5.43    62 %    1.23  455   0.76    0    0.00 XXX   0 X   -0.00 ASP 518 A   -0.38 LYS 515 A
ASP 518 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.02 ASP 456 A
ASP 526 A   3.97     0 %    0.17  169   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.03 LYS 503 A
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ASP 526 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.04 LYS 522 A
ASP 526 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.11 ARG 615 A
ASP 526 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.16 GLU 525 A
ASP 542 A   4.02    34 %    1.37  377   0.28    0    0.00 XXX   0 X   -0.81 TRP 499 A   -0.05 ARG 536 A
ASP 542 A                                            0.00 XXX   0 X   -0.01 GLU 544 A    0.06 GLU 544 A
ASP 542 A                                            0.00 XXX   0 X   -0.62 MET 545 A    0.00 XXX   0 X
ASP 561 A   2.66   100 %    3.52  609   0.68    0   -1.60 HIS 604 A   -0.61 ILE 426 A   -0.43 LYS 515 A
ASP 561 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.88 ARG 477 A
ASP 561 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -1.82 HIS 604 A
ASP 592 A   4.02     0 %    0.22  202   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.00 XXX   0 X
ASP 610 A   4.24    17 %    0.89  329   0.04    0    0.00 XXX   0 X   -0.03 ASP 610 A    0.01 GLU 601 A
ASP 610 A                                            0.00 XXX   0 X   -0.35 ALA 613 A   -0.12 HIS 604 A
ASP 624 A   3.93     0 %    0.13  161   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.00 XXX   0 X
GLU  28 A   4.41     0 %    0.26  185   0.00    0    0.00 XXX   0 X   -0.26 GLU  28 A   -0.10 ARG  27 A
GLU  35 A   4.59     0 %    0.16  277   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.06 ARG  38 A
GLU  35 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.00 LYS 291 A
GLU  36 A   4.95    28 %    1.84  359   0.22    0    0.00 XXX   0 X   -0.83 LEU  12 A   -0.03 ARG  43 A
GLU  36 A                                            0.00 XXX   0 X   -0.84 LEU  13 A   -0.11 ARG  94 A
GLU  36 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.02 ASP   9 A
GLU  36 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.14 ASP  14 A
GLU  36 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.04 GLU  40 A
GLU  40 A   4.20    57 %    1.62  440   0.17    0   -0.54 ARG  43 A    0.00 XXX   0 X    0.07 ASP  14 A
GLU  40 A                                           -0.69 ARG  94 A    0.00 XXX   0 X    0.08 ASP  95 A
GLU  40 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.40 ARG  43 A
GLU  40 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.60 ARG  94 A
GLU 103 A   3.66     0 %    0.37  248   0.00    0   -0.85 SER 602 A    0.00 XXX   0 X   -0.33 ARG 606 A
GLU 103 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.03 HIS 597 A
GLU 114 A   4.03    64 %    2.45  461   0.71    0   -0.85 LYS  88 A   -0.80 SER 107 A   -0.09 LYS 111 A
GLU 114 A                                           -0.49 ARG  93 A    0.00 XXX   0 X   -0.10 HIS  87 A
GLU 114 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.18 HIS 597 A
GLU 114 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -1.01 LYS  88 A
GLU 114 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.66 ARG  93 A
GLU 114 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.57 ASP 118 A
GLU 116 A   4.36     0 %    0.31  255   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.07 LYS  20 A
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GLU 116 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.13 ARG  73 A
GLU 116 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.01 ARG  75 A
GLU 116 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.25 HIS 117 A
GLU 184 A   5.15    16 %    0.32  325   0.04    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.08 MG   MG A
GLU 184 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.15 ASP 154 A
GLU 184 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.23 ASP 182 A
GLU 189 A   3.74    29 %    0.67  362   0.00    0   -0.33 ARG 350 A   -0.61 GLU 189 A   -0.03 LYS 289 A
GLU 189 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.05 ARG 360 A
GLU 189 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.03 ASP 299 A
GLU 189 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.43 ARG 350 A
GLU 266 A   5.09     7 %    0.43  300   0.05    0    0.00 XXX   0 X    0.00 XXX   0 X    0.11 ASP 260 A
GLU 272 A   4.24     8 %    0.62  304   0.05    0   -0.54 ARG  27 A    0.00 XXX   0 X   -0.40 ARG  27 A
GLU 297 A   4.13    17 %    0.70  330   0.13    0    0.00 XXX   0 X   -0.64 GLY 292 A   -0.10 ARG  38 A
GLU 297 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.36 LYS 291 A
GLU 297 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.10 HIS 262 A
GLU 315 A   4.73     0 %    0.12  142   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.11 ASP 310 A
GLU 330 A   4.67    20 %    0.90  337   0.12    0   -0.14 GLN 485 A    0.00 XXX   0 X   -0.01 LYS 337 A
GLU 330 A                                           -0.62 TYR 322 A    0.00 XXX   0 X   -0.23 ARG 461 A
GLU 330 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.11 GLU 334 A
GLU 330 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.05 GLU 357 A
GLU 334 A   2.73    12 %    0.92  316   0.08    0   -0.66 TRP 491 A   -0.58 GLY 489 A   -0.13 LYS 337 A
GLU 334 A                                           -0.91 ARG 461 A    0.00 XXX   0 X   -0.49 ARG 461 A
GLU 351 A   4.75    60 %    2.02  448   0.00    0   -0.85 SER 188 A   -0.07 GLU 351 A   -0.06 LYS 289 A
GLU 351 A                                           -0.33 ARG 350 A    0.00 XXX   0 X   -0.09 ARG 360 A
GLU 351 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.24 GLU 189 A
GLU 351 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.04 ASP 299 A
GLU 351 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.66 ARG 350 A
GLU 357 A   4.56     0 %    0.26  275   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.11 LYS 337 A
GLU 357 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.04 ARG 360 A
GLU 357 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.04 HIS 362 A
GLU 373 A   8.47   100 %    3.73  588   0.84    0    0.00 XXX   0 X   -0.53 GLU 373 A    0.57 GLU 374 A
GLU 373 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.64 ARG 401 A
GLU 374 A   5.56    60 %    1.43  448   0.37    0    0.00 XXX   0 X   -0.36 GLU 374 A   -0.37 ARG 401 A
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GLU 413 A   4.63     0 %    0.14  179   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.01 HIS 414 A
GLU 459 A   5.00    81 %    3.11  507   0.29    0   -0.48 ASN 534 A   -0.84 LYS 455 A    0.45 ASP 456 A
GLU 459 A                                           -0.45 LYS 455 A    0.00 XXX   0 X    0.10 GLU 500 A
GLU 459 A                                           -0.26 ARG 536 A    0.00 XXX   0 X   -0.74 LYS 455 A
GLU 459 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.67 ARG 536 A
GLU 498 A   4.82     0 %    0.33  278   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.24 LYS 495 A
GLU 498 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.12 ARG 536 A
GLU 498 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.19 GLU 500 A
GLU 498 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.17 ASP 542 A
GLU 500 A   4.53    16 %    0.46  325   0.12    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.18 LYS 455 A
GLU 500 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.00 LYS 495 A
GLU 500 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.43 ARG 536 A
GLU 500 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.06 ASP 542 A
GLU 525 A   3.59     0 %    0.30  205   0.00    0   -0.73 LYS 522 A    0.00 XXX   0 X   -0.10 ARG 615 A
GLU 525 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.38 LYS 522 A
GLU 543 A   4.98    14 %    0.46  321   0.04    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.12 ARG 547 A
GLU 543 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.04 ASP 542 A
GLU 543 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.08 GLU 544 A
GLU 544 A   3.95     0 %    0.21  189   0.00    0   -0.48 ARG 547 A    0.00 XXX   0 X   -0.27 ARG 547 A
GLU 548 A   4.64     0 %    0.17  240   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.07 ARG 501 A
GLU 548 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.05 ARG 552 A
GLU 548 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.03 ASP 506 A
GLU 548 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.04 ASP 542 A
GLU 548 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.03 GLU 544 A
GLU 560 A   6.95    96 %    3.34  550   1.19    0   -0.10 ASN 562 A   -0.76 PHE 568 A   -0.11 ARG 444 A
GLU 560 A                                            0.00 XXX   0 X   -0.84 GLY 569 A   -0.31 ARG 477 A
GLU 560 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.02 ASP 439 A
GLU 560 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.02 ASP 561 A
GLU 574 A   3.73     8 %    0.48  305   0.06    0   -0.82 ARG 444 A    0.00 XXX   0 X   -0.01 LYS 539 A
GLU 574 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.48 ARG 444 A
GLU 593 A   4.70     0 %    0.14  184   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.00 ARG 606 A
GLU 593 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.04 ASP 592 A
GLU 593 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.02 GLU 596 A
GLU 596 A   4.39    20 %    0.42  337   0.02    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.37 LYS 111 A
GLU 596 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.01 ARG 606 A
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GLU 596 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.01 GLU 114 A
GLU 596 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.18 HIS 597 A
GLU 601 A   4.18    19 %    0.50  334   0.00    0    0.00 XXX   0 X   -0.45 GLU 601 A   -0.05 ARG 480 A
GLU 601 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.16 LYS 515 A
GLU 601 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.15 HIS 604 A
GLU 620 A   4.26     0 %    0.31  249   0.00    0   -0.22 ARG 586 A    0.00 XXX   0 X   -0.34 ARG 586 A
HIS  17 A   6.53     0 %   -0.23  253   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.00 ARG  24 A
HIS  17 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.02 ARG  94 A
HIS  17 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.02 ASP  14 A
HIS  17 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.20 ASP  21 A
HIS  17 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.06 ASP  95 A
HIS  51 A   1.06   100 %   -2.59  639   0.00    0    0.00 XXX   0 X    0.27 HIS 304 A   -1.49 LYS 101 A
HIS  51 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.10 LYS 289 A
HIS  51 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -1.11 HIS  82 A
HIS  51 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -1.26 HIS 304 A
HIS  51 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.27 HIS 434 A
HIS  51 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.28 TDP O21 A
HIS  51 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.84 ASP 430 A
HIS  66 A   1.56   100 %   -2.88  603   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.26 LYS  23 A
HIS  66 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.12 ARG  93 A
HIS  66 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -1.34 HIS  87 A
HIS  66 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.40 HIS 117 A
HIS  66 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.08 ASP 118 A
HIS  82 A   5.29   100 %   -3.20  664   0.00    0    0.56 TDP O11 A    0.00 XXX   0 X   -0.72 MG   MG A
HIS  82 A                                            0.83 TDP O21 A    0.00 XXX   0 X   -0.06 LYS 101 A
HIS  82 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.41 LYS 289 A
HIS  82 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.24 ASP  79 A
HIS  82 A                                            0.00 XXX   0 X    0.00 XXX   0 X    1.56 TDP O21 A
HIS  87 A   4.47   100 %   -3.14  615   0.00    0    1.60 ASP 118 A    0.02 HIS 117 A   -0.46 LYS  88 A
HIS  87 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -1.23 ARG  93 A
HIS  87 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.10 GLU 114 A
HIS  87 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.38 HIS 117 A
HIS  87 A                                            0.00 XXX   0 X    0.00 XXX   0 X    1.47 ASP 118 A
HIS 117 A   5.29    49 %   -1.54  419   0.00    0    0.00 XXX   0 X    0.31 SER  71 A   -0.05 LYS  20 A
HIS 117 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.04 LYS  23 A
HIS 117 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.09 ARG  73 A
HIS 117 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.23 ARG  93 A
HIS 117 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.02 ASP  70 A
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HIS 117 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.25 GLU 116 A
HIS 117 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.15 ASP 118 A
HIS 124 A   2.62    92 %   -2.42  540   0.00    0    0.00 XXX   0 X    0.04 THR 433 A   -0.63 ARG 401 A
HIS 124 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.86 HIS 434 A
HIS 147 A   8.30    44 %   -1.14  404   0.00    0    1.60 ASP  74 A    0.00 XXX   0 X   -0.10 ARG 139 A
HIS 147 A                                            0.51 ASP 276 A    0.00 XXX   0 X   -0.06 LYS 175 A
HIS 147 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.08 ASP  70 A
HIS 147 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.08 ASP 145 A
HIS 147 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.56 ASP  74 A
HIS 147 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.28 ASP 276 A
HIS 262 A   6.11    72 %   -2.27  484   0.00    0    1.60 ASP  60 A    0.01 GLY 261 A   -0.61 ARG  38 A
HIS 262 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.26 LYS 291 A
HIS 262 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.26 ASP 260 A
HIS 262 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.10 GLU 297 A
HIS 262 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.77 ASP  60 A
HIS 284 A   6.81    59 %   -1.94  446   0.00    0    1.60 ASP 182 A    0.00 XXX   0 X    0.11 ASP 154 A
HIS 284 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.55 ASP 182 A
HIS 304 A   2.33   100 %   -2.82  619   0.00    0    0.17 TDP O21 A    0.00 XXX   0 X   -0.23 MG   MG A
HIS 304 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.06 LYS 101 A
HIS 304 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -1.64 LYS 289 A
HIS 304 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -1.07 HIS  82 A
HIS 304 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.03 ASP 430 A
HIS 304 A                                            0.00 XXX   0 X    0.00 XXX   0 X    1.46 TDP O21 A
HIS 362 A   5.25    25 %   -1.11  352   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.13 LYS 337 A
HIS 362 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.05 ARG 365 A
HIS 362 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.04 GLU 357 A
HIS 364 A   6.26     0 %   -0.15  160   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.09 ARG 365 A
HIS 408 A   7.42     0 %   -0.25  206   0.00    0    0.63 ASP 409 A    0.00 XXX   0 X    0.22 ASP 404 A
HIS 408 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.32 ASP 409 A
HIS 414 A   5.62    19 %   -0.67  335   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.39 ARG 450 A
HIS 414 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.01 LYS 539 A
HIS 414 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.01 GLU 413 A
HIS 414 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.18 ASP 471 A
HIS 434 A   4.72   100 %   -2.87  589   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.49 LYS 101 A
HIS 434 A                                            0.00 XXX   0 X    0.00 XXX   0 X    1.57 ASP 430 A
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HIS 470 A   5.65    13 %   -0.83  318   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.04 ARG 389 A
HIS 470 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.05 ARG 450 A
HIS 470 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.00 LYS 465 A
HIS 470 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.06 ASP 471 A
HIS 470 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.02 ASP 493 A
HIS 582 A   6.30     0 %   -0.20  168   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.00 XXX   0 X
HIS 597 A   5.69    48 %   -1.37  416   0.00    0    0.00 XXX   0 X    0.49 LYS 102 A   -0.13 LYS  88 A
HIS 597 A                                            0.00 XXX   0 X    0.00 HIS 597 A   -0.12 LYS 101 A
HIS 597 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.10 LYS 111 A
HIS 597 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.03 GLU 103 A
HIS 597 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.18 GLU 114 A
HIS 597 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.02 ASP 430 A
HIS 597 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.18 GLU 596 A
HIS 604 A   7.47    77 %   -2.46  496   0.00    0    1.60 ASP 561 A    0.00 XXX   0 X   -0.00 ARG 477 A
HIS 604 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.24 LYS 515 A
HIS 604 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.01 ARG 606 A
HIS 604 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.15 GLU 601 A
HIS 604 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.12 ASP 610 A
HIS 604 A                                            0.00 XXX   0 X    0.00 XXX   0 X    1.82 ASP 561 A
CYS  45 A  12.61   100 %    3.82  570   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.15 ARG  47 A
CYS  45 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.06 LYS 101 A
CYS 420 A  12.64   100 %    3.56  731   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.09 ASP 422 A
TYR  67 A  10.55    16 %    0.83  325   0.00    0   -0.18 ARG  27 A    0.00 XXX   0 X   -0.31 ARG  27 A
TYR  67 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.08 GLU  28 A
TYR  67 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.13 GLU 272 A
TYR  85 A  13.91   100 %    3.39  596   0.00    0    0.00 XXX   0 X   -0.81 HIS  51 A    1.31 CYS  45 A
TYR  85 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.18 ARG  47 A
TYR  85 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.21 ASP 430 A
TYR 255 A  11.49    28 %    1.40  359   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.09 ASP 182 A
TYR 295 A  11.77    25 %    1.65  352   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.12 ASP 310 A
TYR 302 A  10.96    23 %    1.44  347   0.00    0    0.00 XXX   0 X   -0.77 ALA 307 A    0.05 ASP 299 A
TYR 302 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.24 TYR 316 A
TYR 316 A  10.47     0 %    0.30  264   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.15 ASP 299 A
TYR 316 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.01 GLU 315 A
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TYR 322 A  12.45    30 %    1.50  365   0.00    0    0.62 GLU 330 A    0.00 XXX   0 X    0.03 GLU 334 A
TYR 322 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.18 ARG 461 A
TYR 322 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.48 GLU 330 A
TYR 366 A  13.79    73 %    3.09  485   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.06 GLU 189 A
TYR 366 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.44 ARG 350 A
TYR 366 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.25 GLU 351 A
TYR 366 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.84 ASP 368 A
TYR 395 A  11.94   100 %    2.90  585   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -2.03 ARG 423 A
TYR 395 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.20 ASP 430 A
TYR 395 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.20 ARG 480 A
TYR 395 A                                            0.00 XXX   0 X    0.00 XXX   0 X    1.08 ASP 422 A
TYR 403 A  10.35     0 %    0.31  276   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.05 ASP 404 A
TYR 466 A  10.65    21 %    0.76  339   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.11 ARG 450 A
TYR 466 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.01 ASP 471 A
TYR 466 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.01 GLU 498 A
TYR 466 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.02 LYS 495 A
TYR 478 A  16.85   100 %    3.92  663   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    1.47 CYS 420 A
TYR 478 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.17 ARG 423 A
TYR 478 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.08 TYR 395 A
TYR 478 A                                            0.00 XXX   0 X    0.00 XXX   0 X    1.55 ASP 422 A
TYR 519 A  12.47    48 %    1.57  416   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.12 ASP 518 A
TYR 519 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.30 ASP 561 A
TYR 519 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.26 GLU 601 A
TYR 519 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.22 ASP 610 A
LYS  20 A  10.07     0 %   -0.22  208   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.04 ASP  21 A
LYS  20 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.03 ARG  24 A
LYS  20 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.09 ASP  70 A
LYS  20 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.38 ARG  73 A
LYS  20 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.07 GLU 116 A
LYS  23 A   9.06    49 %   -1.65  419   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.01 ASP  21 A
LYS  23 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.01 ARG  24 A
LYS  23 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.28 ASP  70 A
LYS  23 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.07 ARG  73 A
LYS  23 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.07 ASP  74 A
LYS  23 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.07 LYS  20 A
LYS  88 A   8.79    88 %   -3.57  529   0.00    0    0.85 GLU 114 A    0.00 XXX   0 X   -0.94 ARG  93 A
LYS  88 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.02 LYS 101 A
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LYS  88 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.04 LYS 111 A
LYS  88 A                                            0.00 XXX   0 X    0.00 XXX   0 X    1.01 GLU 114 A
LYS  88 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.99 ASP 118 A
LYS 101 A  10.47   100 %   -2.85  572   0.00    0    0.85 ASP 430 A    0.00 XXX   0 X    0.06 CYS  45 A
LYS 101 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.06 ARG  47 A
LYS 101 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.07 ARG 480 A
LYS 101 A                                            0.00 XXX   0 X    0.00 XXX   0 X    2.03 ASP 430 A
LYS 102 A  10.91     0 %   -0.44  258   0.00    0    0.85 ASP  99 A    0.00 XXX   0 X   -0.38 ARG  47 A
LYS 102 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.38 ASP  99 A
LYS 111 A  10.37    25 %   -0.60  352   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.09 GLU 114 A
LYS 111 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.01 ASP 118 A
LYS 111 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.37 GLU 596 A
LYS 144 A  10.30     0 %   -0.20  177   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.00 ARG  75 A
LYS 175 A  10.40     2 %   -0.31  288   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.30 ARG 139 A
LYS 175 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.25 ASP 140 A
LYS 175 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.11 ASP 145 A
LYS 175 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.03 ARG 174 A
LYS 175 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.02 ASP 276 A
LYS 175 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.15 ASP 278 A
LYS 196 A  10.39     0 %   -0.11  166   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.00 XXX   0 X
LYS 289 A   8.34    98 %   -3.61  556   0.00    0    0.20 TDP O21 A    0.00 XXX   0 X   -1.34 MG   MG A
LYS 289 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.19 ASP 154 A
LYS 289 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.03 GLU 189 A
LYS 289 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.04 ASP 299 A
LYS 289 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.06 GLU 351 A
LYS 289 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.25 TDP O13 A
LYS 289 A                                            0.00 XXX   0 X    0.00 XXX   0 X    2.03 TDP O21 A
LYS 291 A  10.53     7 %   -0.30  302   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.00 GLU  35 A
LYS 291 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.19 ARG  38 A
LYS 291 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.10 ASP  60 A
LYS 291 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.06 ASP 260 A
LYS 291 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.36 GLU 297 A
LYS 308 A  10.37     0 %   -0.13  195   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.00 ASP 310 A
LYS 337 A  10.47     0 %   -0.28  280   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.01 GLU 330 A
LYS 337 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.13 GLU 334 A
LYS 337 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.11 GLU 357 A
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LYS 337 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.01 ARG 461 A
LYS 455 A  10.52    41 %   -1.28  396   0.00    0    0.45 GLU 459 A    0.00 XXX   0 X    0.27 ASP 456 A
LYS 455 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.18 GLU 500 A
LYS 455 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.34 ARG 536 A
LYS 455 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.74 GLU 459 A
LYS 465 A  11.18     4 %   -0.55  292   0.00    0    0.85 ASP 493 A    0.00 XXX   0 X    0.38 ASP 493 A
LYS 495 A  10.68     0 %   -0.09  148   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.24 GLU 498 A
LYS 495 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.00 GLU 500 A
LYS 495 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.02 TYR 466 A
LYS 503 A   9.86     9 %   -0.64  306   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.03 ARG 501 A
LYS 503 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.03 ASP 526 A
LYS 515 A  10.07    68 %   -1.36  471   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.05 ARG 480 A
LYS 515 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.38 ASP 518 A
LYS 515 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.43 ASP 561 A
LYS 515 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.16 GLU 601 A
LYS 522 A  11.34     0 %   -0.24  201   0.00    0    0.73 GLU 525 A    0.00 XXX   0 X    0.04 ASP 526 A
LYS 522 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.06 ARG 615 A
LYS 522 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.38 GLU 525 A
LYS 539 A   9.22    41 %   -1.12  396   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.10 ARG 444 A
LYS 539 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.07 ARG 450 A
LYS 539 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.01 GLU 574 A
ARG  24 A  12.77     0 %   -0.22  193   0.00    0    0.22 ASP  21 A    0.00 XXX   0 X    0.28 ASP  21 A
ARG  27 A  13.63     0 %   -0.39  282   0.00    0    0.18 TYR  67 A    0.00 XXX   0 X    0.10 GLU  28 A
ARG  27 A                                            0.54 GLU 272 A    0.00 XXX   0 X    0.31 TYR  67 A
ARG  27 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.40 GLU 272 A
ARG  38 A  12.94    79 %   -2.43  503   0.00    0    1.58 ASP  60 A    0.00 XXX   0 X    0.06 GLU  35 A
ARG  38 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.01 ASP 260 A
ARG  38 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.10 GLU 297 A
ARG  38 A                                            0.00 XXX   0 X    0.00 XXX   0 X    1.13 ASP  60 A
ARG  43 A  12.70    25 %   -0.71  352   0.00    0    0.54 GLU  40 A    0.00 XXX   0 X    0.05 ASP   9 A
ARG  43 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.02 ASP  14 A
ARG  43 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.03 GLU  36 A
ARG  43 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.13 ARG  94 A
ARG  43 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.40 GLU  40 A
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ARG  47 A  11.71    35 %   -1.24  378   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.15 CYS  45 A
ARG  47 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.18 TYR  85 A
ARG  47 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.13 ASP  99 A
ARG  73 A  12.97     0 %   -0.34  246   0.00    0    0.36 ASP  70 A    0.00 XXX   0 X    0.05 ASP  74 A
ARG  73 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.13 GLU 116 A
ARG  73 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.27 ASP  70 A
ARG  75 A  11.65    41 %   -0.85  395   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.01 GLU 116 A
ARG  93 A  13.33    80 %   -2.92  506   0.00    0    0.49 GLU 114 A    0.00 XXX   0 X    0.66 GLU 114 A
ARG  93 A                                            1.47 ASP 118 A    0.00 XXX   0 X    1.13 ASP 118 A
ARG  94 A  13.65    31 %   -1.01  368   0.00    0    0.32 ASP  14 A    0.00 XXX   0 X    0.11 GLU  36 A
ARG  94 A                                            0.69 GLU  40 A    0.00 XXX   0 X    0.17 ASP  95 A
ARG  94 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.27 ASP  14 A
ARG  94 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.60 GLU  40 A
ARG 139 A  12.42    36 %   -1.35  381   0.00    0    0.84 ASP 140 A    0.00 XXX   0 X    0.03 ASP  74 A
ARG 139 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.04 ASP 145 A
ARG 139 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.05 ARG 174 A
ARG 139 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.41 ASP 140 A
ARG 174 A  13.16     0 %   -0.35  247   0.00    0    0.74 ASP 140 A    0.00 XXX   0 X    0.01 ASP 171 A
ARG 174 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.26 ASP 140 A
ARG 254 A  12.00    10 %   -0.56  309   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.06 ASP 278 A
ARG 273 A  12.32     0 %   -0.18  160   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.00 XXX   0 X
ARG 341 A  12.38     0 %   -0.33  278   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.21 ASP 339 A
ARG 350 A  13.63    43 %   -1.26  403   0.00    0    0.33 GLU 189 A    0.00 XXX   0 X    0.44 TYR 366 A
ARG 350 A                                            0.33 GLU 351 A    0.00 XXX   0 X    0.19 ASP 368 A
ARG 350 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.43 GLU 189 A
ARG 350 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.66 GLU 351 A
ARG 360 A  12.32     0 %   -0.22  225   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.05 GLU 189 A
ARG 360 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.09 GLU 351 A
ARG 360 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.04 GLU 357 A
ARG 360 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.14 ARG 350 A
ARG 365 A  12.24     0 %   -0.29  271   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.04 ASP 339 A
ARG 389 A  11.54    23 %   -0.76  347   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.12 ASP 339 A
ARG 389 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.08 ASP 471 A
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ARG 389 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.40 ARG 341 A
ARG 401 A  11.96    72 %   -1.77  482   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.22 ASP  79 A
ARG 401 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.37 GLU 374 A
ARG 401 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.64 GLU 373 A
ARG 423 A  14.85    93 %   -2.40  541   0.00    0    0.62 ASP 422 A    0.00 XXX   0 X    2.03 TYR 395 A
ARG 423 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.16 ASP 430 A
ARG 423 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.17 TYR 478 A
ARG 423 A                                            0.00 XXX   0 X    0.00 XXX   0 X    1.77 ASP 422 A
ARG 444 A  12.71    41 %   -1.21  397   0.00    0    0.82 GLU 574 A    0.00 XXX   0 X    0.11 GLU 560 A
ARG 444 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.48 GLU 574 A
ARG 450 A  10.85    51 %   -1.86  425   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.11 TYR 466 A
ARG 450 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.10 ASP 471 A
ARG 461 A  12.72    42 %   -1.59  399   0.00    0    0.91 GLU 334 A    0.00 XXX   0 X    0.18 TYR 322 A
ARG 461 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.23 GLU 330 A
ARG 461 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.49 GLU 334 A
ARG 477 A  12.67   100 %   -3.47  679   0.00    0    0.42 ASP 439 A    0.00 XXX   0 X    0.31 GLU 560 A
ARG 477 A                                            0.00 XXX   0 X    0.00 XXX   0 X    2.03 ASP 439 A
ARG 477 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.88 ASP 561 A
ARG 480 A  11.77    71 %   -0.83  481   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.20 TYR 395 A
ARG 480 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.05 ASP 422 A
ARG 480 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.32 ASP 430 A
ARG 480 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.05 GLU 601 A
ARG 480 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.52 ARG 423 A
ARG 501 A  11.92    28 %   -0.84  361   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.20 ASP 506 A
ARG 501 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.07 GLU 548 A
ARG 501 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.02 ARG 552 A
ARG 536 A  12.28    53 %   -1.78  430   0.00    0    0.26 GLU 459 A    0.00 XXX   0 X    0.03 ASP 456 A
ARG 536 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.12 GLU 498 A
ARG 536 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.43 GLU 500 A
ARG 536 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.05 ASP 542 A
ARG 536 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.67 GLU 459 A
ARG 547 A  13.11     0 %   -0.27  204   0.00    0    0.48 GLU 544 A    0.00 XXX   0 X    0.12 GLU 543 A
ARG 547 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.27 GLU 544 A
ARG 552 A  12.72     0 %   -0.10  150   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.28 ASP 506 A
ARG 552 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.05 GLU 548 A
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ARG 554 A  12.63     0 %   -0.34  264   0.00    0    0.09 ASP 507 A    0.00 XXX   0 X    0.38 ASP 507 A
ARG 586 A  12.70     0 %   -0.36  281   0.00    0    0.22 GLU 620 A    0.00 XXX   0 X    0.34 GLU 620 A
ARG 606 A  12.40     3 %   -0.44  291   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.33 GLU 103 A
ARG 606 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.00 GLU 593 A
ARG 606 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.01 GLU 596 A
ARG 615 A  12.25     0 %   -0.45  273   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.10 GLU 525 A
ARG 615 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.11 ASP 526 A
N+    5 A   7.94     0 %   -0.07   70   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.00 ASP  14 A
TDP N1' A  -0.58   100 %   -3.93  581   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.48 ARG 401 A
TDP N1' A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.78 HIS 124 A
TDP N1' A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.38 HIS 434 A
TDP O13 A   8.30*  100 %    3.41  638   0.00    0   -0.52 SER 156 A    0.00 XXX   0 X   -3.48 MG   MG A
TDP O13 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.25 LYS 289 A
TDP O13 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.03 ASP 182 A
TDP O13 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.85 ASP  79 A
TDP O13 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.90 ASP 154 A
TDP O13 A                                            0.00 XXX   0 X    0.00 XXX   0 X    1.36 TDP O21 A
TDP O21 A  -0.86*  100 %    3.86  613   0.00    0   -0.85 SER  54 A    0.00 XXX   0 X   -3.35 MG   MG A
TDP O21 A                                           -0.83 HIS  82 A    0.00 XXX   0 X   -0.28 HIS  51 A
TDP O21 A                                           -0.20 LYS 289 A    0.00 XXX   0 X   -1.56 HIS  82 A
TDP O21 A                                           -0.17 HIS 304 A    0.00 XXX   0 X   -2.03 LYS 289 A
TDP O21 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -1.46 HIS 304 A
Coupled residues (marked *) were detected. Please rerun PropKa with the --display-coupled-residues 
or -d option for detailed information.
--------------------------------------------------------------------------------------------------------
SUMMARY OF THIS PREDICTION
       Group      pKa  model-pKa   ligand atom-type
   ASP   9 A     3.88       3.80                      
   ASP  14 A     2.41       3.80                      
   ASP  21 A     2.72       3.80                      
   ASP  60 A     2.08       3.80                      
   ASP  70 A     4.70       3.80                      
   ASP  74 A     1.39       3.80                      
   ASP  79 A     4.78       3.80                      
   ASP  95 A     3.85       3.80                      
   ASP  99 A     2.75       3.80                      
   ASP 118 A     0.14       3.80                      
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   ASP 140 A     2.00       3.80                      
   ASP 145 A     3.69       3.80                      
   ASP 154 A     4.87       3.80                      
   ASP 171 A     3.96       3.80                      
   ASP 182 A     1.80       3.80                      
   ASP 260 A     3.25       3.80                      
   ASP 276 A     3.36       3.80                      
   ASP 278 A     3.75       3.80                      
   ASP 299 A     3.71       3.80                      
   ASP 310 A     3.71       3.80                      
   ASP 339 A     3.64       3.80                      
   ASP 368 A     5.57       3.80                      
   ASP 404 A     4.06       3.80                      
   ASP 409 A     2.62       3.80                      
   ASP 422 A     4.51       3.80                      
   ASP 430 A     0.37       3.80                      
   ASP 439 A     5.32       3.80                      
   ASP 456 A     4.07       3.80                      
   ASP 471 A     3.58       3.80                      
   ASP 493 A     2.83       3.80                      
   ASP 506 A     3.37       3.80                      
   ASP 507 A     3.96       3.80                      
   ASP 518 A     5.43       3.80                      
   ASP 526 A     3.97       3.80                      
   ASP 542 A     4.02       3.80                      
   ASP 561 A     2.66       3.80                      
   ASP 592 A     4.02       3.80                      
   ASP 610 A     4.24       3.80                      
   ASP 624 A     3.93       3.80                      
   GLU  28 A     4.41       4.50                      
   GLU  35 A     4.59       4.50                      
   GLU  36 A     4.95       4.50                      
   GLU  40 A     4.20       4.50                      
   GLU 103 A     3.66       4.50                      
   GLU 114 A     4.03       4.50                      
   GLU 116 A     4.36       4.50                      
   GLU 184 A     5.15       4.50                      
   GLU 189 A     3.74       4.50                      
   GLU 266 A     5.09       4.50                      
   GLU 272 A     4.24       4.50                      
   GLU 297 A     4.13       4.50                      
   GLU 315 A     4.73       4.50                      
   GLU 330 A     4.67       4.50                      
   GLU 334 A     2.73       4.50                      
   GLU 351 A     4.75       4.50                      
   GLU 357 A     4.56       4.50                      
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   GLU 373 A     8.47       4.50                      
   GLU 374 A     5.56       4.50                      
   GLU 413 A     4.63       4.50                      
   GLU 459 A     5.00       4.50                      
   GLU 498 A     4.82       4.50                      
   GLU 500 A     4.53       4.50                      
   GLU 525 A     3.59       4.50                      
   GLU 543 A     4.98       4.50                      
   GLU 544 A     3.95       4.50                      
   GLU 548 A     4.64       4.50                      
   GLU 560 A     6.95       4.50                      
   GLU 574 A     3.73       4.50                      
   GLU 593 A     4.70       4.50                      
   GLU 596 A     4.39       4.50                      
   GLU 601 A     4.18       4.50                      
   GLU 620 A     4.26       4.50                      
   HIS  17 A     6.53       6.50                      
   HIS  51 A     1.06       6.50                      
   HIS  66 A     1.56       6.50                      
   HIS  82 A     5.29       6.50                      
   HIS  87 A     4.47       6.50                      
   HIS 117 A     5.29       6.50                      
   HIS 124 A     2.62       6.50                      
   HIS 147 A     8.30       6.50                      
   HIS 262 A     6.11       6.50                      
   HIS 284 A     6.81       6.50                      
   HIS 304 A     2.33       6.50                      
   HIS 362 A     5.25       6.50                      
   HIS 364 A     6.26       6.50                      
   HIS 408 A     7.42       6.50                      
   HIS 414 A     5.62       6.50                      
   HIS 434 A     4.72       6.50                      
   HIS 470 A     5.65       6.50                      
   HIS 582 A     6.30       6.50                      
   HIS 597 A     5.69       6.50                      
   HIS 604 A     7.47       6.50                      
   CYS  45 A    12.61       9.00                      
   CYS 420 A    12.64       9.00                      
   TYR  67 A    10.55      10.00                      
   TYR  85 A    13.91      10.00                      
   TYR 255 A    11.49      10.00                      
   TYR 295 A    11.77      10.00                      
   TYR 302 A    10.96      10.00                      
   TYR 316 A    10.47      10.00                      
   TYR 322 A    12.45      10.00                      
   TYR 366 A    13.79      10.00                      
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   TYR 395 A    11.94      10.00                      
   TYR 403 A    10.35      10.00                      
   TYR 466 A    10.65      10.00                      
   TYR 478 A    16.85      10.00                      
   TYR 519 A    12.47      10.00                      
   LYS  20 A    10.07      10.50                      
   LYS  23 A     9.06      10.50                      
   LYS  88 A     8.79      10.50                      
   LYS 101 A    10.47      10.50                      
   LYS 102 A    10.91      10.50                      
   LYS 111 A    10.37      10.50                      
   LYS 144 A    10.30      10.50                      
   LYS 175 A    10.40      10.50                      
   LYS 196 A    10.39      10.50                      
   LYS 289 A     8.34      10.50                      
   LYS 291 A    10.53      10.50                      
   LYS 308 A    10.37      10.50                      
   LYS 337 A    10.47      10.50                      
   LYS 455 A    10.52      10.50                      
   LYS 465 A    11.18      10.50                      
   LYS 495 A    10.68      10.50                      
   LYS 503 A     9.86      10.50                      
   LYS 515 A    10.07      10.50                      
   LYS 522 A    11.34      10.50                      
   LYS 539 A     9.22      10.50                      
   ARG  24 A    12.77      12.50                      
   ARG  27 A    13.63      12.50                      
   ARG  38 A    12.94      12.50                      
   ARG  43 A    12.70      12.50                      
   ARG  47 A    11.71      12.50                      
   ARG  73 A    12.97      12.50                      
   ARG  75 A    11.65      12.50                      
   ARG  93 A    13.33      12.50                      
   ARG  94 A    13.65      12.50                      
   ARG 139 A    12.42      12.50                      
   ARG 174 A    13.16      12.50                      
   ARG 254 A    12.00      12.50                      
   ARG 273 A    12.32      12.50                      
   ARG 341 A    12.38      12.50                      
   ARG 350 A    13.63      12.50                      
   ARG 360 A    12.32      12.50                      
   ARG 365 A    12.24      12.50                      
   ARG 389 A    11.54      12.50                      
   ARG 401 A    11.96      12.50                      
   ARG 423 A    14.85      12.50                      
   ARG 444 A    12.71      12.50                      
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   ARG 450 A    10.85      12.50                      
   ARG 461 A    12.72      12.50                      
   ARG 477 A    12.67      12.50                      
   ARG 480 A    11.77      12.50                      
   ARG 501 A    11.92      12.50                      
   ARG 536 A    12.28      12.50                      
   ARG 547 A    13.11      12.50                      
   ARG 552 A    12.72      12.50                      
   ARG 554 A    12.63      12.50                      
   ARG 586 A    12.70      12.50                      
   ARG 606 A    12.40      12.50                      
   ARG 615 A    12.25      12.50                      
   N+    5 A     7.94       8.00                      
   TDP N1' A    -0.58       5.00                NAR   
   TDP O13 A     8.30       6.00                 OP   
   TDP O21 A    -0.86       6.00                 OP   
--------------------------------------------------------------------------------------------------------
--------------------------------------------------------------------------------------------------------
Free energy of   folding (kcal/mol) as a function of pH (using neutral reference)
  0.00    121.58
  1.00    114.56
  2.00    102.32
  3.00     82.92
  4.00     63.15
  5.00     54.15
  6.00     47.75
  7.00     46.01
  8.00     50.01
  9.00     52.49
 10.00     55.52
 11.00     64.72
 12.00     74.13
 13.00     82.54
 14.00     90.18
The pH of optimum stability is  6.7 for which the free energy is  45.5 kcal/mol at 298K
Could not determine pH values where the free energy is within 80 % of minimum
Could not determine the pH-range where the free energy is negative
Protein charge of folded and unfolded state as a function of pH
    pH  unfolded  folded
  0.00     75.99   72.32
  1.00     75.93   69.11
  2.00     75.28   63.76
  3.00     69.62   53.32
  4.00     43.87   33.19
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  5.00     12.26    7.93
  6.00     -3.38   -7.79
  7.00    -16.81  -14.82
  8.00    -22.21  -19.43
  9.00    -25.65  -24.47
 10.00    -36.21  -31.88
 11.00    -53.00  -44.94
 12.00    -65.18  -59.50
 13.00    -83.00  -76.21
 14.00    -89.98  -86.04
The pI is  6.00 (folded) and  6.00 (unfolded)
143
Below will be found the ProPKA3.1 results for monomer B of DXS:
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propka3.1                                                                                    2014-09-29
-------------------------------------------------------------------------------------------------------
--                                                                                                   --
--                                   PROPKA: A PROTEIN PKA PREDICTOR                                 --
--                                                                                                   --
--                                 VERSION 1.0,  04/25/2004, IOWA CITY                               --
--                                             BY HUI LI                                             --
--                                                                                                   --
--                            VERSION 2.0,  11/05/2007, IOWA CITY/COPENHAGEN                         --
--                                BY DELPHINE C. BAS AND DAVID M. ROGERS                             --
--                                                                                                   --
--                                VERSION 3.0,  01/06/2011, COPENHAGEN                               --
--                            BY MATS H.M. OLSSON AND CHRESTEN R. SONDERGARD                         --
--                                                                                                   --
--                                VERSION 3.1,  07/01/2011, COPENHAGEN                               --
--                            BY CHRESTEN R. SONDERGARD AND MATS H.M. OLSSON                         --
-------------------------------------------------------------------------------------------------------
-------------------------------------------------------------------------------------------------------
 References:
   Very Fast Empirical Prediction and Rationalization of Protein pKa Values
   Hui Li, Andrew D. Robertson and Jan H. Jensen
   PROTEINS: Structure, Function, and Bioinformatics 61:704-721 (2005)
   
   Very Fast Prediction and Rationalization of pKa Values for Protein-Ligand Complexes
   Delphine C. Bas, David M. Rogers and Jan H. Jensen
   PROTEINS: Structure, Function, and Bioinformatics 73:765-783 (2008)
   
   PROPKA3: Consistent Treatment of Internal and Surface Residues in Empirical pKa predictions
   Mats H.M. Olsson, Chresten R. Sondergard, Michal Rostkowski, and Jan H. Jensen
   Journal of Chemical Theory and Computation, 7(2):525-537 (2011)
   
   Improved Treatment of Ligands and Coupling Effects in Empirical Calculation
    and Rationalization of pKa Values
   Chresten R. Sondergaard, Mats H.M. Olsson, Michal Rostkowski, and Jan H. Jensen
   Journal of Chemical Theory and Computation, (2011)
   
-------------------------------------------------------------------------------------------------------
---------  -----   ------   ---------------------    --------------    --------------    --------------
                            DESOLVATION  EFFECTS       SIDECHAIN          BACKBONE        COULOMBIC    
 RESIDUE    pKa    BURIED     REGULAR      RE        HYDROGEN BOND     HYDROGEN BOND      INTERACTION  
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---------  -----   ------   ---------   ---------    --------------    --------------    --------------
ASP   9 B   3.68     0 %    0.15  186   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.11 N+    8 B
ASP   9 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.19 ARG  43 B
ASP   9 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.01 ARG  94 B
ASP   9 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.02 ASP  14 B
ASP   9 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.02 GLU  40 B
ASP  14 B   1.43     0 %    0.47  244   0.00    0   -0.80 SER   8 B    0.00 XXX   0 X   -0.14 N+    8 B
ASP  14 B                                           -0.77 THR  10 B    0.00 XXX   0 X   -0.01 ARG  43 B
ASP  14 B                                           -0.81 ARG  94 B    0.00 XXX   0 X   -0.02 HIS  17 B
ASP  14 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.28 ARG  94 B
ASP  21 B   2.19     0 %    0.48  275   0.00    0   -0.68 ARG  24 B   -0.77 HIS  17 B   -0.08 LYS  20 B
ASP  21 B                                            0.00 XXX   0 X   -0.01 GLY  18 B   -0.23 HIS  17 B
ASP  21 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.33 ARG  24 B
ASP  60 B   2.17    85 %    3.16  519   1.16    0   -0.50 THR  34 B   -0.15 ASP  60 B   -0.13 LYS 291 B
ASP  60 B                                           -1.62 ARG  38 B    0.00 XXX   0 X   -1.17 ARG  38 B
ASP  60 B                                           -1.60 HIS 262 B    0.00 XXX   0 X   -0.79 HIS 262 B
ASP  70 B   3.34     8 %    0.59  304   0.07    0   -0.81 ARG  73 B    0.00 XXX   0 X   -0.05 LYS  20 B
ASP  70 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.21 LYS  23 B
ASP  70 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.33 ASP  74 B
ASP  70 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.01 HIS 117 B
ASP  70 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.04 HIS 147 B
ASP  70 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.32 ARG  73 B
ASP  74 B   2.18    53 %    1.80  429   0.42    0   -1.60 HIS 147 B   -0.77 ASP  70 B   -0.13 LYS  23 B
ASP  74 B                                            0.00 XXX   0 X   -0.73 HIS 147 B   -0.05 ARG  73 B
ASP  74 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.00 ARG 139 B
ASP  74 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.55 HIS 147 B
ASP  79 B   4.72   100 %    3.96  616   0.37    0   -0.69 SER 128 B   -0.82 SER 126 B   -0.25 ARG 401 B
ASP  79 B                                           -0.73 SER 156 B   -0.03 THR 127 B   -0.21 HIS  82 B
ASP  79 B                                            0.00 XXX   0 X   -0.67 SER 128 B    0.00 XXX   0 X
ASP  95 B   3.93     0 %    0.21  274   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.12 ARG  94 B
ASP  95 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.01 ASP  14 B
ASP  95 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.05 HIS  17 B
ASP  95 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.07 GLU  40 B
ASP  99 B   2.94     0 %    0.30  236   0.00    0   -0.69 LYS 102 B    0.00 XXX   0 X   -0.10 ARG  47 B
ASP  99 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.37 LYS 102 B
ASP 118 B   0.13    81 %    3.24  507   0.81    0   -1.60 HIS  87 B   -0.83 LYS 111 B   -0.01 LYS 111 B
146
9/29/2014 propka.ki.ku.dk/pka/2o1x.pka
http://propka.ki.ku.dk/pka/2o1x.pka 3/21
ASP 118 B                                           -1.59 ARG  93 B    0.00 XXX   0 X   -0.07 HIS  66 B
ASP 118 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.15 HIS 117 B
ASP 118 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -1.43 HIS  87 B
ASP 118 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.96 LYS  88 B
ASP 118 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -1.09 ARG  93 B
ASP 140 B   2.50     3 %    0.64  290   0.04    0   -0.55 ARG 139 B    0.00 XXX   0 X   -0.17 LYS 175 B
ASP 140 B                                           -0.54 ARG 174 B    0.00 XXX   0 X   -0.44 ARG 139 B
ASP 140 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.27 ARG 174 B
ASP 145 B   3.72     0 %    0.21  247   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.09 ARG 139 B
ASP 145 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.16 LYS 175 B
ASP 145 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.06 ASP  74 B
ASP 145 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.03 ASP 140 B
ASP 145 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.13 HIS 147 B
ASP 154 B   5.46*  100 %    4.05  577   1.25    0    0.00 XXX   0 X   -0.28 ASP 154 B   -4.07 MG   MG B
ASP 154 B                                            0.00 XXX   0 X   -0.09 GLY 155 B   -0.40 LYS 289 B
ASP 154 B                                            0.00 XXX   0 X   -0.64 ASN 183 B    0.13 GLU 184 B
ASP 154 B                                            0.00 XXX   0 X   -0.01 GLU 184 B   -0.08 HIS 284 B
ASP 154 B                                            0.00 XXX   0 X   -0.06 MET 185 B    0.94 ASP 182 B
ASP 154 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.91 TDP O21 B
ASP 171 B   3.95     0 %    0.15  163   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.00 XXX   0 X
ASP 182 B   2.62    69 %    2.61  475   0.12    0   -1.60 HIS 284 B   -0.67 GLU 184 B   -1.08 MG   MG B
ASP 182 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.56 HIS 284 B
ASP 260 B   3.44    15 %    0.61  324   0.02    0    0.00 XXX   0 X   -0.74 HIS 262 B   -0.11 LYS 291 B
ASP 260 B                                            0.00 XXX   0 X   -0.01 ASN 263 B    0.11 ASP  60 B
ASP 260 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.24 HIS 262 B
ASP 276 B   3.91     0 %    0.28  276   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.01 LYS 175 B
ASP 276 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.01 ARG 273 B
ASP 276 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.02 ASP 145 B
ASP 276 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.20 HIS 147 B
ASP 276 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.02 GLU 272 B
ASP 276 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.01 ASP 278 B
ASP 278 B   3.67     0 %    0.16  200   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.22 LYS 175 B
ASP 278 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.07 ARG 254 B
ASP 299 B   3.78    21 %    0.83  340   0.03    0    0.00 XXX   0 X   -0.09 ILE 301 B    0.00 XXX   0 X
ASP 299 B                                            0.00 XXX   0 X   -0.79 TYR 302 B    0.00 XXX   0 X
ASP 310 B   3.34     0 %    0.39  201   0.00    0   -0.14 THR 313 B   -0.65 ALA 312 B    0.00 XXX   0 X
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ASP 310 B                                            0.00 XXX   0 X   -0.06 THR 313 B    0.00 XXX   0 X
ASP 339 B   3.08    40 %    1.46  393   0.07    0   -0.46 TRP 335 B   -0.58 ARG 341 B   -0.22 ARG 341 B
ASP 339 B                                           -0.69 THR 342 B    0.00 XXX   0 X   -0.17 ARG 365 B
ASP 339 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.13 ARG 389 B
ASP 368 B   5.38    82 %    2.39  512   0.45    0    0.00 XXX   0 X   -0.32 ALA 348 B   -0.21 ARG 350 B
ASP 368 B                                            0.00 XXX   0 X   -0.80 GLY 370 B    0.06 GLU 189 B
ASP 404 B   4.07     0 %    0.33  254   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.21 HIS 408 B
ASP 404 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.15 ASP 409 B
ASP 409 B   2.72     2 %    0.55  287   0.01    0   -0.65 THR 378 B    0.00 XXX   0 X   -0.32 HIS 408 B
ASP 409 B                                           -0.68 HIS 408 B    0.00 XXX   0 X    0.00 XXX   0 X
ASP 422 B   4.89   100 %    3.67  576   1.05    0   -0.79 SER 325 B   -0.61 ARG 423 B   -0.01 ARG 480 B
ASP 422 B                                           -0.52 ARG 423 B    0.00 XXX   0 X   -1.70 ARG 423 B
ASP 430 B   0.22   100 %    2.30  575   0.00    0   -0.85 LYS 101 B    0.00 XXX   0 X   -0.18 ARG 423 B
ASP 430 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.38 ARG 480 B
ASP 430 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.03 HIS 304 B
ASP 430 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.01 HIS 597 B
ASP 430 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.77 HIS  51 B
ASP 430 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -2.03 LYS 101 B
ASP 430 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -1.61 HIS 434 B
ASP 439 B   4.77   100 %    3.84  645   0.42    0   -0.85 SER 396 B    0.00 XXX   0 X    0.11 ASP 561 B
ASP 439 B                                           -0.52 ARG 477 B    0.00 XXX   0 X   -2.03 ARG 477 B
ASP 456 B   4.44    56 %    1.74  438   0.00    0    0.00 XXX   0 X   -0.00 ASP 456 B   -0.35 LYS 455 B
ASP 456 B                                            0.00 XXX   0 X   -0.00 ALA 458 B   -0.04 ARG 536 B
ASP 456 B                                            0.00 XXX   0 X   -0.79 GLU 459 B    0.09 GLU 500 B
ASP 471 B   3.61     0 %    0.20  260   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.01 ARG 341 B
ASP 471 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.18 ARG 389 B
ASP 471 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.05 ARG 450 B
ASP 471 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.10 HIS 414 B
ASP 471 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.06 HIS 470 B
ASP 493 B   3.31     0 %    0.25  231   0.00    0   -0.34 LYS 465 B    0.00 XXX   0 X   -0.03 LYS 495 B
ASP 493 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.02 HIS 470 B
ASP 493 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.35 LYS 465 B
ASP 506 B   3.61     0 %    0.24  235   0.00    0    0.00 XXX   0 X   -0.11 ASP 506 B   -0.18 ARG 501 B
ASP 506 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.18 ARG 552 B
ASP 506 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.04 ASP 507 B
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ASP 507 B   3.21     3 %    0.48  291   0.02    0   -0.71 ARG 554 B    0.00 XXX   0 X   -0.38 ARG 554 B
ASP 518 B   4.66    53 %    0.89  429   0.36    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.34 LYS 515 B
ASP 518 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.06 LYS 522 B
ASP 526 B   3.84     0 %    0.15  171   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.03 LYS 503 B
ASP 526 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.07 ARG 615 B
ASP 542 B   4.13    35 %    1.53  380   0.31    0    0.00 XXX   0 X   -0.80 TRP 499 B   -0.06 ARG 536 B
ASP 542 B                                            0.00 XXX   0 X   -0.64 MET 545 B    0.00 XXX   0 X
ASP 561 B   4.23   100 %    3.39  621   0.87    0    0.00 XXX   0 X   -0.68 ILE 426 B   -0.28 LYS 515 B
ASP 561 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.95 ARG 477 B
ASP 561 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -1.92 HIS 604 B
ASP 592 B   4.04     0 %    0.24  208   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.00 XXX   0 X
ASP 610 B   4.13    19 %    0.96  335   0.04    0    0.00 XXX   0 X   -0.03 ASP 610 B   -0.10 HIS 604 B
ASP 610 B                                            0.00 XXX   0 X   -0.54 ALA 613 B    0.00 XXX   0 X
ASP 624 B   3.93     0 %    0.13  171   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.01 ARG 554 B
ASP 624 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.01 ASP 507 B
GLU  28 B   4.26     0 %    0.28  194   0.00    0    0.00 XXX   0 X   -0.42 GLU  28 B   -0.10 ARG  27 B
GLU  35 B   4.72    20 %    0.37  338   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.19 ARG  38 B
GLU  35 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.01 LYS 291 B
GLU  35 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.04 ASP  60 B
GLU  36 B   4.72    21 %    1.47  339   0.17    0    0.00 XXX   0 X   -0.63 LEU  12 B   -0.06 N+    8 B
GLU  36 B                                            0.00 XXX   0 X   -0.82 LEU  13 B   -0.02 ARG  43 B
GLU  36 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.10 ARG  94 B
GLU  36 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.04 ASP   9 B
GLU  36 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.13 ASP  14 B
GLU  36 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.04 GLU  40 B
GLU  40 B   3.24    46 %    1.47  409   0.11    0   -0.46 ARG  43 B    0.00 XXX   0 X    0.08 ASP  14 B
GLU  40 B                                           -1.59 ARG  94 B    0.00 XXX   0 X   -0.35 ARG  43 B
GLU  40 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.52 ARG  94 B
GLU 103 B   4.02     0 %    0.34  244   0.00    0   -0.45 SER 602 B    0.00 XXX   0 X   -0.35 ARG 606 B
GLU 103 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.03 HIS 597 B
GLU 114 B   3.93    64 %    2.45  461   0.66    0   -0.65 LYS  88 B   -0.80 SER 107 B   -0.07 LYS 111 B
GLU 114 B                                           -0.74 ARG  93 B    0.00 XXX   0 X   -0.11 HIS  87 B
149
9/29/2014 propka.ki.ku.dk/pka/2o1x.pka
http://propka.ki.ku.dk/pka/2o1x.pka 6/21
GLU 114 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.16 HIS 597 B
GLU 114 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -1.03 LYS  88 B
GLU 114 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.72 ARG  93 B
GLU 114 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.59 ASP 118 B
GLU 116 B   4.37     0 %    0.20  233   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.05 LYS  20 B
GLU 116 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.11 ARG  73 B
GLU 116 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.01 ARG  75 B
GLU 116 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.17 HIS 117 B
GLU 184 B   5.09    15 %    0.32  324   0.04    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.06 MG   MG B
GLU 184 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.01 ARG 199 B
GLU 184 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.29 ASP 182 B
GLU 184 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.02 GLU 189 B
GLU 184 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.02 HIS 284 B
GLU 189 B   5.03    25 %    0.42  350   0.31    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.20 ARG 350 B
GLU 266 B   5.63    18 %    0.78  333   0.14    0    0.00 XXX   0 X    0.00 XXX   0 X    0.22 ASP 260 B
GLU 272 B   3.65     7 %    0.62  300   0.05    0   -0.30 ARG  27 B    0.00 XXX   0 X   -0.39 ARG  27 B
GLU 272 B                                           -0.57 ARG 273 B    0.00 XXX   0 X   -0.24 ARG 273 B
GLU 297 B   3.97    10 %    0.47  308   0.06    0   -0.15 LYS 291 B   -0.42 GLY 292 B   -0.05 ARG  38 B
GLU 297 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.35 LYS 291 B
GLU 297 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.09 HIS 262 B
GLU 315 B   4.70     0 %    0.14  142   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.06 ASP 310 B
GLU 330 B   4.39    20 %    0.82  337   0.11    0   -0.38 GLN 485 B    0.00 XXX   0 X   -0.00 LYS 337 B
GLU 330 B                                           -0.61 TYR 322 B    0.00 XXX   0 X   -0.16 ARG 461 B
GLU 330 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.12 GLU 334 B
GLU 334 B   3.20    17 %    0.92  328   0.13    0   -0.37 TRP 491 B   -0.76 GLY 489 B   -0.13 LYS 337 B
GLU 334 B                                           -0.60 ARG 461 B    0.00 XXX   0 X   -0.50 ARG 461 B
GLU 351 B   5.63    55 %    1.78  434   0.00    0   -0.09 ARG 350 B    0.00 XXX   0 X   -0.10 ARG 360 B
GLU 351 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.07 GLU 189 B
GLU 351 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.05 ASP 299 B
GLU 351 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.07 ASP 368 B
GLU 351 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.63 ARG 350 B
GLU 357 B   4.58     0 %    0.25  261   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.13 LYS 337 B
GLU 357 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.04 ARG 360 B
GLU 357 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.05 GLU 330 B
GLU 357 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.04 HIS 362 B
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GLU 373 B   7.98   100 %    3.55  587   0.83    0    0.00 XXX   0 X   -0.74 GLU 373 B    0.51 GLU 374 B
GLU 373 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.67 ARG 401 B
GLU 374 B   5.25    57 %    1.27  440   0.34    0    0.00 XXX   0 X   -0.49 GLU 374 B   -0.36 ARG 401 B
GLU 413 B   4.64     0 %    0.14  177   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.01 HIS 414 B
GLU 459 B   5.19    79 %    3.13  503   0.24    0   -0.82 ASN 534 B   -0.76 LYS 455 B    0.46 ASP 456 B
GLU 459 B                                           -0.61 ARG 536 B    0.00 XXX   0 X    0.35 GLU 500 B
GLU 459 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.51 LYS 455 B
GLU 459 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.78 ARG 536 B
GLU 498 B   4.73     0 %    0.41  278   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.23 LYS 495 B
GLU 498 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.12 ARG 536 B
GLU 498 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.17 ASP 542 B
GLU 500 B   3.59    25 %    0.70  350   0.09    0   -0.85 LYS 455 B    0.00 XXX   0 X   -0.35 ARG 536 B
GLU 500 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.49 LYS 455 B
GLU 525 B   4.56     0 %    0.21  213   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.04 LYS 503 B
GLU 525 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.18 LYS 522 B
GLU 525 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.07 ARG 615 B
GLU 525 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.12 ASP 526 B
GLU 525 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.03 GLU 628 B
GLU 543 B   4.84    14 %    0.40  321   0.03    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.13 ARG 547 B
GLU 543 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.02 ASP 542 B
GLU 543 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.03 GLU 544 B
GLU 544 B   4.58     0 %    0.12  172   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.14 ARG 547 B
GLU 544 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.07 ASP 542 B
GLU 544 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.03 GLU 548 B
GLU 548 B   4.43     0 %    0.19  219   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.01 ARG 501 B
GLU 548 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.28 ARG 552 B
GLU 548 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.03 ASP 542 B
GLU 560 B   7.65    93 %    3.47  543   1.59    0    0.00 XXX   0 X   -0.72 PHE 568 B   -0.12 ARG 444 B
GLU 560 B                                            0.00 XXX   0 X   -0.82 GLY 569 B   -0.28 ARG 477 B
GLU 560 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.02 ASP 561 B
GLU 574 B   3.77    11 %    0.50  311   0.07    0   -0.80 ARG 444 B    0.00 XXX   0 X   -0.02 LYS 539 B
GLU 574 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.49 ARG 444 B
GLU 593 B   4.70     0 %    0.14  193   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.04 ASP 592 B
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GLU 593 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.02 GLU 596 B
GLU 596 B   4.44    26 %    0.59  354   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.41 LYS 111 B
GLU 596 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.01 ARG 606 B
GLU 596 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.01 GLU 114 B
GLU 596 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.25 HIS 597 B
GLU 601 B   4.45    18 %    0.48  331   0.00    0    0.00 XXX   0 X   -0.19 GLU 601 B   -0.08 ARG 480 B
GLU 601 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.15 LYS 515 B
GLU 601 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.11 HIS 604 B
GLU 620 B   4.62     0 %    0.26  240   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.14 ARG 586 B
GLU 628 B   4.29     0 %    0.36  195   0.00    0   -0.22 ARG 615 B    0.00 XXX   0 X    0.03 ASP 526 B
GLU 628 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.38 ARG 615 B
HIS  17 B   6.51     0 %   -0.25  239   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.02 ARG  24 B
HIS  17 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.02 ARG  94 B
HIS  17 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.02 ASP  14 B
HIS  17 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.23 ASP  21 B
HIS  17 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.05 ASP  95 B
HIS  51 B   0.43   100 %   -2.59  642   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -1.66 LYS 101 B
HIS  51 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.12 LYS 289 B
HIS  51 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -1.12 HIS  82 B
HIS  51 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -1.24 HIS 304 B
HIS  51 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.25 HIS 434 B
HIS  51 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.15 TDP O21 B
HIS  51 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.77 ASP 430 B
HIS  66 B   1.51   100 %   -2.89  590   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.34 LYS  23 B
HIS  66 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.09 ARG  93 B
HIS  66 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -1.32 HIS  87 B
HIS  66 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.41 HIS 117 B
HIS  66 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.07 ASP 118 B
HIS  82 B   4.51   100 %   -3.32  669   0.00    0    0.01 GLN  83 B    0.00 XXX   0 X   -0.74 MG   MG B
HIS  82 B                                            0.53 TDP O11 B    0.00 XXX   0 X   -0.08 LYS 101 B
HIS  82 B                                            0.71 TDP O21 B    0.00 XXX   0 X   -0.54 LYS 289 B
HIS  82 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.21 ASP  79 B
HIS  82 B                                            0.00 XXX   0 X    0.00 XXX   0 X    1.23 TDP O21 B
HIS  87 B   4.64   100 %   -3.12  614   0.00    0    1.60 ASP 118 B    0.07 HIS 117 B   -0.46 LYS  88 B
HIS  87 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -1.11 ARG  93 B
HIS  87 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.11 GLU 114 B
HIS  87 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.37 HIS 117 B
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HIS  87 B                                            0.00 XXX   0 X    0.00 XXX   0 X    1.43 ASP 118 B
HIS 117 B   5.19    49 %   -1.46  419   0.00    0    0.00 XXX   0 X    0.18 SER  71 B   -0.06 LYS  20 B
HIS 117 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.01 LYS  23 B
HIS 117 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.07 ARG  73 B
HIS 117 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.22 ARG  93 B
HIS 117 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.01 ASP  70 B
HIS 117 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.17 GLU 116 B
HIS 117 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.15 ASP 118 B
HIS 124 B   2.70    92 %   -2.38  539   0.00    0    0.00 XXX   0 X    0.11 THR 433 B   -0.70 ARG 401 B
HIS 124 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.83 HIS 434 B
HIS 147 B   7.66    47 %   -1.24  412   0.00    0    1.60 ASP  74 B    0.00 XXX   0 X   -0.07 ARG 139 B
HIS 147 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.04 LYS 175 B
HIS 147 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.04 ASP  70 B
HIS 147 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.13 ASP 145 B
HIS 147 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.20 ASP 276 B
HIS 147 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.55 ASP  74 B
HIS 262 B   5.90    72 %   -2.33  484   0.00    0    1.60 ASP  60 B    0.00 GLY 261 B   -0.57 ARG  38 B
HIS 262 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.42 LYS 291 B
HIS 262 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.24 ASP 260 B
HIS 262 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.09 GLU 297 B
HIS 262 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.79 ASP  60 B
HIS 284 B   6.61    66 %   -2.12  466   0.00    0    1.60 ASP 182 B    0.00 XXX   0 X   -0.03 ARG 199 B
HIS 284 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.08 ASP 154 B
HIS 284 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.02 GLU 184 B
HIS 284 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.56 ASP 182 B
HIS 304 B   1.71   100 %   -2.79  617   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.33 MG   MG B
HIS 304 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.12 LYS 101 B
HIS 304 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -1.62 LYS 289 B
HIS 304 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -1.08 HIS  82 B
HIS 304 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.03 ASP 430 B
HIS 304 B                                            0.00 XXX   0 X    0.00 XXX   0 X    1.12 TDP O21 B
HIS 362 B   5.16    21 %   -1.05  340   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.12 LYS 337 B
HIS 362 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.22 ARG 365 B
HIS 362 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.04 GLU 357 B
HIS 364 B   6.34     0 %   -0.15  160   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.01 ARG 365 B
HIS 408 B   7.47     0 %   -0.23  202   0.00    0    0.68 ASP 409 B    0.00 XXX   0 X    0.21 ASP 404 B
HIS 408 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.32 ASP 409 B
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HIS 414 B   5.56    20 %   -0.67  338   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.37 ARG 450 B
HIS 414 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.00 LYS 539 B
HIS 414 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.01 GLU 413 B
HIS 414 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.10 ASP 471 B
HIS 434 B   4.76   100 %   -2.87  585   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.48 LYS 101 B
HIS 434 B                                            0.00 XXX   0 X    0.00 XXX   0 X    1.61 ASP 430 B
HIS 470 B   5.59    12 %   -0.87  316   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.06 ARG 389 B
HIS 470 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.05 ARG 450 B
HIS 470 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.01 LYS 465 B
HIS 470 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.06 ASP 471 B
HIS 470 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.02 ASP 493 B
HIS 582 B   6.27     0 %   -0.23  170   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.00 XXX   0 X
HIS 597 B   5.56    49 %   -1.34  418   0.00    0    0.00 XXX   0 X    0.03 LYS 101 B   -0.11 LYS  88 B
HIS 597 B                                            0.00 XXX   0 X    0.20 LYS 102 B   -0.08 LYS 101 B
HIS 597 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.08 LYS 111 B
HIS 597 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.03 GLU 103 B
HIS 597 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.16 GLU 114 B
HIS 597 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.01 ASP 430 B
HIS 597 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.25 GLU 596 B
HIS 604 B   5.95    80 %   -2.48  504   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.01 ARG 477 B
HIS 604 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.18 LYS 515 B
HIS 604 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.01 ARG 606 B
HIS 604 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.11 GLU 601 B
HIS 604 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.10 ASP 610 B
HIS 604 B                                            0.00 XXX   0 X    0.00 XXX   0 X    1.92 ASP 561 B
CYS  45 B  12.62   100 %    3.73  575   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.09 ARG  47 B
CYS  45 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.02 LYS 101 B
CYS 420 B  12.82   100 %    3.73  737   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.09 ASP 422 B
TYR  67 B  10.59    19 %    0.87  335   0.00    0   -0.16 ARG  27 B    0.00 XXX   0 X   -0.27 ARG  27 B
TYR  67 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.08 GLU  28 B
TYR  67 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.08 GLU 272 B
TYR  85 B  13.82   100 %    3.47  601   0.00    0    0.00 XXX   0 X   -0.84 HIS  51 B    1.13 CYS  45 B
TYR  85 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.12 ARG  47 B
TYR  85 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.18 ASP 430 B
TYR 255 B  11.64    34 %    1.62  377   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.09 ASP 182 B
154
9/29/2014 propka.ki.ku.dk/pka/2o1x.pka
http://propka.ki.ku.dk/pka/2o1x.pka 11/21
TYR 255 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.07 ARG 199 B
TYR 295 B  10.62     0 %    0.50  247   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.09 ASP 310 B
TYR 295 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.03 GLU 315 B
TYR 302 B  11.37    23 %    1.43  347   0.00    0    0.00 XXX   0 X   -0.35 ALA 307 B    0.05 ASP 299 B
TYR 302 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.24 TYR 316 B
TYR 316 B  10.51     0 %    0.32  271   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.19 ASP 299 B
TYR 316 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.00 GLU 315 B
TYR 322 B  12.12    26 %    1.38  355   0.00    0   -0.25 GLN 485 B    0.00 XXX   0 X    0.05 GLU 334 B
TYR 322 B                                            0.61 GLU 330 B    0.00 XXX   0 X   -0.14 ARG 461 B
TYR 322 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.47 GLU 330 B
TYR 366 B  12.68    70 %    2.64  477   0.00    0   -0.48 ARG 350 B    0.00 XXX   0 X    0.03 GLU 189 B
TYR 366 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.51 ARG 350 B
TYR 366 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.21 GLU 351 B
TYR 366 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.79 ASP 368 B
TYR 395 B  12.09   100 %    2.96  586   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -2.03 ARG 423 B
TYR 395 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.20 ASP 430 B
TYR 395 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.16 ARG 480 B
TYR 395 B                                            0.00 XXX   0 X    0.00 XXX   0 X    1.12 ASP 422 B
TYR 403 B  10.37     0 %    0.33  277   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.04 ASP 404 B
TYR 466 B  10.67    20 %    0.82  337   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.14 ARG 450 B
TYR 466 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.01 ASP 471 B
TYR 466 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.02 LYS 495 B
TYR 478 B  16.80   100 %    3.86  663   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    1.46 CYS 420 B
TYR 478 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.15 ARG 423 B
TYR 478 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.10 TYR 395 B
TYR 478 B                                            0.00 XXX   0 X    0.00 XXX   0 X    1.54 ASP 422 B
TYR 519 B  12.32    48 %    1.49  415   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.14 ASP 518 B
TYR 519 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.32 ASP 561 B
TYR 519 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.21 GLU 601 B
TYR 519 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.17 ASP 610 B
LYS  20 B  10.29     0 %   -0.15  205   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.08 ASP  21 B
LYS  20 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.05 ARG  24 B
LYS  20 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.05 ASP  70 B
LYS  20 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.19 ARG  73 B
LYS  20 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.05 GLU 116 B
155
9/29/2014 propka.ki.ku.dk/pka/2o1x.pka
http://propka.ki.ku.dk/pka/2o1x.pka 12/21
LYS  23 B   8.57    58 %   -2.24  443   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.21 ASP  70 B
LYS  23 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.02 ARG  73 B
LYS  23 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.13 ASP  74 B
LYS  88 B   8.66    90 %   -3.58  532   0.00    0    0.65 GLU 114 B    0.00 XXX   0 X   -0.88 ARG  93 B
LYS  88 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.02 LYS 111 B
LYS  88 B                                            0.00 XXX   0 X    0.00 XXX   0 X    1.03 GLU 114 B
LYS  88 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.96 ASP 118 B
LYS 101 B  10.50   100 %   -2.70  567   0.00    0    0.85 ASP 430 B    0.00 XXX   0 X    0.02 CYS  45 B
LYS 101 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.05 ARG  47 B
LYS 101 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.15 ARG 480 B
LYS 101 B                                            0.00 XXX   0 X    0.00 XXX   0 X    2.03 ASP 430 B
LYS 102 B  10.84     0 %   -0.39  248   0.00    0    0.69 ASP  99 B    0.00 XXX   0 X   -0.34 ARG  47 B
LYS 102 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.37 ASP  99 B
LYS 111 B  10.41    21 %   -0.58  339   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.07 GLU 114 B
LYS 111 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.01 ASP 118 B
LYS 111 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.41 GLU 596 B
LYS 144 B  10.28     0 %   -0.21  174   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.01 ARG  75 B
LYS 175 B  10.63     0 %   -0.22  269   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.18 ARG 139 B
LYS 175 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.17 ASP 140 B
LYS 175 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.16 ASP 145 B
LYS 175 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.02 ARG 174 B
LYS 175 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.01 ASP 276 B
LYS 175 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.22 ASP 278 B
LYS 196 B   9.82    20 %   -0.68  338   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.00 XXX   0 X
LYS 289 B   8.42   100 %   -3.62  575   0.00    0    0.80 TDP O21 B    0.00 XXX   0 X   -2.08 MG   MG B
LYS 289 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.40 ASP 154 B
LYS 289 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.39 TDP O13 B
LYS 289 B                                            0.00 XXX   0 X    0.00 XXX   0 X    2.03 TDP O21 B
LYS 291 B  10.57    18 %   -0.49  332   0.00    0    0.15 GLU 297 B    0.00 XXX   0 X    0.01 GLU  35 B
LYS 291 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.18 ARG  38 B
LYS 291 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.13 ASP  60 B
LYS 291 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.11 ASP 260 B
LYS 291 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.35 GLU 297 B
LYS 308 B  10.37     0 %   -0.13  174   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.00 XXX   0 X
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LYS 337 B  10.52     0 %   -0.24  271   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.00 GLU 330 B
LYS 337 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.13 GLU 334 B
LYS 337 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.13 GLU 357 B
LYS 455 B  11.53    31 %   -1.00  368   0.00    0    0.85 GLU 500 B    0.00 XXX   0 X    0.35 ASP 456 B
LYS 455 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.18 ARG 536 B
LYS 455 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.51 GLU 459 B
LYS 455 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.49 GLU 500 B
LYS 465 B  10.84     2 %   -0.36  288   0.00    0    0.34 ASP 493 B    0.00 XXX   0 X    0.35 ASP 493 B
LYS 495 B  10.68     0 %   -0.10  165   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.03 ASP 493 B
LYS 495 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.23 GLU 498 B
LYS 495 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.02 TYR 466 B
LYS 503 B  10.11     8 %   -0.45  304   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.01 ARG 501 B
LYS 503 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.04 GLU 525 B
LYS 503 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.03 ASP 526 B
LYS 515 B  10.25    58 %   -1.00  444   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.02 ARG 480 B
LYS 515 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.34 ASP 518 B
LYS 515 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.28 ASP 561 B
LYS 515 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.15 GLU 601 B
LYS 522 B  10.60     0 %   -0.14  220   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.06 ASP 518 B
LYS 522 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.18 GLU 525 B
LYS 539 B   9.01    40 %   -1.36  392   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.11 ARG 444 B
LYS 539 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.04 ARG 450 B
LYS 539 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.02 GLU 574 B
ARG  24 B  13.22     0 %   -0.28  201   0.00    0    0.68 ASP  21 B    0.00 XXX   0 X    0.33 ASP  21 B
ARG  27 B  13.34     0 %   -0.38  282   0.00    0    0.16 TYR  67 B    0.00 XXX   0 X    0.10 GLU  28 B
ARG  27 B                                            0.30 GLU 272 B    0.00 XXX   0 X    0.27 TYR  67 B
ARG  27 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.39 GLU 272 B
ARG  38 B  13.02    80 %   -2.51  505   0.00    0    1.62 ASP  60 B    0.00 XXX   0 X    0.19 GLU  35 B
ARG  38 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.05 GLU 297 B
ARG  38 B                                            0.00 XXX   0 X    0.00 XXX   0 X    1.17 ASP  60 B
ARG  43 B  12.72    21 %   -0.70  341   0.00    0    0.46 GLU  40 B    0.00 XXX   0 X    0.19 ASP   9 B
ARG  43 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.01 ASP  14 B
ARG  43 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.02 GLU  36 B
ARG  43 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.12 ARG  94 B
ARG  43 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.35 GLU  40 B
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ARG  47 B  11.77    29 %   -1.05  363   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.09 CYS  45 B
ARG  47 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.12 TYR  85 B
ARG  47 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.10 ASP  99 B
ARG  73 B  13.49     0 %   -0.30  237   0.00    0    0.81 ASP  70 B    0.00 XXX   0 X    0.05 ASP  74 B
ARG  73 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.11 GLU 116 B
ARG  73 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.32 ASP  70 B
ARG  75 B  11.63    41 %   -0.88  395   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.01 GLU 116 B
ARG  93 B  13.83    78 %   -2.81  501   0.00    0    0.74 GLU 114 B    0.00 XXX   0 X    0.72 GLU 114 B
ARG  93 B                                            1.59 ASP 118 B    0.00 XXX   0 X    1.09 ASP 118 B
ARG  94 B  15.05    18 %   -0.88  333   0.00    0    0.81 ASP  14 B    0.00 XXX   0 X    0.01 ASP   9 B
ARG  94 B                                            1.59 GLU  40 B    0.00 XXX   0 X    0.10 GLU  36 B
ARG  94 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.12 ASP  95 B
ARG  94 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.28 ASP  14 B
ARG  94 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.52 GLU  40 B
ARG 139 B  12.36    29 %   -1.16  362   0.00    0    0.55 ASP 140 B    0.00 XXX   0 X    0.00 ASP  74 B
ARG 139 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.09 ASP 145 B
ARG 139 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.07 ARG 174 B
ARG 139 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.44 ASP 140 B
ARG 174 B  12.96     0 %   -0.35  246   0.00    0    0.54 ASP 140 B    0.00 XXX   0 X    0.27 ASP 140 B
ARG 199 B  12.42     0 %   -0.15  195   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.01 GLU 184 B
ARG 199 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.07 TYR 255 B
ARG 254 B  12.04     8 %   -0.53  304   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.07 ASP 278 B
ARG 273 B  12.77     0 %   -0.48  212   0.00    0    0.57 GLU 272 B    0.00 XXX   0 X    0.01 ASP 276 B
ARG 273 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.09 ARG  27 B
ARG 273 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.24 GLU 272 B
ARG 341 B  12.46     0 %   -0.28  280   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.22 ASP 339 B
ARG 341 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.01 ASP 471 B
ARG 350 B  13.50    41 %   -1.12  395   0.00    0    0.48 TYR 366 B    0.00 XXX   0 X    0.20 GLU 189 B
ARG 350 B                                            0.09 GLU 351 B    0.00 XXX   0 X    0.51 TYR 366 B
ARG 350 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.21 ASP 368 B
ARG 350 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.63 GLU 351 B
ARG 360 B  12.30     0 %   -0.23  231   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.10 GLU 351 B
ARG 360 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.04 GLU 357 B
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ARG 360 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.12 ARG 350 B
ARG 365 B  11.33    32 %   -1.35  370   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.17 ASP 339 B
ARG 389 B  11.57    30 %   -0.89  365   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.13 ASP 339 B
ARG 389 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.18 ASP 471 B
ARG 389 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.34 ARG 341 B
ARG 401 B  11.90    73 %   -1.89  486   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.25 ASP  79 B
ARG 401 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.36 GLU 374 B
ARG 401 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.67 GLU 373 B
ARG 423 B  14.76    92 %   -2.33  540   0.00    0    0.52 ASP 422 B    0.00 XXX   0 X    2.03 TYR 395 B
ARG 423 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.18 ASP 430 B
ARG 423 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.15 TYR 478 B
ARG 423 B                                            0.00 XXX   0 X    0.00 XXX   0 X    1.70 ASP 422 B
ARG 444 B  12.71    41 %   -1.19  397   0.00    0    0.80 GLU 574 B    0.00 XXX   0 X    0.12 GLU 560 B
ARG 444 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.49 GLU 574 B
ARG 450 B  10.92    48 %   -1.77  416   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.14 TYR 466 B
ARG 450 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.05 ASP 471 B
ARG 461 B  12.33    39 %   -1.57  391   0.00    0    0.60 GLU 334 B    0.00 XXX   0 X    0.14 TYR 322 B
ARG 461 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.16 GLU 330 B
ARG 461 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.50 GLU 334 B
ARG 477 B  12.71   100 %   -3.57  679   0.00    0    0.52 ASP 439 B    0.00 XXX   0 X    0.28 GLU 560 B
ARG 477 B                                            0.00 XXX   0 X    0.00 XXX   0 X    2.03 ASP 439 B
ARG 477 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.95 ASP 561 B
ARG 480 B  11.82    71 %   -0.85  481   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.16 TYR 395 B
ARG 480 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.01 ASP 422 B
ARG 480 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.38 ASP 430 B
ARG 480 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.08 GLU 601 B
ARG 480 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.46 ARG 423 B
ARG 501 B  11.73    29 %   -0.91  362   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.18 ASP 506 B
ARG 501 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.01 GLU 548 B
ARG 501 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.06 ARG 552 B
ARG 536 B  12.63    58 %   -1.85  443   0.00    0    0.61 GLU 459 B    0.00 XXX   0 X    0.04 ASP 456 B
ARG 536 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.12 GLU 498 B
ARG 536 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.35 GLU 500 B
ARG 536 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.06 ASP 542 B
ARG 536 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.78 GLU 459 B
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ARG 547 B  12.49     0 %   -0.28  208   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.13 GLU 543 B
ARG 547 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.14 GLU 544 B
ARG 552 B  12.73     0 %   -0.23  222   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.18 ASP 506 B
ARG 552 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.28 GLU 548 B
ARG 554 B  13.25     0 %   -0.35  266   0.00    0    0.71 ASP 507 B    0.00 XXX   0 X    0.01 ASP 624 B
ARG 554 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.38 ASP 507 B
ARG 586 B  12.35     0 %   -0.28  261   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.14 GLU 620 B
ARG 606 B  12.38     3 %   -0.47  291   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.35 GLU 103 B
ARG 606 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.01 GLU 596 B
ARG 615 B  12.80     0 %   -0.46  279   0.00    0    0.22 GLU 628 B    0.00 XXX   0 X    0.07 GLU 525 B
ARG 615 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.07 ASP 526 B
ARG 615 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.38 GLU 628 B
N+    8 B   8.05     0 %   -0.26  136   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.11 ASP   9 B
N+    8 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.14 ASP  14 B
N+    8 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.06 GLU  36 B
TDP N1' B  -0.57   100 %   -3.89  578   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.55 ARG 401 B
TDP N1' B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.77 HIS 124 B
TDP N1' B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.35 HIS 434 B
TDP O13 B   8.33*  100 %    3.53  644   0.00    0   -0.78 SER 156 B    0.00 XXX   0 X   -3.48 MG   MG B
TDP O13 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.39 LYS 289 B
TDP O13 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.07 ASP 182 B
TDP O13 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.79 ASP  79 B
TDP O13 B                                            0.00 XXX   0 X    0.00 XXX   0 X    1.20 ASP 154 B
TDP O13 B                                            0.00 XXX   0 X    0.00 XXX   0 X    1.38 TDP O21 B
TDP O21 B  -1.66*  100 %    3.87  616   0.00    0   -0.85 SER  54 B    0.00 XXX   0 X   -4.07 MG   MG B
TDP O21 B                                           -0.58 ASN 183 B    0.00 XXX   0 X   -0.15 HIS  51 B
TDP O21 B                                           -0.71 HIS  82 B    0.00 XXX   0 X   -1.23 HIS  82 B
TDP O21 B                                           -0.80 LYS 289 B    0.00 XXX   0 X   -2.03 LYS 289 B
TDP O21 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -1.12 HIS 304 B
Coupled residues (marked *) were detected. Please rerun PropKa with the --display-coupled-residues 
or -d option for detailed information.
--------------------------------------------------------------------------------------------------------
SUMMARY OF THIS PREDICTION
       Group      pKa  model-pKa   ligand atom-type
   ASP   9 B     3.68       3.80                      
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   ASP  14 B     1.43       3.80                      
   ASP  21 B     2.19       3.80                      
   ASP  60 B     2.17       3.80                      
   ASP  70 B     3.34       3.80                      
   ASP  74 B     2.18       3.80                      
   ASP  79 B     4.72       3.80                      
   ASP  95 B     3.93       3.80                      
   ASP  99 B     2.94       3.80                      
   ASP 118 B     0.13       3.80                      
   ASP 140 B     2.50       3.80                      
   ASP 145 B     3.72       3.80                      
   ASP 154 B     5.46       3.80                      
   ASP 171 B     3.95       3.80                      
   ASP 182 B     2.62       3.80                      
   ASP 260 B     3.44       3.80                      
   ASP 276 B     3.91       3.80                      
   ASP 278 B     3.67       3.80                      
   ASP 299 B     3.78       3.80                      
   ASP 310 B     3.34       3.80                      
   ASP 339 B     3.08       3.80                      
   ASP 368 B     5.38       3.80                      
   ASP 404 B     4.07       3.80                      
   ASP 409 B     2.72       3.80                      
   ASP 422 B     4.89       3.80                      
   ASP 430 B     0.22       3.80                      
   ASP 439 B     4.77       3.80                      
   ASP 456 B     4.44       3.80                      
   ASP 471 B     3.61       3.80                      
   ASP 493 B     3.31       3.80                      
   ASP 506 B     3.61       3.80                      
   ASP 507 B     3.21       3.80                      
   ASP 518 B     4.66       3.80                      
   ASP 526 B     3.84       3.80                      
   ASP 542 B     4.13       3.80                      
   ASP 561 B     4.23       3.80                      
   ASP 592 B     4.04       3.80                      
   ASP 610 B     4.13       3.80                      
   ASP 624 B     3.93       3.80                      
   GLU  28 B     4.26       4.50                      
   GLU  35 B     4.72       4.50                      
   GLU  36 B     4.72       4.50                      
   GLU  40 B     3.24       4.50                      
   GLU 103 B     4.02       4.50                      
   GLU 114 B     3.93       4.50                      
   GLU 116 B     4.37       4.50                      
   GLU 184 B     5.09       4.50                      
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   GLU 189 B     5.03       4.50                      
   GLU 266 B     5.63       4.50                      
   GLU 272 B     3.65       4.50                      
   GLU 297 B     3.97       4.50                      
   GLU 315 B     4.70       4.50                      
   GLU 330 B     4.39       4.50                      
   GLU 334 B     3.20       4.50                      
   GLU 351 B     5.63       4.50                      
   GLU 357 B     4.58       4.50                      
   GLU 373 B     7.98       4.50                      
   GLU 374 B     5.25       4.50                      
   GLU 413 B     4.64       4.50                      
   GLU 459 B     5.19       4.50                      
   GLU 498 B     4.73       4.50                      
   GLU 500 B     3.59       4.50                      
   GLU 525 B     4.56       4.50                      
   GLU 543 B     4.84       4.50                      
   GLU 544 B     4.58       4.50                      
   GLU 548 B     4.43       4.50                      
   GLU 560 B     7.65       4.50                      
   GLU 574 B     3.77       4.50                      
   GLU 593 B     4.70       4.50                      
   GLU 596 B     4.44       4.50                      
   GLU 601 B     4.45       4.50                      
   GLU 620 B     4.62       4.50                      
   GLU 628 B     4.29       4.50                      
   HIS  17 B     6.51       6.50                      
   HIS  51 B     0.43       6.50                      
   HIS  66 B     1.51       6.50                      
   HIS  82 B     4.51       6.50                      
   HIS  87 B     4.64       6.50                      
   HIS 117 B     5.19       6.50                      
   HIS 124 B     2.70       6.50                      
   HIS 147 B     7.66       6.50                      
   HIS 262 B     5.90       6.50                      
   HIS 284 B     6.61       6.50                      
   HIS 304 B     1.71       6.50                      
   HIS 362 B     5.16       6.50                      
   HIS 364 B     6.34       6.50                      
   HIS 408 B     7.47       6.50                      
   HIS 414 B     5.56       6.50                      
   HIS 434 B     4.76       6.50                      
   HIS 470 B     5.59       6.50                      
   HIS 582 B     6.27       6.50                      
   HIS 597 B     5.56       6.50                      
   HIS 604 B     5.95       6.50                      
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   CYS  45 B    12.62       9.00                      
   CYS 420 B    12.82       9.00                      
   TYR  67 B    10.59      10.00                      
   TYR  85 B    13.82      10.00                      
   TYR 255 B    11.64      10.00                      
   TYR 295 B    10.62      10.00                      
   TYR 302 B    11.37      10.00                      
   TYR 316 B    10.51      10.00                      
   TYR 322 B    12.12      10.00                      
   TYR 366 B    12.68      10.00                      
   TYR 395 B    12.09      10.00                      
   TYR 403 B    10.37      10.00                      
   TYR 466 B    10.67      10.00                      
   TYR 478 B    16.80      10.00                      
   TYR 519 B    12.32      10.00                      
   LYS  20 B    10.29      10.50                      
   LYS  23 B     8.57      10.50                      
   LYS  88 B     8.66      10.50                      
   LYS 101 B    10.50      10.50                      
   LYS 102 B    10.84      10.50                      
   LYS 111 B    10.41      10.50                      
   LYS 144 B    10.28      10.50                      
   LYS 175 B    10.63      10.50                      
   LYS 196 B     9.82      10.50                      
   LYS 289 B     8.42      10.50                      
   LYS 291 B    10.57      10.50                      
   LYS 308 B    10.37      10.50                      
   LYS 337 B    10.52      10.50                      
   LYS 455 B    11.53      10.50                      
   LYS 465 B    10.84      10.50                      
   LYS 495 B    10.68      10.50                      
   LYS 503 B    10.11      10.50                      
   LYS 515 B    10.25      10.50                      
   LYS 522 B    10.60      10.50                      
   LYS 539 B     9.01      10.50                      
   ARG  24 B    13.22      12.50                      
   ARG  27 B    13.34      12.50                      
   ARG  38 B    13.02      12.50                      
   ARG  43 B    12.72      12.50                      
   ARG  47 B    11.77      12.50                      
   ARG  73 B    13.49      12.50                      
   ARG  75 B    11.63      12.50                      
   ARG  93 B    13.83      12.50                      
   ARG  94 B    15.05      12.50                      
   ARG 139 B    12.36      12.50                      
   ARG 174 B    12.96      12.50                      
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   ARG 199 B    12.42      12.50                      
   ARG 254 B    12.04      12.50                      
   ARG 273 B    12.77      12.50                      
   ARG 341 B    12.46      12.50                      
   ARG 350 B    13.50      12.50                      
   ARG 360 B    12.30      12.50                      
   ARG 365 B    11.33      12.50                      
   ARG 389 B    11.57      12.50                      
   ARG 401 B    11.90      12.50                      
   ARG 423 B    14.76      12.50                      
   ARG 444 B    12.71      12.50                      
   ARG 450 B    10.92      12.50                      
   ARG 461 B    12.33      12.50                      
   ARG 477 B    12.71      12.50                      
   ARG 480 B    11.82      12.50                      
   ARG 501 B    11.73      12.50                      
   ARG 536 B    12.63      12.50                      
   ARG 547 B    12.49      12.50                      
   ARG 552 B    12.73      12.50                      
   ARG 554 B    13.25      12.50                      
   ARG 586 B    12.35      12.50                      
   ARG 606 B    12.38      12.50                      
   ARG 615 B    12.80      12.50                      
   N+    8 B     8.05       8.00                      
   TDP N1' B    -0.57       5.00                NAR   
   TDP O13 B     8.33       6.00                 OP   
   TDP O21 B    -1.66       6.00                 OP   
--------------------------------------------------------------------------------------------------------
--------------------------------------------------------------------------------------------------------
Free energy of   folding (kcal/mol) as a function of pH (using neutral reference)
  0.00    124.42
  1.00    117.04
  2.00    104.84
  3.00     86.18
  4.00     66.66
  5.00     57.47
  6.00     50.36
  7.00     47.60
  8.00     50.78
  9.00     52.28
 10.00     54.93
 11.00     63.98
 12.00     72.65
 13.00     80.85
 14.00     88.96
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The pH of optimum stability is  6.8 for which the free energy is  47.4 kcal/mol at 298K
Could not determine pH values where the free energy is within 80 % of minimum
Could not determine the pH-range where the free energy is negative
Protein charge of folded and unfolded state as a function of pH
    pH  unfolded  folded
  0.00     76.99   73.05
  1.00     76.93   69.92
  2.00     76.28   65.06
  3.00     70.59   54.84
  4.00     44.63   33.90
  5.00     12.51    7.85
  6.00     -3.35   -8.48
  7.00    -16.81  -15.46
  8.00    -22.21  -20.12
  9.00    -25.65  -25.07
 10.00    -36.21  -31.88
 11.00    -53.03  -45.35
 12.00    -65.42  -60.25
 13.00    -83.76  -76.79
 14.00    -90.95  -86.50
The pI is  5.40 (folded) and  5.80 (unfolded)165
Appendix B: Supporting Information for “Computational Examination of
the Magnesium Ion Binding Modes of 1-Deoxy-D-xylulose 5-Phosphate
Reductoisomerase”
B.1 Results from the ProPKA3.0 Calculations of a
DXR with Substrates Bound
Below will be found the ProPKA3.0 results for of crystal structure, PDB:1Q0Q, for DXR
with bound NADPH and DXP:
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propka3.0, revision 182                                                                      2015-01-13
-------------------------------------------------------------------------------------------------------
--                                                                                                   --
--                                   PROPKA: A PROTEIN PKA PREDICTOR                                 --
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--                                                                                                   --
--                              VERSION 3.0,  xx/xx/2010, COPENHAGEN                                 --
--                              BY MATS H.M. OLSSON AND CHRESTEN R. SONDERGARD                       --
--                                                                                                   --
-------------------------------------------------------------------------------------------------------
-------------------------------------------------------------------------------------------------------
 References:
   Very Fast Empirical Prediction and Rationalization of Protein pKa Values
   Hui Li, Andrew D. Robertson and Jan H. Jensen
   PROTEINS: Structure, Function, and Bioinformatics 61:704-721 (2005)
   
   Very Fast Prediction and Rationalization of pKa Values for Protein-Ligand Complexes
   Delphine C. Bas, David M. Rogers and Jan H. Jensen
   PROTEINS: Structure, Function, and Bioinformatics 73:765-783 (2008)
   
   PROPKA3: Consistent Treatment of Internal and Surface Residues in Empirical pKa predictions
   Mats H.M. Olsson, Chresten R. Sondergard, Michal Rostkowski, and Jan H. Jensen
   Journal of Chemical Theory and Computation, to be submitted (2010)
-------------------------------------------------------------------------------------------------------
-------------------------------------------------------------------------------------------------------
 WARNING !
   Propka3.0 is not identical to propka2.0 and does not work with ligands
-------------------------------------------------------------------------------------------------------
---------  -----   ------   ---------------------    --------------    --------------    --------------
                            DESOLVATION  EFFECTS       SIDECHAIN          BACKBONE        COULOMBIC
 RESIDUE    pKa    BURIED     REGULAR      RE        HYDROGEN BOND     HYDROGEN BOND      INTERACTION
---------  -----   ------   ---------   ---------    --------------    --------------    --------------
ASP  19 A   3.18    29 %    1.00  362   0.13    0   -0.48 ARG  22 A    0.00 XXX   0 X   -0.38 HIS  23 A
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ASP  19 A                                           -0.11 ARG 277 A    0.00 XXX   0 X   -0.33 ARG  22 A
ASP  19 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.47 ARG 277 A
ASP  57 A   4.68    27 %    0.80  356   0.01    0    0.00 XXX   0 X    0.00 XXX   0 X    0.08 ASP  58 A
ASP  58 A   2.97     0 %    0.38  241   0.00    0   -0.39 SER  61 A   -0.20 ALA  60 A   -0.07 LYS  37 A
ASP  58 A                                            0.00 XXX   0 X   -0.54 SER  61 A    0.00 XXX   0 X
ASP  87 A   3.70     1 %    0.38  284   0.01    0   -0.50 GLN  83 A    0.00 XXX   0 X    0.00 XXX   0 X
ASP  93 A   3.29     0 %    0.26  215   0.00    0   -0.36 ARG  52 A    0.00 XXX   0 X   -0.10 ARG  29 A
ASP  93 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.05 LYS 118 A
ASP  93 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.25 ARG  52 A
ASP  95 A   3.65    17 %    0.65  330   0.24    0    0.00 XXX   0 X   -0.81 GLN   3 A   -0.06 LYS   2 A
ASP  95 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.02 ARG  29 A
ASP  95 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.14 LYS 118 A
ASP  95 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.08 N+    1 A
ASP  95 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.06 ASP  93 A
ASP 137 A   3.26    10 %    0.65  309   0.07    0   -0.85 TYR 170 A    0.00 XXX   0 X   -0.28 ARG 133 A
ASP 137 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.13 LYS 140 A
ASP 150 A   1.23*  100 %    4.83  738   0.26    0   -0.85 LYS 125 A   -0.03 SER 151 A   -2.03 LYS 125 A
ASP 150 A                                           -0.56 GLU 152 A    0.00 XXX   0 X   -1.69 HIS 153 A
ASP 150 A                                           -0.57 GLU 231 A    0.00 XXX   0 X   -0.59 LYS 228 A
ASP 150 A                                           -1.34 GLU 234 A    0.00 XXX   0 X    0.00 XXX   0 X
ASP 172 A   3.56     0 %    0.36  272   0.00    0    0.00 XXX   0 X   -0.03 GLU 174 A    0.00 XXX   0 X
ASP 172 A                                            0.00 XXX   0 X   -0.57 GLN 175 A    0.00 XXX   0 X
ASP 197 A   4.06     0 %    0.26  157   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.00 XXX   0 X
ASP 204 A   3.06     0 %    0.22  214   0.00    0   -0.65 ARG 216 A    0.00 XXX   0 X   -0.31 ARG 216 A
ASP 221 A   4.58   100 %    3.64  679   0.94    0   -0.84 ASN 339 A    0.00 XXX   0 X   -0.29 LYS 125 A
ASP 221 A                                           -0.85 LYS 217 A    0.00 XXX   0 X    0.22 GLU 340 A
ASP 221 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -2.03 LYS 217 A
ASP 264 A   4.07   100 %    3.58  601   0.78    0   -0.84 SER 266 A   -0.08 ASP 264 A   -1.86 ARG 289 B
ASP 264 A                                           -0.50 ARG 289 B   -0.82 SER 266 A    0.00 XXX   0 X
ASP 275 A   4.13    62 %    1.88  455   0.00    0   -0.39 ARG 277 A   -0.68 ARG 277 A   -0.04 LYS 295 A
ASP 275 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.11 ASP  19 A
ASP 275 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.01 HIS  23 A
ASP 275 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.55 ARG 277 A
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ASP 298 A   3.40     0 %    0.36  261   0.00    0    0.00 XXX   0 X   -0.46 CYS 300 A   -0.03 LYS 295 A
ASP 298 A                                            0.00 XXX   0 X   -0.15 LYS 301 A   -0.08 LYS 301 A
ASP 298 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.09 ARG 261 B
ASP 298 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.05 GLU 247 B
ASP 311 A   3.36     0 %    0.37  264   0.00    0    0.00 XXX   0 X   -0.21 ASP 313 A   -0.21 ARG 314 A
ASP 311 A                                            0.00 XXX   0 X   -0.39 ARG 314 A    0.00 XXX   0 X
ASP 313 A   3.96     0 %    0.16  173   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.19 LYS 319 A
ASP 313 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.19 ASP 311 A
ASP 355 A   3.98    28 %    1.05  361   0.13    0    0.00 XXX   0 X   -0.81 ARG 352 A   -0.19 ARG 352 A
ASP 368 A   3.91     0 %    0.14  192   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.03 ARG 370 A
ASP 376 A   4.05     0 %    0.17  194   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.08 ASP 377 A
ASP 377 A   3.27     0 %    0.36  214   0.00    0   -0.12 CYS 374 A   -0.76 GLN 373 A   -0.00 ARG 370 A
ASP 382 A   4.83    67 %    2.05  469   0.38    0   -1.12 ARG 386 A    0.00 XXX   0 X   -0.05 ARG 390 A
ASP 382 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.59 GLU 340 A
ASP 382 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.83 ARG 386 A
GLU  26 A   4.44     0 %    0.08  119   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.03 N+    1 A
GLU  26 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.11 HIS  27 A
GLU  44 A   4.37     1 %    0.36  283   0.00    0   -0.11 ARG  41 A    0.00 XXX   0 X   -0.10 ARG  22 A
GLU  44 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.12 GLU  48 A
GLU  44 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.41 ARG  41 A
GLU  48 A   3.41     9 %    0.70  306   0.01    0   -1.40 ARG  22 A    0.00 XXX   0 X   -0.04 ARG  41 A
GLU  48 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.06 ASP  19 A
GLU  48 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.43 ARG  22 A
GLU  59 A   4.50     0 %    0.17  166   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.21 LYS  63 A
GLU  59 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.04 ASP  58 A
GLU  77 A   4.52     0 %    0.17  226   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.11 LYS  66 A
GLU  77 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.04 ARG  75 A
GLU  92 A   4.61     0 %    0.09  164   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.14 LYS 118 A
GLU  92 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.14 ASP  93 A
GLU  92 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.01 ASP  95 A
GLU 126 A   6.06   100 %    3.88  645   0.15    0   -0.68 LYS 217 A   -0.35 GLY 103 A   -0.00 ARG 386 A
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GLU 126 A                                            0.00 XXX   0 X   -0.65 GLU 126 A    0.17 ASP 150 A
GLU 126 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.62 LYS 125 A
GLU 126 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -1.97 LYS 217 A
GLU 126 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.74 ASP 221 A
GLU 126 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.90 GLU 340 A
GLU 152 A  10.96*  100 %    5.00  712   0.81    0   -0.77 LYS 228 A   -0.74 GLU 152 A   -1.03 LYS 125 A
GLU 152 A                                            0.56 ASP 150 A    0.00 XXX   0 X   -2.03 LYS 228 A
GLU 152 A                                            1.12 GLU 231 A    0.00 XXX   0 X    1.50 ASP 150 A
GLU 152 A                                            0.00 XXX   0 X    0.00 XXX   0 X    2.03 GLU 231 A
GLU 174 A   4.82     0 %    0.20  279   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.12 ASP 172 A
GLU 192 A   4.49     0 %    0.14  235   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.13 ARG 191 A
GLU 192 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.02 ARG 314 A
GLU 231 A   4.51*  100 %    5.25  721   0.66    0   -0.50 ASN 227 A    0.00 XXX   0 X   -2.03 LYS 125 A
GLU 231 A                                           -0.85 LYS 125 A    0.00 XXX   0 X    2.03 ASP 150 A
GLU 231 A                                            0.57 ASP 150 A    0.00 XXX   0 X   -1.11 HIS 153 A
GLU 231 A                                           -1.12 GLU 152 A    0.00 XXX   0 X   -2.03 LYS 228 A
GLU 231 A                                           -0.85 LYS 228 A    0.00 XXX   0 X    0.00 XXX   0 X
GLU 234 A  12.81*  100 %    4.27  713   0.66    0    1.34 ASP 150 A    0.00 XXX   0 X   -1.17 LYS 125 A
GLU 234 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.05 LYS 228 A
GLU 234 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.18 GLU 126 A
GLU 234 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.33 GLU 152 A
GLU 234 A                                            0.00 XXX   0 X    0.00 XXX   0 X    2.03 ASP 150 A
GLU 234 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.72 GLU 231 A
GLU 247 A   3.44    61 %    1.67  451   0.05    0   -0.78 SER 180 A    0.00 XXX   0 X    0.05 ASP 298 B
GLU 247 A                                           -1.21 ARG 261 A    0.00 XXX   0 X   -0.84 ARG 261 A
GLU 273 A   5.10    30 %    0.86  365   0.06    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.32 LYS 295 A
GLU 273 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.12 LYS 301 A
GLU 273 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.00 ARG 261 B
GLU 273 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.09 ASP 275 A
GLU 273 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.04 ASP 298 A
GLU 323 A   4.69     6 %    0.36  297   0.03    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.20 LYS 319 A
GLU 326 A   3.96     2 %    0.35  288   0.01    0   -0.53 ARG 236 A    0.00 XXX   0 X   -0.36 ARG 236 A
GLU 340 A   3.88   100 %    2.82  569   0.67    0   -0.44 ASN 336 A   -0.77 ALA 104 A   -1.09 LYS 217 A
GLU 340 A                                           -0.60 ARG 386 A    0.00 XXX   0 X   -1.21 ARG 386 A
GLU 365 A   4.74     0 %    0.28  234   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.04 LYS 366 A
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GLU 371 A   3.97    19 %    0.78  334   0.06    0    0.00 XXX   0 X   -0.61 GLN 329 A   -0.04 ARG 370 A
GLU 371 A                                            0.00 XXX   0 X   -0.73 ALA 330 A    0.00 XXX   0 X
GLU 387 A   4.63     0 %    0.20  212   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.07 ARG 390 A
GLU 392 A   4.20     2 %    0.60  287   0.01    0   -0.04 SER 362 A    0.00 XXX   0 X   -0.32 LYS 366 A
GLU 392 A                                           -0.02 ARG 395 A    0.00 XXX   0 X   -0.14 LYS 391 A
GLU 392 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.38 ARG 395 A
C-  398 A   3.31     0 %    0.11   95   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.00 XXX   0 X
HIS  23 A   6.08     8 %   -0.51  305   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.08 ARG  22 A
HIS  23 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.22 ARG 277 A
HIS  23 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.38 ASP  19 A
HIS  23 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.01 ASP 275 A
HIS  27 A   6.02     7 %   -0.39  301   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.08 LYS   2 A
HIS  27 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.11 N+    1 A
HIS  27 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.11 GLU  26 A
HIS 153 A   5.02   100 %   -3.95  718   0.00    0    0.00 XXX   0 X    0.77 HIS 153 A   -0.74 LYS 125 A
HIS 153 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.35 LYS 228 A
HIS 153 A                                            0.00 XXX   0 X    0.00 XXX   0 X    1.69 ASP 150 A
HIS 153 A                                            0.00 XXX   0 X    0.00 XXX   0 X    1.11 GLU 231 A
HIS 166 A   5.89    18 %   -0.61  331   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.00 XXX   0 X
HIS 209 A   2.93    86 %   -3.09  522   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.20 ARG 191 A
HIS 209 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.28 LYS 228 A
HIS 251 A   2.88   100 %   -3.33  569   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.02 ARG 191 A
HIS 251 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.26 HIS 257 A
HIS 257 A   3.99   100 %   -3.13  667   0.00    0    0.29 GLN 270 A    0.23 HIS 257 A   -0.00 LYS 228 A
HIS 257 A                                            0.00 XXX   0 X    0.11 HIS 257 A    0.00 XXX   0 X
HIS 282 A   2.01   100 %   -3.10  641   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -1.39 ARG 289 A
CYS  15 A  10.34    61 %    1.82  453   0.00    0   -0.02 ARG  41 A    0.00 XXX   0 X   -0.09 ARG  22 A
CYS  15 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.55 ARG  41 A
CYS  15 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.02 ASP  19 A
CYS  15 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.15 GLU  44 A
CYS  15 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.01 GLU  48 A
CYS  46 A  11.92    80 %    2.97  504   0.00    0   -0.05 THR  76 A    0.00 XXX   0 X    0.00 XXX   0 X
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CYS  86 A  10.56    42 %    1.59  399   0.00    0    0.00 XXX   0 X   -0.03 CYS  86 A   -0.15 ARG 115 A
CYS  86 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.14 ASP  87 A
CYS 131 A  11.75    80 %    2.75  505   0.00    0    0.00 XXX   0 X   -0.02 PHE 135 A    0.01 ASP 137 A
CYS 131 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.02 CYS 374 A
CYS 207 A  10.78    55 %    2.19  436   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.53 ARG 216 A
CYS 207 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.13 ASP 204 A
CYS 300 A  10.02    17 %    0.74  329   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.03 ARG 261 B
CYS 300 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.26 ASP 298 A
CYS 300 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.04 GLU 247 B
CYS 317 A  11.85   100 %    3.20  588   0.00    0   -0.40 THR 224 A    0.00 XXX   0 X   -0.00 LYS 217 A
CYS 317 A                                           -0.32 ASN 360 A    0.00 XXX   0 X    0.38 ASP 221 A
CYS 374 A   9.07     0 %    0.46  224   0.00    0    0.12 ASP 377 A   -0.34 ASP 376 A    0.20 ASP 376 A
CYS 374 A                                            0.00 XXX   0 X   -0.75 ASP 377 A    0.38 ASP 377 A
TYR  53 A  10.17     0 %    0.28  268   0.00    0   -0.05 ARG  52 A    0.00 XXX   0 X   -0.21 ARG  52 A
TYR  53 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.14 GLU  77 A
TYR  53 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.01 ASP  93 A
TYR 170 A  11.71    22 %    1.23  342   0.00    0   -0.34 ARG 133 A    0.00 XXX   0 X   -0.47 ARG 133 A
TYR 170 A                                            0.85 ASP 137 A    0.00 XXX   0 X    0.44 ASP 137 A
TYR 232 A  10.66    50 %    1.63  422   0.00    0   -0.66 ARG 236 A    0.00 XXX   0 X   -0.56 ARG 236 A
TYR 232 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.25 GLU 326 A
TYR 262 A  12.82   100 %    3.71  631   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.13 ASP 264 A
TYR 262 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -1.02 ARG 289 B
TYR 312 A  11.37    48 %    1.26  416   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.10 TYR 232 A
TYR 315 A  11.98    70 %    2.28  476   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.15 ARG 191 A
TYR 315 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.01 GLU 192 A
TYR 315 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.10 ASP 311 A
TYR 315 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.26 ARG 314 A
LYS   2 A   9.13    54 %   -1.43  432   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.06 ASP  95 A
LYS  37 A  10.33     9 %   -0.25  306   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.07 ASP  58 A
LYS  63 A  10.62     0 %   -0.09  136   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.21 GLU  59 A
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LYS  66 A  10.36     0 %   -0.25  250   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.11 GLU  77 A
LYS 118 A   9.81    22 %   -1.02  344   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.14 GLU  92 A
LYS 118 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.05 ASP  93 A
LYS 118 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.14 ASP  95 A
LYS 125 A  13.89   100 %   -5.49  702   0.00    0    0.85 ASP 150 A    0.00 XXX   0 X    1.03 GLU 152 A
LYS 125 A                                            0.85 GLU 231 A    0.00 XXX   0 X    0.29 ASP 221 A
LYS 125 A                                            0.00 XXX   0 X    0.00 XXX   0 X    1.17 GLU 234 A
LYS 125 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.62 GLU 126 A
LYS 125 A                                            0.00 XXX   0 X    0.00 XXX   0 X    2.03 ASP 150 A
LYS 125 A                                            0.00 XXX   0 X    0.00 XXX   0 X    2.03 GLU 231 A
LYS 140 A  10.29     0 %   -0.27  212   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.07 ARG 133 A
LYS 140 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.13 ASP 137 A
LYS 143 A  10.10     0 %   -0.30  184   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.10 LYS 140 A
LYS 217 A  13.30   100 %   -3.47  645   0.00    0    0.68 GLU 126 A    0.00 XXX   0 X    0.00 CYS 317 A
LYS 217 A                                            0.85 ASP 221 A    0.00 XXX   0 X   -0.12 ARG 386 A
LYS 217 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.24 LYS 125 A
LYS 217 A                                            0.00 XXX   0 X    0.00 XXX   0 X    1.97 GLU 126 A
LYS 217 A                                            0.00 XXX   0 X    0.00 XXX   0 X    2.03 ASP 221 A
LYS 217 A                                            0.00 XXX   0 X    0.00 XXX   0 X    1.09 GLU 340 A
LYS 228 A  10.72   100 %   -5.43  704   0.00    0    0.77 GLU 152 A    0.00 XXX   0 X    2.03 GLU 152 A
LYS 228 A                                            0.85 GLU 231 A    0.00 XXX   0 X    0.05 GLU 234 A
LYS 228 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.68 LYS 125 A
LYS 228 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.59 ASP 150 A
LYS 228 A                                            0.00 XXX   0 X    0.00 XXX   0 X    2.03 GLU 231 A
LYS 295 A  10.71     0 %   -0.17  232   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.32 GLU 273 A
LYS 295 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.04 ASP 275 A
LYS 295 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.01 ARG 277 A
LYS 295 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.03 ASP 298 A
LYS 301 A  10.43     0 %   -0.12  199   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.12 GLU 273 A
LYS 301 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.08 ASP 298 A
LYS 301 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.15 LYS 295 A
LYS 319 A  10.72     0 %   -0.17  209   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.19 ASP 313 A
LYS 319 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.20 GLU 323 A
LYS 366 A  10.40     0 %   -0.23  216   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.04 GLU 365 A
LYS 366 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.32 GLU 392 A
LYS 366 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.24 ARG 395 A
173
1/13/2015 nbcr-222.ucsd.edu/opal-jobs/apppdb2pqr_1.8142120924984288311816/1q0q.propka
http://nbcr-222.ucsd.edu/opal-jobs/apppdb2pqr_1.8142120924984288311816/1q0q.propka 8/22
LYS 391 A  10.17     0 %   -0.13  174   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.14 GLU 392 A
LYS 391 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.15 ARG 395 A
LYS 391 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.19 LYS 366 A
ARG  22 A  14.57    20 %   -0.76  337   0.00    0    0.48 ASP  19 A    0.00 XXX   0 X    0.09 CYS  15 A
ARG  22 A                                            1.40 GLU  48 A    0.00 XXX   0 X    0.10 GLU  44 A
ARG  22 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.33 ASP  19 A
ARG  22 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.43 GLU  48 A
ARG  29 A  11.94    12 %   -0.53  314   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.10 ASP  93 A
ARG  29 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.02 ASP  95 A
ARG  29 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.16 ARG  52 A
ARG  41 A  13.08    14 %   -0.45  321   0.00    0    0.02 CYS  15 A    0.00 XXX   0 X    0.55 CYS  15 A
ARG  41 A                                            0.11 GLU  44 A    0.00 XXX   0 X    0.04 GLU  48 A
ARG  41 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.09 ARG  22 A
ARG  41 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.41 GLU  44 A
ARG  52 A  12.96     2 %   -0.41  286   0.00    0    0.05 TYR  53 A    0.00 XXX   0 X    0.21 TYR  53 A
ARG  52 A                                            0.36 ASP  93 A    0.00 XXX   0 X    0.25 ASP  93 A
ARG  75 A  12.46     0 %   -0.08  166   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.04 GLU  77 A
ARG 115 A  12.16    18 %   -0.49  331   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.15 CYS  86 A
ARG 133 A  12.71    31 %   -0.89  367   0.00    0    0.34 TYR 170 A    0.00 XXX   0 X    0.28 ASP 137 A
ARG 133 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.47 TYR 170 A
ARG 191 A  11.47    47 %   -1.30  414   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.13 GLU 192 A
ARG 191 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.15 TYR 315 A
ARG 196 A  12.41     0 %   -0.09  117   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.00 XXX   0 X
ARG 208 A  12.42     0 %   -0.08  172   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.00 XXX   0 X
ARG 216 A  13.46    13 %   -0.53  318   0.00    0    0.65 ASP 204 A    0.00 XXX   0 X    0.53 CYS 207 A
ARG 216 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.31 ASP 204 A
ARG 236 A  13.16    43 %   -1.46  402   0.00    0    0.66 TYR 232 A    0.00 XXX   0 X    0.56 TYR 232 A
ARG 236 A                                            0.53 GLU 326 A    0.00 XXX   0 X    0.36 GLU 326 A
ARG 261 A  12.56    73 %   -2.14  485   0.00    0    1.21 GLU 247 A    0.00 XXX   0 X    0.03 GLU 273 B
ARG 261 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.10 ASP 298 B
ARG 261 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.02 CYS 300 B
ARG 261 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.84 GLU 247 A
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ARG 277 A  13.08    28 %   -0.90  359   0.00    0    0.11 ASP  19 A    0.00 XXX   0 X   -0.04 ARG  22 A
ARG 277 A                                            0.39 ASP 275 A    0.00 XXX   0 X    0.47 ASP  19 A
ARG 277 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.55 ASP 275 A
ARG 289 A  12.78   100 %   -3.29  617   0.00    0    0.60 ASP 264 B    0.00 XXX   0 X    1.01 TYR 262 B
ARG 289 A                                            0.00 XXX   0 X    0.00 XXX   0 X    1.96 ASP 264 B
ARG 314 A  12.66     0 %   -0.33  280   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.02 GLU 192 A
ARG 314 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.21 ASP 311 A
ARG 314 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.26 TYR 315 A
ARG 352 A  12.55     0 %   -0.14  225   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.19 ASP 355 A
ARG 370 A  12.49     0 %   -0.08  119   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.03 ASP 368 A
ARG 370 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.04 GLU 371 A
ARG 370 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.00 ASP 377 A
ARG 386 A  14.66    65 %   -1.60  463   0.00    0    0.60 GLU 340 A    0.00 XXX   0 X    0.00 GLU 126 A
ARG 386 A                                            1.12 ASP 382 A    0.00 XXX   0 X    1.21 GLU 340 A
ARG 386 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.83 ASP 382 A
ARG 390 A  12.10     2 %   -0.36  287   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.05 ASP 382 A
ARG 390 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.07 GLU 387 A
ARG 390 A                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.16 ARG 386 A
ARG 395 A  12.64     0 %   -0.27  208   0.00    0    0.02 GLU 392 A    0.00 XXX   0 X    0.38 GLU 392 A
N+    1 A   7.77     0 %   -0.25  225   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.09 LYS   2 A
N+    1 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.03 GLU  26 A
N+    1 A                                            0.00 XXX   0 X    0.00 XXX   0 X    0.08 ASP  95 A
ASP  19 B   2.91    26 %    0.94  355   0.11    0   -0.49 ARG  22 B    0.00 XXX   0 X   -0.40 HIS  23 B
ASP  19 B                                           -0.33 ARG 277 B    0.00 XXX   0 X   -0.32 ARG  22 B
ASP  19 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.40 ARG 277 B
ASP  57 B   4.81    31 %    0.92  367   0.02    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.02 LYS  37 B
ASP  57 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.08 ASP  58 B
ASP  58 B   2.80     0 %    0.41  234   0.00    0   -0.79 SER  61 B   -0.38 SER  61 B   -0.24 LYS  37 B
ASP  87 B   3.54     4 %    0.43  292   0.03    0   -0.71 GLN  83 B    0.00 XXX   0 X   -0.00 ARG 115 B
ASP  93 B   2.15     0 %    0.31  245   0.00    0   -0.80 GLN   3 B    0.00 XXX   0 X   -0.05 ARG  29 B
ASP  93 B                                           -0.75 ARG  52 B    0.00 XXX   0 X   -0.05 LYS 118 B
ASP  93 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.32 ARG  52 B
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ASP  95 B   3.42    17 %    0.62  330   0.21    0    0.00 XXX   0 X   -0.83 GLN   3 B   -0.23 LYS   2 B
ASP  95 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.01 ARG  29 B
ASP  95 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.13 LYS 118 B
ASP  95 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.09 N+    1 B
ASP  95 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.07 ASP  93 B
ASP 137 B   3.22     6 %    0.54  297   0.04    0   -0.81 TYR 170 B    0.00 XXX   0 X   -0.26 ARG 133 B
ASP 137 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.09 LYS 140 B
ASP 150 B   6.49*  100 %    4.88  737   0.24    0   -0.78 LYS 125 B   -0.02 SER 151 B    0.15 GLU 126 B
ASP 150 B                                           -0.52 GLU 152 B    0.00 XXX   0 X   -2.03 LYS 125 B
ASP 150 B                                            0.54 GLU 231 B    0.00 XXX   0 X   -0.60 LYS 228 B
ASP 150 B                                           -1.21 GLU 234 B    0.00 XXX   0 X    2.03 GLU 231 B
ASP 172 B   3.44     0 %    0.41  270   0.00    0    0.00 XXX   0 X   -0.04 GLU 174 B    0.00 XXX   0 X
ASP 172 B                                            0.00 XXX   0 X   -0.73 GLN 175 B    0.00 XXX   0 X
ASP 197 B   4.13     0 %    0.33  165   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.00 XXX   0 X
ASP 204 B   3.70     0 %    0.21  215   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.21 ARG 208 B
ASP 204 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.10 ARG 216 B
ASP 221 B   4.35   100 %    3.68  679   0.72    0   -0.84 ASN 339 B    0.00 XXX   0 X   -0.33 LYS 125 B
ASP 221 B                                           -0.85 LYS 217 B    0.00 XXX   0 X    0.21 GLU 340 B
ASP 221 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -2.03 LYS 217 B
ASP 264 B   3.88   100 %    3.64  600   0.75    0   -0.85 SER 266 B   -0.09 ASP 264 B   -1.96 ARG 289 A
ASP 264 B                                           -0.60 ARG 289 A   -0.81 SER 266 B    0.00 XXX   0 X
ASP 275 B   3.98    61 %    1.96  451   0.00    0   -0.58 ARG 277 B   -0.69 ARG 277 B   -0.01 LYS 295 B
ASP 275 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.10 ASP  19 B
ASP 275 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.02 HIS  23 B
ASP 275 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.59 ARG 277 B
ASP 298 B   3.26     0 %    0.40  265   0.00    0    0.00 XXX   0 X   -0.58 CYS 300 B   -0.10 ARG 261 A
ASP 298 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.10 LYS 295 B
ASP 298 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.17 LYS 301 B
ASP 311 B   3.62     0 %    0.43  282   0.00    0   -0.07 ARG 314 B   -0.32 ARG 314 B   -0.22 ARG 314 B
ASP 313 B   4.03     0 %    0.15  172   0.00    0    0.00 XXX   0 X   -0.02 ASP 313 B   -0.08 LYS 319 B
ASP 313 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.17 ASP 311 B
ASP 355 B   3.97    28 %    1.07  361   0.13    0    0.00 XXX   0 X   -0.83 ARG 352 B   -0.20 ARG 352 B
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ASP 368 B   3.92     0 %    0.13  197   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.01 ARG 370 B
ASP 376 B   4.07     0 %    0.18  196   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.09 ASP 377 B
ASP 377 B   3.27     0 %    0.35  208   0.00    0   -0.16 CYS 374 B   -0.71 GLN 373 B   -0.01 ARG 370 B
ASP 382 B   4.82    67 %    2.06  469   0.40    0   -1.14 ARG 386 B    0.00 XXX   0 X   -0.05 ARG 390 B
ASP 382 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.61 GLU 340 B
ASP 382 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.86 ARG 386 B
GLU  26 B   4.35     0 %    0.18  188   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.03 N+    1 B
GLU  26 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.31 HIS  27 B
GLU  44 B   4.46     0 %    0.34  278   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.09 ARG  22 B
GLU  44 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.40 ARG  41 B
GLU  44 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.11 GLU  48 B
GLU  48 B   3.46     9 %    0.73  306   0.01    0   -1.37 ARG  22 B    0.00 XXX   0 X   -0.03 ARG  41 B
GLU  48 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.06 ASP  19 B
GLU  48 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.43 ARG  22 B
GLU  59 B   4.66     0 %    0.10  155   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.05 ASP  58 B
GLU  77 B   4.72     0 %    0.26  265   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.04 LYS  66 B
GLU  92 B   4.52     0 %    0.08  165   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.08 LYS 118 B
GLU  92 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.02 ASP  93 B
GLU 126 B   5.71   100 %    3.86  643   0.15    0   -0.78 LYS 217 B   -0.35 GLY 103 B   -0.03 ARG 386 B
GLU 126 B                                            0.00 XXX   0 X   -0.65 GLU 126 B   -0.61 LYS 125 B
GLU 126 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -2.03 LYS 217 B
GLU 126 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.72 ASP 221 B
GLU 126 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.93 GLU 340 B
GLU 152 B  10.62*  100 %    4.88  707   0.80    0   -0.74 LYS 228 B   -0.74 GLU 152 B   -0.99 LYS 125 B
GLU 152 B                                            0.52 ASP 150 B    0.00 XXX   0 X   -2.03 LYS 228 B
GLU 152 B                                            0.87 GLU 231 B    0.00 XXX   0 X    1.52 ASP 150 B
GLU 152 B                                            0.00 XXX   0 X    0.00 XXX   0 X    2.03 GLU 231 B
GLU 174 B   4.79     0 %    0.16  251   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.12 ASP 172 B
GLU 192 B   4.32     0 %    0.19  245   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.34 ARG 191 B
GLU 192 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.03 ARG 314 B
GLU 231 B   1.51*  100 %    5.13  724   0.66    0   -0.47 ASN 227 B    0.00 XXX   0 X   -0.03 HIS 209 B
GLU 231 B                                           -0.85 LYS 125 B    0.00 XXX   0 X   -2.03 LYS 125 B
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GLU 231 B                                           -0.54 ASP 150 B    0.00 XXX   0 X   -1.09 HIS 153 B
GLU 231 B                                           -0.87 GLU 152 B    0.00 XXX   0 X   -2.03 LYS 228 B
GLU 231 B                                           -0.85 LYS 228 B    0.00 XXX   0 X    0.00 XXX   0 X
GLU 234 B  12.78*  100 %    4.37  712   0.66    0    1.21 ASP 150 B    0.00 XXX   0 X   -1.14 LYS 125 B
GLU 234 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.06 LYS 228 B
GLU 234 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.18 GLU 126 B
GLU 234 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.34 GLU 152 B
GLU 234 B                                            0.00 XXX   0 X    0.00 XXX   0 X    1.97 ASP 150 B
GLU 234 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.78 GLU 231 B
GLU 247 B   3.30    58 %    1.63  445   0.04    0   -0.80 SER 180 B    0.00 XXX   0 X   -0.80 ARG 261 B
GLU 247 B                                           -1.27 ARG 261 B    0.00 XXX   0 X    0.00 XXX   0 X
GLU 273 B   4.91    28 %    0.85  361   0.10    0   -0.29 LYS 295 B    0.00 XXX   0 X   -0.03 ARG 261 A
GLU 273 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.09 ASP 275 B
GLU 273 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.05 ASP 298 B
GLU 273 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.36 LYS 295 B
GLU 323 B   4.58     0 %    0.34  282   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.27 LYS 319 B
GLU 326 B   4.71     0 %    0.16  216   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.05 ARG 236 B
GLU 326 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.10 GLU 323 B
GLU 340 B   3.93   100 %    2.89  577   0.65    0   -0.48 ASN 336 B   -0.75 ALA 104 B   -1.03 LYS 217 B
GLU 340 B                                           -0.52 ARG 386 B    0.00 XXX   0 X   -1.33 ARG 386 B
GLU 365 B   4.68     0 %    0.26  223   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.10 LYS 366 B
GLU 365 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.02 GLU 392 B
GLU 371 B   3.85    18 %    0.81  333   0.08    0    0.00 XXX   0 X   -0.68 GLN 329 B   -0.14 ARG 370 B
GLU 371 B                                            0.00 XXX   0 X   -0.71 ALA 330 B    0.00 XXX   0 X
GLU 387 B   3.95     0 %    0.22  204   0.00    0   -0.20 ARG 390 B    0.00 XXX   0 X   -0.26 ARG 390 B
GLU 387 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.31 LYS 391 B
GLU 392 B   2.80     1 %    0.53  283   0.00    0   -0.85 SER 362 B    0.00 XXX   0 X   -0.00 LYS 391 B
GLU 392 B                                           -0.69 LYS 366 B    0.00 XXX   0 X   -0.31 ARG 395 B
GLU 392 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.38 LYS 366 B
C-  398 B   3.30     0 %    0.10  110   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.00 XXX   0 X
HIS  23 B   6.72    10 %   -0.55  309   0.00    0    0.00 XXX   0 X    0.65 HIS  23 B   -0.08 ARG  22 B
HIS  23 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.22 ARG 277 B
HIS  23 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.40 ASP  19 B
HIS  23 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.02 ASP 275 B
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HIS  27 B   6.17    10 %   -0.53  308   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.00 LYS   2 B
HIS  27 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.10 N+    1 B
HIS  27 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.31 GLU  26 B
HIS 153 B   2.68   100 %   -3.92  718   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.66 LYS 125 B
HIS 153 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.34 LYS 228 B
HIS 153 B                                            0.00 XXX   0 X    0.00 XXX   0 X    1.09 GLU 231 B
HIS 166 B   5.91    17 %   -0.59  330   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.00 XXX   0 X
HIS 209 B   3.25    85 %   -3.02  519   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.26 LYS 228 B
HIS 209 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.03 GLU 231 B
HIS 251 B   3.40   100 %   -3.33  564   0.00    0    0.02 GLN 253 B    0.48 HIS 251 B   -0.00 ARG 191 B
HIS 251 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.26 HIS 257 B
HIS 257 B   3.97   100 %   -3.14  666   0.00    0    0.28 GLN 270 B    0.23 HIS 257 B   -0.01 LYS 228 B
HIS 257 B                                            0.00 XXX   0 X    0.12 HIS 257 B    0.00 XXX   0 X
HIS 282 B   2.10   100 %   -3.09  640   0.00    0    0.00 XXX   0 X    0.07 HIS 282 B   -1.39 ARG 289 B
CYS  15 B   9.90    59 %    1.76  447   0.00    0   -0.35 ARG  41 B   -0.04 CYS  15 B   -0.09 ARG  22 B
CYS  15 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.01 ASP  19 B
CYS  15 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.15 GLU  44 B
CYS  15 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.53 ARG  41 B
CYS  46 B  11.93    77 %    2.93  498   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.00 XXX   0 X
CYS  86 B  10.64    44 %    1.63  404   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.14 ARG 115 B
CYS  86 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.01 ASP  57 B
CYS  86 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.14 ASP  87 B
CYS 131 B  11.77    81 %    2.76  509   0.00    0    0.00 XXX   0 X   -0.01 PHE 135 B    0.01 CYS 374 B
CYS 207 B  10.83    54 %    2.01  432   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.03 ARG 208 B
CYS 207 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.27 ARG 216 B
CYS 207 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.12 ASP 204 B
CYS 300 B   9.97    15 %    0.73  324   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.02 ARG 261 A
CYS 300 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.02 LYS 301 B
CYS 300 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.04 GLU 247 A
CYS 300 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.25 ASP 298 B
CYS 317 B  12.04   100 %    3.22  592   0.00    0   -0.34 THR 224 B   -0.02 CYS 317 B    0.39 ASP 221 B
CYS 317 B                                           -0.22 ASN 360 B    0.00 XXX   0 X    0.00 XXX   0 X
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CYS 374 B   9.14     0 %    0.47  227   0.00    0    0.16 ASP 377 B   -0.43 ASP 376 B    0.23 ASP 376 B
CYS 374 B                                            0.00 XXX   0 X   -0.68 ASP 377 B    0.38 ASP 377 B
TYR  53 B  10.37     0 %    0.28  275   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.18 ARG  52 B
TYR  53 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.24 GLU  77 B
TYR  53 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.02 ASP  87 B
TYR  53 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.02 ASP  93 B
TYR 170 B  11.85    25 %    1.32  352   0.00    0   -0.37 ARG 133 B    0.00 XXX   0 X   -0.34 ARG 133 B
TYR 170 B                                            0.81 ASP 137 B    0.00 XXX   0 X    0.44 ASP 137 B
TYR 232 B  10.47    51 %    1.60  423   0.00    0   -0.62 ARG 236 B    0.00 XXX   0 X   -0.59 ARG 236 B
TYR 232 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.08 GLU 326 B
TYR 262 B  12.79   100 %    3.66  629   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -1.01 ARG 289 A
TYR 262 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.14 ASP 264 B
TYR 312 B  11.10    43 %    1.02  402   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.08 TYR 232 B
TYR 315 B  12.23    72 %    2.54  483   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.15 ARG 191 B
TYR 315 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.02 GLU 192 B
TYR 315 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.14 ASP 311 B
TYR 315 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.32 ARG 314 B
LYS   2 B  10.38    16 %   -0.34  325   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.23 ASP  95 B
LYS  37 B  10.63     0 %   -0.14  243   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.02 ASP  57 B
LYS  37 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.24 ASP  58 B
LYS  63 B  10.43     0 %   -0.07  124   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.00 XXX   0 X
LYS  66 B  10.29     0 %   -0.25  244   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.04 GLU  77 B
LYS 118 B   9.57    27 %   -1.19  358   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.08 GLU  92 B
LYS 118 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.05 ASP  93 B
LYS 118 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.13 ASP  95 B
LYS 125 B  13.75   100 %   -5.52  703   0.00    0    0.78 ASP 150 B    0.00 XXX   0 X    0.99 GLU 152 B
LYS 125 B                                            0.85 GLU 231 B    0.00 XXX   0 X    0.33 ASP 221 B
LYS 125 B                                            0.00 XXX   0 X    0.00 XXX   0 X    1.14 GLU 234 B
LYS 125 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.61 GLU 126 B
LYS 125 B                                            0.00 XXX   0 X    0.00 XXX   0 X    2.03 ASP 150 B
LYS 125 B                                            0.00 XXX   0 X    0.00 XXX   0 X    2.03 GLU 231 B
LYS 140 B  10.38     0 %   -0.19  208   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.02 ARG 133 B
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LYS 140 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.09 ASP 137 B
LYS 143 B  10.43     0 %   -0.07  121   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.00 XXX   0 X
LYS 217 B  13.29   100 %   -3.53  643   0.00    0    0.78 GLU 126 B    0.00 XXX   0 X   -0.12 ARG 386 B
LYS 217 B                                            0.85 ASP 221 B    0.00 XXX   0 X   -0.30 LYS 125 B
LYS 217 B                                            0.00 XXX   0 X    0.00 XXX   0 X    2.03 GLU 126 B
LYS 217 B                                            0.00 XXX   0 X    0.00 XXX   0 X    2.03 ASP 221 B
LYS 217 B                                            0.00 XXX   0 X    0.00 XXX   0 X    1.03 GLU 340 B
LYS 228 B  10.85   100 %   -5.30  707   0.00    0    0.74 GLU 152 B    0.00 XXX   0 X    2.03 GLU 152 B
LYS 228 B                                            0.85 GLU 231 B    0.00 XXX   0 X    0.06 GLU 234 B
LYS 228 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.66 LYS 125 B
LYS 228 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.60 ASP 150 B
LYS 228 B                                            0.00 XXX   0 X    0.00 XXX   0 X    2.03 GLU 231 B
LYS 295 B  11.01     0 %   -0.24  252   0.00    0    0.29 GLU 273 B    0.00 XXX   0 X   -0.01 ARG 261 A
LYS 295 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.01 ASP 275 B
LYS 295 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.10 ASP 298 B
LYS 295 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.36 GLU 273 B
LYS 301 B  10.58     0 %   -0.07  103   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.17 ASP 298 B
LYS 301 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.02 CYS 300 B
LYS 301 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.04 LYS 295 B
LYS 319 B  10.69     0 %   -0.15  203   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.08 ASP 313 B
LYS 319 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.27 GLU 323 B
LYS 366 B  11.02     0 %   -0.48  254   0.00    0    0.69 GLU 392 B    0.00 XXX   0 X    0.10 GLU 365 B
LYS 366 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.17 ARG 395 B
LYS 366 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.38 GLU 392 B
LYS 391 B  10.43     0 %   -0.28  193   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.31 GLU 387 B
LYS 391 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.04 ARG 390 B
LYS 391 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.00 GLU 392 B
LYS 391 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.06 ARG 395 B
ARG  22 B  14.53    20 %   -0.78  337   0.00    0    0.49 ASP  19 B    0.00 XXX   0 X    0.09 CYS  15 B
ARG  22 B                                            1.37 GLU  48 B    0.00 XXX   0 X    0.09 GLU  44 B
ARG  22 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.32 ASP  19 B
ARG  22 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.43 GLU  48 B
ARG  29 B  12.28     0 %   -0.26  262   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.05 ASP  93 B
ARG  29 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.01 ASP  95 B
ARG  29 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.03 ARG  52 B
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ARG  41 B  13.35    11 %   -0.40  313   0.00    0    0.35 CYS  15 B    0.00 XXX   0 X    0.40 GLU  44 B
ARG  41 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.03 GLU  48 B
ARG  41 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.08 ARG  22 B
ARG  41 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.53 CYS  15 B
ARG  52 B  13.25     5 %   -0.50  296   0.00    0    0.75 ASP  93 B    0.00 XXX   0 X    0.18 TYR  53 B
ARG  52 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.32 ASP  93 B
ARG  75 B  12.44     0 %   -0.06  139   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.00 XXX   0 X
ARG 115 B  12.23    15 %   -0.41  323   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.14 CYS  86 B
ARG 115 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.00 ASP  87 B
ARG 133 B  12.74    26 %   -0.73  354   0.00    0    0.37 TYR 170 B    0.00 XXX   0 X    0.26 ASP 137 B
ARG 133 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.34 TYR 170 B
ARG 191 B  12.22    24 %   -0.74  349   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.34 GLU 192 B
ARG 191 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.15 TYR 315 B
ARG 191 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.03 ARG 314 B
ARG 196 B  12.44     0 %   -0.06   74   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.00 XXX   0 X
ARG 208 B  12.51     0 %   -0.23  199   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.21 ASP 204 B
ARG 208 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.03 CYS 207 B
ARG 216 B  12.47    18 %   -0.40  331   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.10 ASP 204 B
ARG 216 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.27 CYS 207 B
ARG 236 B  12.36    43 %   -1.40  403   0.00    0    0.62 TYR 232 B    0.00 XXX   0 X    0.59 TYR 232 B
ARG 236 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.05 GLU 326 B
ARG 261 B  12.70    70 %   -1.99  476   0.00    0    1.27 GLU 247 B    0.00 XXX   0 X    0.00 GLU 273 A
ARG 261 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.09 ASP 298 A
ARG 261 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.03 CYS 300 A
ARG 261 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.80 GLU 247 B
ARG 277 B  13.49    28 %   -0.89  359   0.00    0    0.33 ASP  19 B    0.00 XXX   0 X   -0.02 ARG  22 B
ARG 277 B                                            0.58 ASP 275 B    0.00 XXX   0 X    0.40 ASP  19 B
ARG 277 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.59 ASP 275 B
ARG 289 B  12.63   100 %   -3.24  618   0.00    0    0.50 ASP 264 A    0.00 XXX   0 X    1.02 TYR 262 A
ARG 289 B                                            0.00 XXX   0 X    0.00 XXX   0 X    1.86 ASP 264 A
ARG 314 B  12.52     8 %   -0.62  303   0.00    0    0.07 ASP 311 B    0.00 XXX   0 X    0.03 GLU 192 B
ARG 314 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.22 ASP 311 B
ARG 314 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.32 TYR 315 B
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ARG 352 B  12.56     0 %   -0.14  212   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.20 ASP 355 B
ARG 370 B  12.47     0 %   -0.19  169   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.01 ASP 368 B
ARG 370 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.14 GLU 371 B
ARG 370 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.01 ASP 377 B
ARG 386 B  14.67    69 %   -1.71  475   0.00    0    0.52 GLU 340 B    0.00 XXX   0 X    0.03 GLU 126 B
ARG 386 B                                            1.14 ASP 382 B    0.00 XXX   0 X    1.33 GLU 340 B
ARG 386 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.86 ASP 382 B
ARG 390 B  12.46     3 %   -0.39  290   0.00    0    0.20 GLU 387 B    0.00 XXX   0 X    0.05 ASP 382 B
ARG 390 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.26 GLU 387 B
ARG 390 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.16 ARG 386 B
ARG 395 B  12.58     0 %   -0.23  197   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X    0.31 GLU 392 B
N+    1 B   7.66     0 %   -0.25  221   0.00    0    0.00 XXX   0 X    0.00 XXX   0 X   -0.14 LYS   2 B
N+    1 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.03 GLU  26 B
N+    1 B                                            0.00 XXX   0 X    0.00 XXX   0 X   -0.06 ARG  29 B
N+    1 B                                            0.00 XXX   0 X    0.00 XXX   0 X    0.09 ASP  95 B
--------------------------------------------------------------------------------------------------------
  Residues that are found to be 'coupled', i.e. titrates together, has been marked by '*' in the above
  section. Please rerun PropKa with the --display-coupled-residues option for detailed information.
--------------------------------------------------------------------------------------------------------
SUMMARY OF THIS PREDICTION
     RESIDUE    pKa   pKmodel   ligand atom-type
   ASP  19 A    3.18      3.80
   ASP  57 A    4.68      3.80
   ASP  58 A    2.97      3.80
   ASP  87 A    3.70      3.80
   ASP  93 A    3.29      3.80
   ASP  95 A    3.65      3.80
   ASP 137 A    3.26      3.80
   ASP 150 A    1.23      3.80
   ASP 172 A    3.56      3.80
   ASP 197 A    4.06      3.80
   ASP 204 A    3.06      3.80
   ASP 221 A    4.58      3.80
   ASP 264 A    4.07      3.80
   ASP 275 A    4.13      3.80
   ASP 298 A    3.40      3.80
   ASP 311 A    3.36      3.80
   ASP 313 A    3.96      3.80
   ASP 355 A    3.98      3.80
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   ASP 368 A    3.91      3.80
   ASP 376 A    4.05      3.80
   ASP 377 A    3.27      3.80
   ASP 382 A    4.83      3.80
   GLU  26 A    4.44      4.50
   GLU  44 A    4.37      4.50
   GLU  48 A    3.41      4.50
   GLU  59 A    4.50      4.50
   GLU  77 A    4.52      4.50
   GLU  92 A    4.61      4.50
   GLU 126 A    6.06      4.50
   GLU 152 A   10.96      4.50
   GLU 174 A    4.82      4.50
   GLU 192 A    4.49      4.50
   GLU 231 A    4.51      4.50
   GLU 234 A   12.81      4.50
   GLU 247 A    3.44      4.50
   GLU 273 A    5.10      4.50
   GLU 323 A    4.69      4.50
   GLU 326 A    3.96      4.50
   GLU 340 A    3.88      4.50
   GLU 365 A    4.74      4.50
   GLU 371 A    3.97      4.50
   GLU 387 A    4.63      4.50
   GLU 392 A    4.20      4.50
   C-  398 A    3.31      3.20
   HIS  23 A    6.08      6.50
   HIS  27 A    6.02      6.50
   HIS 153 A    5.02      6.50
   HIS 166 A    5.89      6.50
   HIS 209 A    2.93      6.50
   HIS 251 A    2.88      6.50
   HIS 257 A    3.99      6.50
   HIS 282 A    2.01      6.50
   CYS  15 A   10.34      9.00
   CYS  46 A   11.92      9.00
   CYS  86 A   10.56      9.00
   CYS 131 A   11.75      9.00
   CYS 207 A   10.78      9.00
   CYS 300 A   10.02      9.00
   CYS 317 A   11.85      9.00
   CYS 374 A    9.07      9.00
   TYR  53 A   10.17     10.00
   TYR 170 A   11.71     10.00
   TYR 232 A   10.66     10.00
   TYR 262 A   12.82     10.00
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   TYR 312 A   11.37     10.00
   TYR 315 A   11.98     10.00
   LYS   2 A    9.13     10.50
   LYS  37 A   10.33     10.50
   LYS  63 A   10.62     10.50
   LYS  66 A   10.36     10.50
   LYS 118 A    9.81     10.50
   LYS 125 A   13.89     10.50
   LYS 140 A   10.29     10.50
   LYS 143 A   10.10     10.50
   LYS 217 A   13.30     10.50
   LYS 228 A   10.72     10.50
   LYS 295 A   10.71     10.50
   LYS 301 A   10.43     10.50
   LYS 319 A   10.72     10.50
   LYS 366 A   10.40     10.50
   LYS 391 A   10.17     10.50
   ARG  22 A   14.57     12.50
   ARG  29 A   11.94     12.50
   ARG  41 A   13.08     12.50
   ARG  52 A   12.96     12.50
   ARG  75 A   12.46     12.50
   ARG 115 A   12.16     12.50
   ARG 133 A   12.71     12.50
   ARG 191 A   11.47     12.50
   ARG 196 A   12.41     12.50
   ARG 208 A   12.42     12.50
   ARG 216 A   13.46     12.50
   ARG 236 A   13.16     12.50
   ARG 261 A   12.56     12.50
   ARG 277 A   13.08     12.50
   ARG 289 A   12.78     12.50
   ARG 314 A   12.66     12.50
   ARG 352 A   12.55     12.50
   ARG 370 A   12.49     12.50
   ARG 386 A   14.66     12.50
   ARG 390 A   12.10     12.50
   ARG 395 A   12.64     12.50
   N+    1 A    7.77      8.00
   ASP  19 B    2.91      3.80
   ASP  57 B    4.81      3.80
   ASP  58 B    2.80      3.80
   ASP  87 B    3.54      3.80
   ASP  93 B    2.15      3.80
   ASP  95 B    3.42      3.80
   ASP 137 B    3.22      3.80
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   ASP 150 B    6.49      3.80
   ASP 172 B    3.44      3.80
   ASP 197 B    4.13      3.80
   ASP 204 B    3.70      3.80
   ASP 221 B    4.35      3.80
   ASP 264 B    3.88      3.80
   ASP 275 B    3.98      3.80
   ASP 298 B    3.26      3.80
   ASP 311 B    3.62      3.80
   ASP 313 B    4.03      3.80
   ASP 355 B    3.97      3.80
   ASP 368 B    3.92      3.80
   ASP 376 B    4.07      3.80
   ASP 377 B    3.27      3.80
   ASP 382 B    4.82      3.80
   GLU  26 B    4.35      4.50
   GLU  44 B    4.46      4.50
   GLU  48 B    3.46      4.50
   GLU  59 B    4.66      4.50
   GLU  77 B    4.72      4.50
   GLU  92 B    4.52      4.50
   GLU 126 B    5.71      4.50
   GLU 152 B   10.62      4.50
   GLU 174 B    4.79      4.50
   GLU 192 B    4.32      4.50
   GLU 231 B    1.51      4.50
   GLU 234 B   12.78      4.50
   GLU 247 B    3.30      4.50
   GLU 273 B    4.91      4.50
   GLU 323 B    4.58      4.50
   GLU 326 B    4.71      4.50
   GLU 340 B    3.93      4.50
   GLU 365 B    4.68      4.50
   GLU 371 B    3.85      4.50
   GLU 387 B    3.95      4.50
   GLU 392 B    2.80      4.50
   C-  398 B    3.30      3.20
   HIS  23 B    6.72      6.50
   HIS  27 B    6.17      6.50
   HIS 153 B    2.68      6.50
   HIS 166 B    5.91      6.50
   HIS 209 B    3.25      6.50
   HIS 251 B    3.40      6.50
   HIS 257 B    3.97      6.50
   HIS 282 B    2.10      6.50
   CYS  15 B    9.90      9.00
186
1/13/2015 nbcr-222.ucsd.edu/opal-jobs/apppdb2pqr_1.8142120924984288311816/1q0q.propka
http://nbcr-222.ucsd.edu/opal-jobs/apppdb2pqr_1.8142120924984288311816/1q0q.propka 21/22
   CYS  46 B   11.93      9.00
   CYS  86 B   10.64      9.00
   CYS 131 B   11.77      9.00
   CYS 207 B   10.83      9.00
   CYS 300 B    9.97      9.00
   CYS 317 B   12.04      9.00
   CYS 374 B    9.14      9.00
   TYR  53 B   10.37     10.00
   TYR 170 B   11.85     10.00
   TYR 232 B   10.47     10.00
   TYR 262 B   12.79     10.00
   TYR 312 B   11.10     10.00
   TYR 315 B   12.23     10.00
   LYS   2 B   10.38     10.50
   LYS  37 B   10.63     10.50
   LYS  63 B   10.43     10.50
   LYS  66 B   10.29     10.50
   LYS 118 B    9.57     10.50
   LYS 125 B   13.75     10.50
   LYS 140 B   10.38     10.50
   LYS 143 B   10.43     10.50
   LYS 217 B   13.29     10.50
   LYS 228 B   10.85     10.50
   LYS 295 B   11.01     10.50
   LYS 301 B   10.58     10.50
   LYS 319 B   10.69     10.50
   LYS 366 B   11.02     10.50
   LYS 391 B   10.43     10.50
   ARG  22 B   14.53     12.50
   ARG  29 B   12.28     12.50
   ARG  41 B   13.35     12.50
   ARG  52 B   13.25     12.50
   ARG  75 B   12.44     12.50
   ARG 115 B   12.23     12.50
   ARG 133 B   12.74     12.50
   ARG 191 B   12.22     12.50
   ARG 196 B   12.44     12.50
   ARG 208 B   12.51     12.50
   ARG 216 B   12.47     12.50
   ARG 236 B   12.36     12.50
   ARG 261 B   12.70     12.50
   ARG 277 B   13.49     12.50
   ARG 289 B   12.63     12.50
   ARG 314 B   12.52     12.50
   ARG 352 B   12.56     12.50
   ARG 370 B   12.47     12.50
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   ARG 386 B   14.67     12.50
   ARG 390 B   12.46     12.50
   ARG 395 B   12.58     12.50
   N+    1 B    7.66      8.00
--------------------------------------------------------------------------------------------------------
--------------------------------------------------------------------------------------------------------
Free energy of   folding (kcal/mol) as a function of pH (using neutral reference)
  0.00    115.93
  1.00    115.34
  2.00    112.14
  3.00    101.87
  4.00     84.92
  5.00     75.56
  6.00     70.96
  7.00     69.49
  8.00     73.69
  9.00     83.58
 10.00    103.51
 11.00    129.66
 12.00    151.92
 13.00    168.65
 14.00    180.06
The pH of optimum stability is  6.7 for which the free energy is  69.2 kcal/mol at 298K
Could not determine pH values where the free energy is within 80 % of maximum
Could not determine where the free energy is positive
Protein charge of folded and unfolded state as a function of pH
    pH  unfolded  folded
  0.00     89.99   89.87
  1.00     89.90   88.92
  2.00     89.06   84.77
  3.00     81.91   70.68
  4.00     51.15   40.23
  5.00     14.24   10.39
  6.00     -0.32   -3.36
  7.00    -10.36   -8.99
  8.00    -16.16  -11.56
  9.00    -25.79  -14.95
 10.00    -43.86  -26.00
 11.00    -66.83  -47.76
 12.00    -83.04  -69.48
 13.00   -105.80  -94.70
 14.00   -114.70 -109.22
The pI is  5.65 (folded) and  5.97 (unfolded)
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